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Classically, the epithelial lining of the urinary bladder, also called the urothelium, has been 
thought of as a passive barrier against toxins present in urine.  However, recent studies are 
beginning to emerge that demonstrate an active role for the urothelium in the sensory functions 
of the bladder.  For example, the urothelium expresses a number of the same receptors as sensory 
nerves and can respond to and release transmitters.  One such transmitter, acetylcholine, has been 
shown to be released from the urothelium in response to physical stimuli, and is thought to act 
back on the urothelium in an autocrine/paracrine manner to effect urothelial signaling.  This 
study was undertaken to determine if the urothelium expresses the proper receptors to respond to 
acetylcholine, specifically nicotinic acetylcholine receptors, and if these receptors play a role in 
influencing bladder physiology.  Our research indicates that the urothelium expresses the proper 
nicotinic receptor subunits to form two classes of receptor: 1) α3 heteromeric receptors and 2) α7 
homomeric receptors.  Both of these classes of urothelial receptor are functional and can alter 
bladder reflexes in the anesthetized rat.  Specifically, α7 receptors mediate an inhibitory pathway 
as measured by a bladder cystometrogram, while α3 receptors mediate an excitatory pathway.  
Finally, we examined intracellular and extracellular pathways that may mediate these 
physiological effects in vivo.  These experiments suggest that nicotinic receptors in the 
urothelium mediate their effects through intracellular calcium signaling, resulting in the 
modulation of the release of the excitatory transmitter ATP.  Specifically, our research indicates 
that α3 stimulation can potentiate the release of ATP from urothelial cells, while α7 stimulation 
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inhibits it.  This effect may be due to the fact that each receptor subtype modulates [Ca+2]i 
through distinct pathways: α3 receptors through influx of extracellular Ca+2 and α7 receptors 
through release from intracellular stores.  Additionally, our research indicates that α7 receptors 
can inhibit signaling through α3 receptors, indicating another possible mechanism for the 
inhibitory effects α7 receptors exhibit in vivo.  This research, which is the first to indicate an 
interaction between two types of nicotinic receptor, suggests that urothelial nicotinic receptors 
could play a significant role in bladder physiology and may represent a viable target for 
treatments into bladder pathology. 
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1.0  INTRODUCTION 
The urinary bladder has two physiological functions; the storage and eventual elimination of 
waste products in the form of urine [1-5].  In order to operate correctly, the bladder must 
properly perform these two functions at the proper time (i.e. store urine when the bladder empty 
and release urine only when the subject is consciously attempting to do so).  To accomplish this, 
the bladder and its outlet, the urethra, are carefully coordinated by neural pathways that act in 
concert to either promote storage or initiate elimination (also known as micturition).  These 
pathways are driven through activity of afferent nerves innervating the bladder, which 
communicate to the central nervous system information on the fullness of the bladder, which the 
brainstem can translate into the sensations of urgency felt when the bladder is full. 
 In the past, it was believed that sensory aspects of micturition were performed solely by 
the afferent nerves innervating the bladder [1-9].  However, it has been recently hypothesized 
that the epithelial lining of the bladder, known as the urothelium, can also play a sensory role in 
the bladder [10-16].  For example, the urothelium has been shown to release a number of 
neurotransmitters, which are thought to play a role in modulating afferent excitability.  These 
transmitters can be released either by mechanical or chemical stimuli, which suggests a role for 
the urothelium in transmitting information on conditions in the bladder to the underlying afferent 
nerves.  The research presented here aims to further the hypothesis that the urothelium can 
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participate in the function of the urinary bladder by demonstrating a role of urothelial nicotinic 
acetylcholine receptors in modulating micturition reflexes. 
1.1 OVERVIEW OF THE BLADDER 
1.1.1 Anatomy of the Bladder 
The urinary bladder is made up of two functional units: 1) a reservoir for storage of urine (the 
bladder) and 2) and an outlet that allows for emptying (the bladder neck and the urethra) [2].  
The bladder itself is commonly divided into three sections, known as the trigone, the equatorial 
region and the dome (Figure 1.1).  The trigone consists of the base of the bladder, and is where 
urine enters the bladder from the kidney through the ureters.  The dome consists of the top 
portion of the bladder, where innervation is the greatest and bladder contractions begin.  The 
equatorial section makes up the central part of the bladder.  
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Figure 1.1 - Anatomy of the Bladder 
Artist’s depiction of the major anatomical features of the urinary bladder.  Inset: a cross section of the bladder wall. 
Reprinted from [17] with permission from The McGraw-Hill Company. 
 
 
The wall of the urinary bladder is made up of 5 distinct layers of tissue (Figure 1.2) [18-
20].  The outside of the bladder wall is composed of three separate layers of smooth muscle, 
collectively described as the detrusor [20, 21].  These layers of smooth muscle are oriented in 3 
separate directions with a layer of circular smooth muscle sandwiched between layers of 
longitudinal smooth muscle (known as the inner and outer longitudinal smooth muscle layers).  
These layers of smooth muscle thicken towards the trigone of the bladder and into the neck 
forming what is referred to as the internal urethral sphincter.  The internal urethral sphincter acts 
as the final barrier in the bladder to urine release into the bladder outlet.  During voiding, these 
muscles relax and the smooth muscle in the rest of the bladder contracts, inducing urine flow.   
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Figure 1.2 - Cross Section of the Bladder 
(A) Urothelium.  (B) Submucosa or the lamina propria. (C) Inner layer of longitudinal smooth muscle. (D) Middle 
circular smooth muscle.  (E) Outer layer of longitudinal smooth muscle.  Figure adapted from Gray (1901) [21]. 
 
 
Surrounding the lumen (or inside) of the bladder sac is a layer of transitional epithelial 
cells known as the urothelium [12, 19, 22].  The urothelium is also made up of three cells layers: 
1) umbrella cells which line the bladder lumen and express the tight junctions that are 
responsible, in part, for the urothelium’s barrier function, 2) intermediate cells and 3) basal cells, 
which anchor the urothelium to the underlying tissue.  The urothelium will be discussed in 
greater detail Section 1.2.   
Between the urothelium and the smooth muscle layers is the lamina propria (sometimes 
referred to as the submucosa), a layer of connective tissue consisting of fibers of collagen and 
elastin [23].  The main purpose of the lamina propria is to anchor the urothelium to the 
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surrounding smooth muscle.  The lamina propria is populated by afferent nerve terminals 
forming the sensory portion of the bladder pathway [24] and is also home to myofibroblasts [25, 
26], which may play a role in bladder function by acting as pacemaker cells during bladder 
contraction.   
1.1.2 The Innervation of the Bladder and the Control of Micturition  
The bladder receives a dual autonomic innervation that works in concert to maintain normal 
bladder function; i.e. storage and voiding [1, 20, 21].  When the bladder is empty, sympathetic 
nerves originating from the thoracolumbar spinal cord and innervating the bladder neck and 
urethra release norepinephrine, which activate α1-adrenoceptors in the smooth muscle to 
maintain tone, keeping the outlet closed.  At the same time, sympathetic neurons activate β-
adrenoceptors in the detrusor to cause relaxation (Figure 1.3).   
Information on conditions in the lower urinary tract is conveyed to the central nervous 
system by afferent nerves contained in the pelvic nerve, as well as the hypogastric and pudendal 
nerves [2, 3, 5-8, 27].  These afferents consist of small myelinated fibers (Aδ) and unmyelinated 
(C) fibers and are responsible for conveying impulses from various parts of the bladder.  Aδ 
afferent nerves that originate near or in the detrusor smooth muscle of the bladder wall convey 
impulses from tension or volume changes as the bladder stretches to accommodate greater 
amounts of urine.  Afferents that originate near the urothelium can respond to transmitters (e.g. 
NO, ATP, ACh, prostaglandins) that are released from the urothelium in response to changes in 
urine composition or in response to mechanical stretch.  C-fiber afferents have been shown to 
function mainly as nociceptive neurons, only responding to noxious stimuli in the bladder, such 
as overdistention, physical damage or inflammation in response to bacterial infection [28].   
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Research has indicated that as the bladder fills, increased afferent nerve activity drives 
increased sympathetic efferent activity, maintaining tone in the urethra and inhibiting the 
bladder, maintaining continence [1-3, 5, 6, 27].  Increased afferent activity also activates a 
spinobulbospinal pathway that passes through a center in the rostral brain stem called the pontine 
micturition center (PMC) [29, 30].  Activation of this pathway results in feelings of bladder 
fullness and urgency.  In an infant (under approximately 4 years of age), activation of this 
pathway results in a switch in the pathways activated in the bladder.  During micturition, 
descending neurons in the spinal cord inhibit the sympathetic pathways maintaining urethral tone 
and inhibiting the bladder and activate parasympathetic neurons in the pelvic nerve (Figure 
1.3B).  These nerves release transmitters that act on purinergic and cholinergic receptors on 
detrusor smooth muscle to evoke a contraction [1, 31-34].  At the same time, nitrergic nerves 
innervating the urethra release NO, relaxing the urethra and resulting in voiding [35-37].  This 
process occurs reflexly in infants, however after the age of 4-6, neural pathways in the cerebral 
cortex and diencephalon develop that can modulate the PMC-driven spinobulbospinal reflex, 
allowing for voluntary control of the bladder.   
 7 
 
Figure 1.3 - Neural Pathways Involved in Storage and Voiding 
(A) During storage, activity in pelvic afferent nerves drives sympathetic nerves that inhibit the bladder (hypogastric 
nerve) and excite the external urethral sphincter (pudendal nerve).  (B) During voiding, descending pathways from 
the pontine micturition center in the brainstem inhibit the sympathetic pathways and activate parasympathetic pelvic 
efferents that contract the bladder and relax the sphincter.  Figures reprinted from [9] with permission of Wiley-
Blackwell. 
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1.2 THE UROTHELIUM 
1.2.1 The Urothelium as a Barrier 
Classically, the urothelium has been thought of as a simple, yet highly effective barrier, 
preventing harmful waste being stored in urine from harming the bladder [38-40].  The 
urothelium performs this function extremely well, as it has been shown to have one of the lowest 
permeabilities of any epithelial layer in the body, with some studies putting its transepithelial 
resistance as high as 300,000 Ω · cm-2 (in the frog; in the rabbit the range is 10,000-75,000 Ω · 
cm-2).  This low permeability makes the urothelium the ultimate “liner” for the bladder, holding 
waste away from where it could damage bladder tissue. 
The urothelium’s impermeability is a function of its composition.  The major players in 
this impermeability are the umbrella cells; large, flat, hexagonally-shaped cells that line the 
superficial surface of the bladder.  These cells express two distinct morphological features that 
contribute to the impermeability of the urothelium.  The first of these is the expression of 
scalloped-shaped plaques of proteins called uroplakins that line the luminal surface of the 
umbrella cells (Figure 1.4) [41-43].  These polygonal shaped plaques are approximately 0.5μm in 
diameter, 12nm in thickness and occupy almost 90% of the apical surface of the umbrella cells.  
They are made up of over 1,000 protein subunits, with each subunit composed of 12 proteins 
arranged in a hexagonal pattern.  It is thought that these plaques, in conjunction with specialized 
apical membrane lipids [44], limit the exposure of the umbrella cell membrane to small 
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molecules (water, urea, ions) to reduce permeability across the apical membrane of the umbrella 
cells.   
The second morphological feature expressed in umbrella cells that attributes to its high 
impermeability is the expression of tight junctions (Figure 1.5) [19, 45].  Tight junctions are a 
dense network of cytoplasmic proteins, cytoskeletal elements and transmembrane proteins that 
link adjacent cells and form a barrier to prevent movement of solutes and ions between them 
(also called paracellular transport) [19, 40, 46, 47].  Tight junctions are made up of a number of 
proteins such as occludin, ZO-1 and various members of a group of transmembrane proteins 
called the claudins.   The claudins comprise a multigene family, of which there are 24 identified 
members [48].  Many different claudins can exist in the same junction, where they can interact in 
both heterotypic and homotypic manners.  Permutations of these claudin interactions in each type 
of epithelial tissue are thought to be responsible for the unique paracellular properties of each 
epithelium.  This is evidenced best in the kidney, where claudin expression, as well as 
paracellular permeability to various ions, varies by segment [49].  The bladder epithelium also 
expresses a number of claudins, including -4, -8 and 12; subtypes which have been previously 
shown to increase transepithelial resistance in heterologous expression systems [50].   
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Figure 1.4 - Composition of the Urothelium 
(A) Schematic diagram depicting the three layers of transitional epithelium which comprise the urothelium.  (B) 
Cross-sectional diagram depicting the structural elements of the umbrella cell layer. (C) Electron micrograph of the 
apical surface of the umbrella cells, depicting the uroplakin plaques. (D) A schematic diagram of the composition of 
a uroplakin plaque unit.   Figure reprinted from Lewis [19], with permission from the American Physiological 
Society. 
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Figure 1.5 - Tight Junction Expression in the Rat/Mouse Urothelium 
Distribution of the tight junction marker ZO-1 in mouse and rat uroepithelium. Cryosections of bladder tissue from 
mice (A) or rats (B) were labeled with anti-ZO-1 antibodies (left) or rhodamine-phalloidin and TO-PRO3 (middle). 
Right: merged images. Images were collected as a z-series with a confocal microscope and then summed and 
displayed as a single composite projection. Right and left: arrows show location of tight junctions. Middle: UCs are 
labeled with arrows, intermediate cells with filled circles, and basal cells with filled triangles. Bar = 50 μm.  Figure 
taken from Acharya, et. al. [50], permission to reprint not required under the American Physiological Society’s rules 
for publication concerning republication of figures by authors of the original manuscript. 
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1.2.2 The Urothelium as a Sensor/Transducer 
While the urothelium has traditionally been thought as only a barrier to contain urine in the 
bladder, more recently it has been discovered that the urothelium can also play a role in the 
regulation of bladder activity.  The first evidence that the urothelium may be more than a barrier 
came from Hypolite, et. al, who demonstrated that the urothelium had a much higher metabolic 
rate than the underlying detrusor smooth muscle of the bladder, suggesting that the urothelium 
may play an active role in bladder physiology rather than a passive one [51].  This led to further 
studies of the urothelium to determine what role it might play in bladder function.  These studies 
have determined that the urothelium expresses a large number of “neuronal” receptors (those 
receptors commonly present in sensory nerves), and can respond to various chemical and 
physical changes in the bladder to release neurotransmitters [10-12, 47].  It is thought that the 
urothelium, through this transmitter release, can modulate the excitability of nearby afferent 
nerves, hence modulating bladder function.  In the following sections, we will review the 
properties of the urothelium that play a role in bladder function. 
1.2.2.1   The Sensory Properties of the Urothelium 
In that it surrounds the luminal surface of the bladder, the urothelium is positioned in the ideal 
location to sense physical, chemical or pathological changes in the bladder.  Therefore it should 
be no surprise that recent data from a number of investigators have demonstrated that the 
urothelium does indeed respond to mechanical stimuli such as stretch when the bladder fills [52-
59], chemical mediators present in the urine [13, 60-68], or pathological conditions such as a 
bacterial infection [69-71].  Each of these responses demonstrates the sensory capability of the 
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urothelium and supports the hypothesis that the urothelium plays an important role in bladder 
function. 
During bladder filling, the urothelium must accommodate the growing volume of urine 
by increasing its apical surface area and hence maintain the urine-blood barrier.  To accomplish 
this, the urothelium responds to stretch by movement of a population of cytoplasmic discoid 
vesicles into the plasma membrane [38, 72].  This cAMP and PKA dependent process results in: 
1) increases in apical surface area, 2) increases in uroplakin expression on the cell surface, 3) 
excretion of secretory proteins apically, and 4) the release of neurotransmitters such as NO, ACh 
and ATP.  It is thought that these neurotransmitters can act on afferent nerve terminals 
underlying the urothelium to modulate sensory input from the bladder into the spinal cord [6, 
73].   
In addition to responding to physical stimuli, such as stretch, the urothelium possesses the 
capability to respond to chemical stimuli as well.  Ongoing studies in a number of laboratories 
have demonstrated that the urothelium expresses a number of “sensory” receptors, i.e. 
receptors/ion channels common to nociceptor/mechanosensor sensory nerves.  Examples of these 
urothelial “sensors” are depicted in Table 1 and include receptors for bradykinin [63], 
acetylcholine [65, 74-77], norepinephrine [61, 78], purines (P2X and P2Y) [79-81], 
neurotrophins (trkA and p75) [82], protease-activated receptors (PARs) [83], 
amiloride/mechanosensitive Na+ channels (ENaC) [84, 85],  calcium activated potassium 
channels (SK channels) [86] and transient receptor potential channels (TRPs) [13, 60, 87].   
Pharmacological or genetic manipulation of many of these receptors present on the urothelium 
can result in the alteration of bladder reflexes in the rat and mouse, confirming a role for 
urothelial receptors in the sensory systems controlling micturition. 
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Table 1 - Similarities Between Urothelial and Sensory Nerve Receptors 
Sensor Function/Stimulus Urothelial Sensor Molecules Neuronal Sensor Molecules 
ATP P2X/P2Y P2X/P2Y 
Capsacin/resiniferatoxin TRPV1 TRPV1 
Heat TRPV1/TRPV2/TRPV4 TRPV1/TRPV2/TRPV3/TRPV4 
Cold TRPM8/TRPA1 TRPM8/TRPA1 
H+ TRPV1 TRPV1/ASIC/DRASIC 
Osmolarity In part TRPV4 In part TRPV4 
Bradyknin B1/B2 B1/B2 
Acetylcholine Nicotinic/Muscarinic Nicotinic/Muscarinic 
Norepinephrine α,β-subtypes α,β-subtypes 
Nerve Growth Factor P75/trkA P75/trkA 
Mechanosensitivy Amiloride-Sensitive Na+ Channels Amiloride-Sensitive Na+ Channels 
(adapted from Birder [12], with permission from the American Physiological Society) 
 
The urothelium can also respond to foreign bodies, such as bacteria, that may be present 
in urine.  Studies in the bladder suggest that the urothelium can internalize bacteria, such as 
Escherichia coli or Mycobacterium bovis, through interactions between bacterial cell wall 
glycoproteins and urothelial surface receptors.  For example, the hyaluronic acid binding protein 
CD44, which is expressed on urothelial cells, is the target for E. coli binding; mice with CD44 
genetically knocked out are highly resistant to E. coli induced urinary tract infections [71].  
Internalization of bacteria by the urothelium leads to degradation in lysosomes and the eventual 
presentation of antigens to CD4+ T cells in the suburothelial layer, leading to the activation of 
the innate immune response to fight off the infection [70]. 
Taken together, the evidence is clear that the urothelium plays a role in sensing the 
physical, chemical and pathological conditions inside the bladder.  As we will discuss in the next 
section, the urothelium can then transduce this sensory information to underlying tissues such as 
nerves in order to modulate bladder physiology.  
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1.2.2.2 The Transducer Properties of the Urothelium 
In addition to possessing the proper receptors to sense mechanical and chemical changes in the 
bladder, the urothelium can also respond to these changes by releasing various factors [16, 58, 
59, 61, 77, 78, 88-91].  It has been hypothesized that this release demonstrates the “transducer” 
properties of the urothelium, in which the urothelium communicates sensory information with 
nerves and other cell types in the bladder through the release of neurotransmitters [10, 12].  In 
this way, the urothelium would play an important role in the function of the urinary bladder. 
Many studies have demonstrated the release of transmitters from the urothelium in 
response to chemical or mechanical stimuli.  Acetylcholine is released from bladder tissue in 
response mechanical stretch [16, 92].  Since this release was significantly diminished following 
surgical removal of the mucosa, it was hypothesized that this release originated in the 
urothelium.  This hypothesis has been strengthened by studies demonstrating the presence of the 
proper machinery to synthesize, store, release and metabolize acetylcholine in urothelial cells 
[89, 93].  In addition to ACh, a number of other chemical mediators have been shown to be 
released from the urothelium in response to chemical or mechanical stimulation: nitric oxide [61, 
65, 78], ATP [58-60, 63, 79, 88, 90, 91], substance P [94], prostaglandins [95], nerve growth 
factor [96].  This release of transmitters, coupled with the proximity of afferent nerves to the 
urothelium, has led to the hypothesis that the urothelium can transmit information about 
conditions in the bladder to sensory nerves through transmitter release.   
This hypothesis was furthered through research by Chapple and Chess-Williams, who 
demonstrated that the urothelium could release a factor that could prevent bladder smooth 
muscle contractions in response to cholinergic stimulation [14, 15].  These experiments 
demonstrated that in a tissue bath, bladder smooth muscle contracted in response to muscarinic 
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receptor activation through carbachol stimulation to a much higher degree when present in the 
bath alone than when a separate piece of tissue containing the urothelium was present.  This led 
the researchers to hypothesize that the urothelium released a soluble factor in response to 
cholinergic stimulation that could inhibit bladder smooth muscle contraction, which they named 
the “urothelial derived inhibitory factor (UDIF)”.  To date, no one has discovered the identity of 
the UDIF, however experiments have confirmed that it is not nitric oxide, ATP, a 
cyclooxengenase product, adenosine, a catecholamine, GABA nor does it mediate its effect 
through the opening of potassium channels.   
Aside from the UDIF and its apparent effects on smooth muscle, other transmitters have 
been shown to be released from the urothelium and may act on various other sites in the bladder.  
For example, cholinergic or adrenergic stimulation of urothelial cells can cause the release of 
nitric oxide [61, 75, 78].  NO has been shown decrease afferent firing, and may represent an 
inhibitory factor in the bladder [97].  ATP is also released by the urothelium in response to 
mechanical or hypotonic stretch [58, 59, 88, 90] and chemical stimulation by ACh [77], which 
may then act on a subpopulation of bladder afferent nerves that express the P2X3 receptor.  
Additionally, hyperreflexia induced by intravesical administration of bradykinin or muscarinic 
agonists can be blocked by the administration of the purinergic antagonist PPADS, suggesting 
that the effects of these agents are mediated through the release of ATP [63, 65].   
In addition to the urothelium’s possible interaction with afferent nerve fibers innervating 
the bladder, a number of other cell types present near the urothelium may also participate.  In 
addition to afferent nerve terminals ending in close proximity to the urothelium, it also appears 
that efferent nerve project to the basal layer of the urothelium.  In some cases, these efferents run 
in close proximity to afferent nerves, suggesting the possible communication between 
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urothelium, afferents and efferents (Figure 1.6).  The sub-urothelium also contains a layer of 
cells that possess the cytological characteristics of both smooth muscle cells and fibroblasts, 
which are termed myofibroblasts (or occasionally interstitial cells) [26, 98, 99].  These 
myofibroblasts form an uninterrupted layer in the lamina propria and are linked to each other and 
to surrounding nerves and smooth muscle through gap junctions.  This connectivity may allow 
bladder myofibroblasts to act as pacemaker cells by integrating signals in the bladder wall, much 
like the interstitial cells of Cajal in the gut.  These cells express a number of purinergic receptors 
(P2X and P2Y), and respond to ATP by generating an intracellular Ca+2 transient, raising the 
possibility that urothelial derived ATP may activate myofibroblasts in the lamina propria (Figure 
1.6) [100-102].  Given its proximity to these other cell types in the bladder, the possibility exists 
that the urothelium could participate in a number of cell-cell interactions important in bladder 
physiology. 
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Figure 1.6 - Hypothetical Model of "Crosstalk" between Cell Types in Bladder Signaling 
Schematic depicting possible interactions between cell types in the urothelium.  Chemical or physical stimulation 
can cause the release of a number of transmitters from the urothelium, which may then act on myofibroblasts, 
afferent or efferent nerves residing in close proximity to the urothelial layer.  It is also possible that factors released 
from nerves or myofibroblasts can act on urothelial cells to modulate urothelial signaling.  Reprinted with 
permission from the Nature Publishing Group / Macmillan Publishers Ltd.: Nature Clinical Practice – Urology 
[103], © 2007.  
1.2.2.3 TRPV1 as an Example of the Sensor/Transducer Role of the Urothelium 
A prime example of the sensor/transducer role of the urothelium concerns the TRPV1 
receptor.  The TRP (transient receptor potential) superfamily of receptors is a diverse family of 
proteins that are expressed throughout the body in tissues such as neurons, smooth muscle and 
epithelial cell layers [104].  TRPV1 (originally named VR1) was the earliest TRP channel cloned 
and has been studied extensively due to its prominent role in nociception [105].  It was 
discovered to be the receptor responsible for the painful sensations induced by capsaicin, the 
pungent vanilloid present in hot peppers.  It was further discovered that TRPV1 could be 
activated by heat, protons, a toxin present in a cactus-like plant (resiniferatoxin) [106] and 
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certain lipid metabolites such as anandamide [107].  In addition to being expressed in the 
unmyelinated C-fiber nociceptors that respond to noxious bladder stimuli, TRPV1 is also 
expressed in urothelial cells, where it is thought to modulate responses to non-noxious stimuli in 
the bladder [13].  For example, bladders from TRPV1 knockout mice exhibit decreases in 
stretch-evoked ATP release and membrane capacitance [60].  Cultured urothelial cells from 
TRPV1 KOs also showed less ATP release in response to hypotonic stretch than cells cultured 
from wild-type counterparts.    Because ATP can excite afferent nerves in the bladder through 
activation of P2X receptors, it has been hypothesized that this lack of ATP release is responsible 
for the higher bladder volumes exhibited by TRPV1 KO mice [6, 73].   
1.2.3 The Role of the Urothelium in Bladder Pathology 
As we have discussed, control of the urinary bladder can be a complicated process, involving a 
number of different cell types in the bladder, peripheral and central nervous pathways, and a host 
of different transmitters.  Therefore it should be no surprise that a number of pathological 
conditions exist as a result of defects in normal bladder physiology.  Symptoms of pathological 
bladder conditions, such as a urinary tract infection, bladder outlet obstruction (as a result of 
enlargement of the prostate), interstitial cystitis or overactive bladder (OAB) often include 
increased bladder sensations, such as urgency or pain, leading investigators to focus on changes 
or defects in the sensory (afferent) nerve pathways in the bladder [7, 8, 12, 32, 74, 108].  Given 
its newly discovered sensory role, however, many investigators are beginning to believe that the 
urothelium may also play a role in bladder pathology.   
The most common form of bladder pathology is the urinary tract infection (UTI).  As 
stated above, the urothelium can internalize bacteria through interactions with the bacterial wall, 
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leading to digestion of the bacteria in lysosomes [109].  It appears that the urothelium may then 
be responsible for presenting bacterial antigens to CD4+ T-cells in the suburothelium to initiate 
the immune response [110-112].  Cytokines, released either from activated T-cells or by 
damaged urothelial cells, can activate mast cells in the suburothelium, initiating the release of 
vasoactive, inflammatory and nociceptive mediators.  These mediators, such as nerve growth 
factor [113] and histamine [114] have been shown to act on C-fiber nociceptive neurons to 
induce pain [115, 116].   Additionally, activated mast cells can release factors that disrupt the 
urothelial barrier, increasing urothelial permeability [117].  This could allow substances in the 
urine, such as ATP, acetylcholine or H+ or K+ ions access to afferent nerves, sensitizing them to 
normally non-noxious stimuli.  The ultimate result is the pain and urgency to void felt by the 
patient with a UTI. 
While the urothelium’s response to a bladder infections and the subsequent inflammatory 
response to a UTI is acute; other, more chronic bladder pathologies exist.  Generally, these 
conditions present themselves as a result of aging, through mechanisms that are not yet fully 
understood, but can also be caused by a physical trauma, such as surgery or stress on muscles in 
women during a pregnancy [118].  These bladder disorders, which include overactive bladder 
(OAB), stress incontinence, bladder outlet obstruction or painful bladder syndrome/interstitial 
cystitis (PBS/IC), are thought to be quite common among adults; for example, it is estimated that 
1 in every 6 men and women in the U.S. and Europe are affected by overactive bladder [74].  
However, given the embarrassing nature of these disorders, their prevalence are thought to be 
under-reported, indicating that the number of people affected by bladder pathology may be much 
higher.  
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Not much is currently known about the etiologies of most of the bladder disorders, 
specifically PBS/IC or OAB, two chronic bladder disorders that are characterized by frequent 
urgency to void.  One possibility may be an increase in the permeability of the urothelial barrier, 
much like that described above for UTIs [119].  A number of IC animal models show increased 
permeability of the urothelial barrier which may allow toxic substances in the urine to seep into 
the bladder wall [108].  It has also been shown that urine taken from human patients diagnosed 
with IC contains a protein known as anti-proliferative factor (APF), which has been 
demonstrated to prevent proliferation of urothelial cells and hence hinder the bladder’s ability to 
maintain the urothelial barrier [120, 121].  In addition to these changes in urothelial permeability, 
however, other factors may play a role in the emergence of bladder pathology. 
A common symptom of bladder pathologies is detrusor overactivity (DO), or the 
involuntary contractions of the bladder smooth muscle during the filling phase [74, 122].  
Because these contractions often lead to leakage and increased frequency of urination, treatments 
were designed to attempt to block the activation of bladder smooth muscle and hence decrease 
these symptoms.  Since previous research had identified ACh as the major transmitter 
responsible for smooth muscle contractions in the bladder through actions on muscarinic 
receptors, antimuscarinic agents were developed as treatments for DO, as well as for OAB [7, 8, 
31, 32, 74, 123, 124].  These agents are very efficacious in treating the frequency of urination in 
patients with OAB, however it became clear that the results were due to actions elsewhere than 
bladder smooth muscle.  To begin, antimuscarinic agents are active during the filling phase of 
the micturition cycle, when parasympathetic nerve activity is generally non-existent [1].  This 
suggested that antimuscarinic agents were working at a different site.  Interest was piqued in the 
urothelium as one possible target following the discovery of two things: 1) the urothelium can 
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release ACh in response to stretch [16] and 2) the urothelium expresses muscarinic receptors, in 
some cases at a much higher density than in the detrusor [31].   Thus, researchers hypothesized 
that urothelial muscarinic receptors, possibly activated in an autocrine/paracrine manner by 
urothelially released ACh, could be playing a role in bladder pathology. 
This hypothesis has been supported by further research into the role of cholinergic 
signaling in the urothelium.  The instance of bladder pathology increases as a population ages, a 
trend which is mirrored by an increase in both basal and stretch-evoked release of ACh from the 
urothelium [92].  Muscarinic receptors can play an excitatory role in the urothelium; intravesical 
stimulation with the high concentrations of the general agonist oxotremorine M can excite 
bladder reflexes in the anesthetized rat [65].  This effect is thought to be mediated through the 
release of an actions on afferent nerves by ATP; muscarinic stimulation of cultured urothelial 
cells can evoke ATP release [77] and the in vivo excitation of bladder reflexes by muscarinic 
stimulation can be blocked by the purinergic antagonist PPADS [65].  Additionally, anti-
muscarinics can decrease bladder afferent activity, however it is not entirely clear whether this is 
an effect of blocking ATP release from the urothelium or a direct effect of the anti-muscarinics 
on afferent nerves [125].   
Bladder pathology can also change the expression of muscarinic receptors in the 
urothelium.  For example, bladder outlet obstruction causes a marked increase in the expression 
of both the M2 and M3 muscarinic receptor subtypes in rats [122].  Conversely, induction of 
cystitis in rats through an injection of cyclophosphamide increased M1 and M5, without 
affecting the expression of the other muscarinic receptors [126].  While these results conflict in 
the subtypes that exhibit plasticity in a given animal model of bladder pathology, they both 
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suggest that increases in muscarinic receptor expression could play a role in increasing 
cholinergic signaling in the urothelium, leading to excitation of the bladder reflex.   
In addition to the cholinergic system, plasticity in other transmitter/receptor systems may 
play a role in bladder pathology.   For example, ATP release from the urothelium is also 
increased in older patients [92].  ATP release is also increased in interstitial cystitis patients [55], 
as well as in a feline model of the disease (FIC)[58].  While it is possible that ATP can directly 
activate bladder afferent nerves, research has demonstrated that ATP, acting through P2X3 
receptors, can also sensitize afferent nerves, lowering the threshold for activation by other 
stimuli [127, 128].  This is especially relevant in C-fiber nociceptors, where ATP has been 
shown to lower the sensitivity of TRPV1 to capsaicin, protons and heat, suggesting increased 
urothelial ATP release may play a role in sensitizing normally silent C-fibers in response to 
innocuous stimuli, causing urgency and pain [129].   
A number of pathological bladder models have also demonstrated urothelial receptor 
plasticity.  For example, normal rat bladders express only the bradykinin receptor B2R, however 
following induction of bladder inflammation using chronic cyclophosphamide treatment; this 
phenotype switches to the B1R [63].  This change in the prominent receptor phenotype may play 
a role in the bladder hyperreflexia observed in CYP treated rats, as the number of non-voiding 
contractions in CYP-treated anesthetized rats were significantly blocked by bradykinin 
antagonists.   This bladder hyperactivity may be mediated through an ATP dependant process, as 
bradykinin evoked ATP release from cultured urothelial cells and bradykinin-induced bladder 
hyperactivity can be blocked by the purinergic antagonist PPADS.   
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1.3 NICOTINIC RECEPTORS 
Acetylcholine is an important transmitter in the control of the bladder, being responsible for 
neurotransmission in the brain stem, spinal cord and autonomic ganglia as well as being the 
major compound responsible for bladder smooth muscle contractions [1, 130-134].  ACh 
mediates its effects in vivo through actions on the two types of cholinergic receptors: 1) the 
metabotropic muscarinic receptors and 2) the ionotropic nicotinic receptors [135].  While the 
muscarinic receptors play an important role in bladder function, our focus for this project is the 
nicotinic receptors, and we will constrain our focus to those receptors. 
Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels 
sensitive to acetylcholine and nicotine [136-141].  To date, sixteen nicotinic subunits have been 
cloned in the mammal, consisting of α1-10, β1-4, δ, γ, and ε.  Nicotinic receptor subtypes are 
separated into two main categories based on the tissue in which they are normally found; those 
found in nervous tissue and those found at neuromuscular junction [136, 139].   Generally, it is 
the subunit composition of the receptor that differs between classes of receptor.  nAChRs found 
at the neuromuscular junction are comprised of α1, β1, and δ subunits together with a γ subunit 
in the fetus or the ε subunit in the adult.  In skeletal muscle, these receptors are activated by ACh 
released by motor neurons that innervate the muscle to cause a contraction. 
Neurons have their own types of receptors, which are further divided into three 
categories: 1) the high-affinity nicotine binding receptors containing the α4 subunit, 2) α-
bungarotoxin sensitive homomeric receptors composed of α7 subunits and 3) the complex 
heteromeric receptors of the autonomic nervous system composed of variations on a basic α3/β4 
receptor [136, 137, 139-141].  These receptors are generally responsible for fast synaptic 
transmission in the brain (in the case of the α4 receptors) [142] or in the autonomic ganglia (as is 
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the case with the α3β4 and α7 receptors) [130].  Interestingly though, in addition to their long-
discovered role as a fast-excitatory ion channel, nAChRs are also responsible for a number of 
other cellular processes in nerves, such as modulation of transmitter release from the presynaptic 
terminal [143], activation of calcium dependant second messenger systems [144-147] and 
initiation of transcriptional systems [148-150].   
The consequence of such a wide array of cellular processes being influenced by the same 
endogenous transmitter would be the separation of signals, i.e. how does stimulation of a cell 
with ACh activate one process and not another?  While the cellular location of nAChR on a 
nerve would play a role in determining which cellular process would be activated (e.g. α7 
receptors on the presynaptic terminal can modulate transmitter release while those located in the 
soma can activate transcriptional systems, Figure 1.7) [151], subunit composition also seems to 
contribute in determining the function of a particular nAChR.  Each nAChR subunit combination 
studied so far has a distinct pharmacological and electrophysiological profile which distinguishes 
it from the other nAChRs [137, 140, 152-156].  For example, each combination of nicotinic 
receptor subunits has different gating properties in response to their endogenous ligand, ACh 
(Figure 1.8).  It is thought that these different electrophysiological properties account for the 
wide variety of functions attributed to nAChR signaling.  In the following sections we will 
discuss the major pharmacological and electrophysiological differences between the three types 
of neuronal nicotinic receptors, as well as their known physiological roles in vivo. 
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Figure 1.7 - nAChR Function is Influenced by Their Location 
Series of figures depicting how cellular location can influence nAChR function.  (A) The classic depiction of fast 
synaptic transmission.  nAChRs present on the postsynaptic terminal are activated by ACh released by the 
presynaptic terminal, propagating the action potential across the synaptic cleft.  (B) Transmitter modulation.  
nAChRs located on the presynaptic terminal can be activated by ACh from an adjacent terminal to modulate 
transmitter release from the presynaptic nerve.  (C) Axonal or preterminal nicotinic modulation.  nAChRs situated 
on the axonal arbor in a position where they may affect propagation of the action potential to one synapse, but not 
another.  Reprinted from [151]: Biological Psychiatry 49(3) by J.A. Dani, “Overview of nicotinic receptors and their 
role in the central nervous system” © 2001, with permission from Elsevier Ltd. 
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Figure 1.8 - Differences in nAChR Channel Properties Due to Subunit Composition 
Inward currents recorded during voltage clamp experiments following stimulation with increasing concentrations of 
ACh to demonstrate the influence of subunit composition on channel gating properties.  All traces were done in 
oocytes injected with mRNA coding for the subunits depicted in each graph.  Cells were held at -100mV during 
recording.  Reprinted from [137]: FEBS Letters 504(3) by V. Itier and D. Bertrand “Neuronal nicotinic receptors: 
from protein structure to function” © 2001 with permission from Elsevier Ltd. 
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1.3.1 α4 Containing Receptors 
α4 containing receptors were the first neuronal nAChRs discovered in the CNS and are 
expressed throughout the cortex, thalamus, hippocampus, substantia nigra, striatum and 
cerebellum [139, 140, 157, 158]. α4 receptors are heteropentameric ion channels which consist 
of two α4 subunits paired with either three β2 subunits or, more rarely, three β4 subunits. α4 
receptors account for the majority of nAChRs in the brain, with α7 receptors making up the rest.  
These receptors exhibit the highest affinity for nicotine of all the nAChRs yet studied, which has 
lead most investigators to focus on them when studying the pharmacology of smoking addiction 
[159].  In addition to their role in smoking cessation, α4 receptors have been found to be 
important in certain neurological pathologies, such as schizophrenia [160, 161], Parkinson’s 
[162] and Alzheimer’s disease [163].  These studies have increased interest in specific α4 
agonists in the treatment of cognitive disorders.   
While α4 receptors have been found to be very important in nicotinic signaling 
pathologies of the brain, they are rarely observed outside of the CNS.  As our research centers on 
the periphery, where α4 receptors are not present, we will move on to discuss nAChRs more 
relevant to our research. 
1.3.2 α3 Containing Receptors 
α3 containing nAChRs (referred to henceforth as α3* receptors) are another classical 
example of neuronal nicotinic receptors found predominantly in sensory and autonomic nerves 
[130, 164].  These receptors are also comprised as heteropentamers, most commonly consisting 
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of two α3 subunits with three β4 subunits [137, 140].  Unlike other nAChRs though, α3 receptors 
seem to exhibit much more variability in their composition.  α3 receptors have been 
demonstrated to co-express with α5, β2 and β4 subunits, suggesting that they can form functional 
receptors with these subunits as well [152, 153, 165, 166].  Studies in heterologous systems such 
as oocytes confirm that the α3 receptor can at least form functional receptors of the following 
compositions (more may be possible): α3β4 (stoichiometry 2:3), α3β2 (2:3), α3β2β4 (2:1:2), 
α3α5β2 (2:1:2) and α3α5β2β4 (2:1:1:1).  While these receptors have not yet been shown to be 
pharmacology distinct, each receptor has measurably different electrophysiological properties 
that distinguish it from the others.  For example, substitution of β4 subunits with β2 subunits in 
the α3β4 receptors increases open time, increases conductance and decreases the rate of 
desensitization of the receptor [165].  Additionally, the presence of an α5 subunit in either an 
α3β2 or α3β4 receptor can alter a receptor’s sensitivity to ACh and increase the Ca+2 
permeability of the channel [152, 165].  It has been hypothesized that these changes in the 
properties of α3* receptors could help “fine tune” nicotinic receptor signaling to perform specific 
functions.   
This heterogeneity of the α3* receptor, however, makes physiological studies difficult; 
given that, as yet, no specific pharmacological agents have been found to differentiate between 
them.  α3* receptors demonstrate a high affinity for nicotine or acetylcholine (approximately 10 
fold lower than α4 receptors) [137, 139, 140] and are also activated by cytisine, 
dimethylphenylpiperazinium (DMPP) and epibatidine (see Table 2 for a listing of nicotinic 
agents).  However, none of these compounds or any α3* antagonist (mecamylamine, TMPH, 
hexamethonium) demonstrates a sufficient selectivity to a particular α3* receptor subtype in 
order to use as a specific agent.  Therefore it becomes near impossible to parse out each 
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receptor’s physiological role in a given system.  In an attempt to answer some of these questions, 
researchers have taken a genetic route, knocking out specific receptor subtypes in the hope to 
observe differences in autonomic function [130, 156, 167].  Most of these studies, however, 
resulted in lethality due to multiple organ failure, suggesting that each receptor subunit plays a 
significant role in autonomic function. 
 
Table 2 - Subtype Specific nAChR Agents* 
Agonists 
Agent Receptor Specificity Potency (EC50 in μM) 
ACh α4>α7≈α3 0.5-68 / 28-180 / 35-203  
Nicotine α4>α3>α7 0.35-5 / 8.1-110 / 49-113 
Choline α7>>α3 400-16,000 (for α7) 
PNU 282987 α7>>α3 ~0.120 (for α7) 
Cytisine α4>α3>α7 0.019 / 5.6 / 72 
Epibatidine α4>α3>>α7 0.0045-0.0085 / 0.024-0.07 / 1.2-1.3 
Dimethylphenylpiperazinium (DMPP) α4>α3>α7 1.9-18 / 14-19 / 26-64  
 
Antagonists 
Agent  Receptor Specificity Potency 
Methyllycaconitine Citrate (MLA) α7 10-200 nM 
α-Bungarotoxin α7 1-100 nM 
Mecamylamine α3* 1-10 μM 
TMPH α3* 0.1-10 μM 
Hexamethonium α3* 1-100 μM 
α-Conotoxin AuIB α3β4 1-10 μM 
α-Contoxin MII α3β2 10-120 nM 
* Data taken from the online review by Wonnacott and Barik [168], and the references contained within. 
 
1.3.3 α7 nAChRs 
α7 nAChRs are unique in that they are comprised of five copies of the same subunit, as opposed 
to the general heteromeric structure of the other nicotinic receptors, which consist of at least two 
separate types of subunits [169].  This homomeric structure gives the α7 receptor some unique 
 31 
pharmacological and physiological properties.  For instance, the α7 receptor is the only common 
nAChR that is sensitive to choline, the metabolic product of acetylcholine [170, 171].  While 
choline is a much less potent agonist against α7 receptors as compared to nicotine or ACh 
(approximately 10-100 fold), it is much more selective [168].  Additionally, α7 receptors are 
susceptible to the snake venom, α-bungarotoxin, which can block α7 receptors almost 
irreversibly [138].   
α7 receptors exhibit very fast activation and desensitization kinetics, as compared to other 
nAChRs [137, 138, 140, 169, 172, 173].  In fact, it has been hypothesized that α7 nicotinic 
receptors can desensitize much more rapidly than modern perfusion systems take to reach 
maximum concentrations of drug, leading to an underestimation of the desensitization kinetics at 
higher concentrations [169, 173].  These kinetics are largely concentration and time dependant, 
with lower concentrations of agonist activating and desensitizing slowly (see Figure 1.9).  Higher 
concentrations of agonist, or longer durations of application can significantly increase the 
number of fully desensitized receptors.   This phenomenon appears to be unique to α7 receptors 
and is certain to be important for nAChR signaling in the brain, however further studies must be 
performed, as no specific benefit has yet been ascertained. 
In addition to their unique gating properties, α7 receptors also exhibit a higher Ca+2 
permeability than the other ligand-gated ion channels yet studied [174, 175].  It has been 
estimated that the ratio of Ca+2 ions flowing through an open α7 channel as compared to other 
cations could be as high as 10:1, much higher than the 1:1 ratio exhibited by other nAChRs.  
This raises the possibility that α7 receptors may play a role in calcium homeostasis, as well as 
activate a number of calcium-dependent processes in cells.  For example, α7 receptors have been 
shown to activate the PI3-kianse/Akt pathway in a calcium dependant manner [176].  Calcium 
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chelators also block nAChR-mediated nitric oxide production in the myenteric plexus, 
suggesting that α7 receptors also mediate this pathway [177].  Additionally, α7 receptors can 
activate transcriptional systems [148, 149] as well as modulate some proteolytic processes [178, 
179], further confirming the receptors role in calcium-dependant cellular processes.   
 
 
 
Figure 1.9 - α7 Currents in Response to ACh and Choline 
Kinetic characteristics of α7 mediated whole cell currents in rat hippocampal neurons.  (A) Currents elicited by a 
750ms pulse of 300μM ACh or 2mM choline in the same neuron, superimposed over one another to show their near 
identical trace.  (B) Concentration dependent kinetics of ACh evoked whole cell currents.  Traces show the initial 
0.4s of a 4s pulse of ACh at 10 (the smallest amplitude), 20, 40, 80, 160, 320 and 3000μM (the largest amplitude).  
The inset shows the entire 4s pulse scaled to the same peak amplitude in order to highlight the concentration 
dependence of the decay.  Reprinted from [171]: Brain Research 882(1-2) by A. Mike, et. al. “Choline and 
acetylcholine have similar kinetic properties of activation and desensitization on the α7 receptors in rat hippocampal 
neurons” © 2000 with permission from Elsevier Ltd.  
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1.3.4 The role of nAChRs in the Control of the Urinary Bladder 
As mentioned previously, ACh is an important transmitter in the bladder.  Not only is ACh, 
released for parasympathetic nerves, responsible for bladder smooth muscle contraction during 
micturition [1, 2, 5, 7, 30, 31, 74], it is an important transmitter at many sites along the spinal-
bulbo-spinal pathways that control micturition [29, 132, 180, 181].  In the following sections, we 
will discuss the role nicotinic receptors have in areas of the body important for controlling 
micturition, such as the brainstem, spinal cord and autonomic ganglia.   
1.3.4.1 Brainstem 
Nicotinic receptors are prevalent in a number of areas of the brain, including the cortex, 
thalamus, hippocampus, substantia nigra, striatum and cerebellum [146, 157, 182-185].  
Therefore, it is reasonable to expect that nicotinic receptors play a role in synaptic transmission 
in areas of the brain that control micturition.  For example, injections of cholinergic agents into 
the pontine micturition center of the cat elicited both inhibition and excitation of bladder reflexes 
in the cat, depending on the site of injection [186].  In both anesthetized and unanaesthetized 
rats, low doses (0.01-0.01 μg) of the ultrapotent agonist epibatidine, injected 
intracerebroventricularly (i.c.v.), inhibited bladder reflexes, suggesting that α4 receptors in the 
brain play a role in micturition [133].  Larger doses (1 μg) of epibatidine excited bladder 
reflexes, however this dose also increased the peak micturition pressure, therefore it may be that 
this excitation is due to non-specific effects elsewhere in the body, such as the autonomic 
ganglia.  Additionally, nicotine injected i.c.v. decreased bladder activity; an effect that returned 
to normal after 40 minutes and which was blocked by the antagonist mecamylamine [180].   
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1.3.4.2 Spinal Cord 
Both the afferent and efferent limbs of the micturition pathway run through spinal interneurons 
that also rely on nicotinic receptors for synaptic transmission [29].  Intrathecal administration of 
nicotine increased voiding frequency transiently without significantly changing any other 
voiding parameters, such as pressure threshold or maximum voiding pressure [180].  This effect 
of nicotine could be reversed using the nicotinic antagonist mecamylamine.  Interestingly, the 
effect of nicotine was also blocked by the NMDA receptor antagonist MK-801, indicating that 
the spinal effects of nicotine are mediated though the stimulation of the glutamate-NMDA 
pathway.  This was consistent with other studies that demonstrate hyperalgesia and/or irritation 
in behavior responses following intrathecal administration of nAChR agonists [187, 188].  These 
studies found a significant increase in glutamate and aspartate levels in spinal fluid of rats 
following stimulation with nicotine, cytisine or epibatidine.  Capsaicin treatment of the bladder 
also significantly blocked nicotine’s spinal effects, suggesting that C-fiber afferents may play a 
limited role in nicotine-induced glutamate release [180].   
1.3.4.3 Autonomic Ganglia 
The urinary tract is innervated by autonomic sympathetic and parasympathetic nerves which 
form the basis of the two phase of micturition: storage and voiding [130, 131, 135, 181].  These 
pathways consist of preganglionic nerves, which originate in the lumbar or sacral spinal cord and 
postganglionic nerves, which innervate the urinary tract.  In the rat or mouse, the postganglionic 
fibers originate in the major pelvic ganglion, while in higher mammals they generally originate 
in intramural ganglia in the bladder wall. 
nAChRs play a major role in bladder function by mediating synaptic transmission for 
both sympathetic and parasympathetic neurons through the autonomic ganglia.  Studies have 
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shown that autonomic ganglia express a number of nAChR subunits, including α3, α4, α5, α7, β2 
and β4, with α3β4 receptors acting as the major functional receptor [131].  This is demonstrated 
both by perforated whole cell patch clamp, where ACh-induced currents could be blocked by 
mecamylamine and α-conotoxin AuIIB [181]; as well as genetic knockout studies, where 
knockout of either the α3 or β4 subunit blocks nicotine induced bladder contractions in vitro 
[131].   
1.3.4.4 Myofibroblasts or Interstitial Cells  
The bladder contains a population of cells similar to the interstitial cells of Cajal (ICC), found in 
the gut [25, 100, 101].  In the gut ICC cells are responsible for maintaining peristaltic activity 
and transmission of signals from nerves to the smooth muscle of the GI tract.  They are thought 
to perform roughly the same function in the bladder; performing “pacemaker” functions to 
propagate smooth muscle contractions along the length of the bladder and act as an intermediate 
in neuron-smooth muscle signaling.  ICC cells of the bladder exist in two locations, in the 
detrusor smooth muscle and in the lamina propria.  ICC cells in the detrusor, also called detrusor 
myofibroblasts, have been shown to release ACh and can respond to cholinergic stimulation with 
increases in intracellular calcium [102].  This is not the case, however, for ICC cells present in 
the lamina propria.  While nicotinic receptors have not yet been located to either type of bladder 
myofibroblasts, they are important players in fibroblast proliferation and signaling [189] in other 
tissues, suggesting that they may also play the same role in the bladder. 
1.3.4.5 The Role of nAChRs in Afferents 
Nicotine has long been known to possess anti-nociceptive properties, as smoking tobacco has 
been used as a folk remedy for pain since the plant was discovered [190].  While undoubtedly 
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some of nicotine’s anti-nociceptive effects are due to actions in the brain and spinal cord, 
nicotinic receptors are also present on peripheral afferent nerves.  While no study to date has 
directly located nicotinic receptors to bladder specific afferent nerves, indirect evidence suggests 
that they could play a significant role in the bladder sensory pathway.   
For example, a number of nicotinic receptor subunits (α2, α3, α4, α5, α6, α7, β2, β3 and 
β4) have been localized to dorsal root ganglion cells, including cells from DRGs known to 
contain bladder afferent nerves (in the rat, L6-S1) [164].  These nicotinic subunits form 
functional receptors that the authors separated into 4 categories based on their pharmacological 
and electrophysiological properties.  For example, 32% of small diameter DRG cells (a common 
measurement to identify C-fiber nociceptors) and 77% of large cells (indicative of A-β and A-δ 
fibers) express the “Category I” nAChR response, characterized by a rapidly desensitizing 
current that was sensitive to choline and α-bungarotoxin, suggesting the presence of α7 
receptors.  A smaller number of cells (9% of small cells, 16% of large cells) exhibit a non-
desensitizing current in response to nicotine and cytisine, suggesting the involvement of α3β4 
receptors.  The other two categories of responses occur in less than 5% of all cells, which did not 
allow the authors to complete an extensive pharmacological profile, however they believe that 
these two responses may be attributed to either α4-containing receptors, or more complex forms 
of the α3β4 receptor (such as α3α5β4).  It is unclear what this wide variety in nicotinic signaling 
in the DRG might mean in terms of sensory function. 
  The site of nicotine’s anti-nociceptive actions is also unclear, however a few hypotheses 
exist.  nAChRs have been localized to afferent nerves terminals entering the spinal cord at the 
level of lamina I-III [191].  Following noxious stimuli, C-fiber afferent axons in these laminae of 
the spinal cord release peptides, such as Substance P (SP) or calcitonin gene-related peptide 
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(CGRP).  Because intrathecal injection of SP or CGRP causes nociceptive behavior in rats and 
mice [192, 193], it is thought that these transmitters modulate the pain response.  Conversely, 
nicotinic agonists such as epibatidine can have anti-nociceptive properties when injected 
intrathecally [194].  It is thought, then, that this analgesic effect of epibatidine is accomplished in 
the same manner as that of opioids, i.e. by acting on receptors located presynaptically on afferent 
nerve axons in the spinal cord.  Activation of these presynaptic receptors would deplete the 
releasable stores of SP or CGRP that are normally released following noxious stimuli in the 
periphery, resulting in analgesia.  Additionally, it is possible that nAChRs present on the 
peripheral terminal of C-fiber afferents play a role in epibatidine’s anti-nociceptive properties.  It 
is believed that epibatidine could desensitize C-fiber nociceptive neurons; much in the same 
manner as capsaicin does, acting on TRPV1 receptors.   
Evidence for these hypotheses can be found both in vivo and in vitro.  nAChR-mediated 
release of SP or CGRP has been well characterized in C-fiber afferent nerves innervating the rat 
trachea [195], as well as the guinea pig bronchi and lungs [196-198].  Epibatidine also causes SP 
release from F11 cells (a DRG cell line with C-fiber properties) [199].  And while release of SP 
or CGRP from afferent nerves seems counterintuitive to anti-nociception, a second, subsequent 
activation of afferent nerves or F11 cells with nicotinic agents results in little peptide release, 
supporting the hypotheses that the epibatidine either desensitizes the nerve or depletes the pool 
of releasable peptides [199].  Additionally, it has been discovered that stimulation of DRGs with 
nicotinic agents significantly decreases calcium transients in response to a subsequent 
stimulation by capsaicin, indicating that nAChRs can desensitize C-fibers to other stimuli. [200]   
In relation to the bladder, little is known about the role of nicotinic receptors on afferent 
nerves.  As mentioned previously, intrathecal injection of nicotine in the rat can transiently excite 
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bladder reflexes [180].  It appears that this effect is modulated at least partly through C-fiber 
afferents, as pretreatment with capsaicin diminished nicotine’s effect.  Additionally, intravesical 
administration of nicotine (in concentrations thought high enough to pass through the urothelial 
barrier to activate underlying nerves) can cause excitation of the bladder reflex.  Given this data, 
it appears that nicotinic receptors on both the peripheral and central terminals of bladder afferent 
nerves play a role in the micturition pathway.   
1.3.5 The Role of Neuronal nAChR in Non-Neuronal Cells 
While we have spent a good deal of time discussing “neuronal” nicotinic receptors and their role 
in neural physiology, it should be noted that these receptors have recently been gaining notoriety 
in non-neuronal systems.  While the “neuronal” receptors that were first cloned in the brain are 
found throughout the nervous system, increasing evidence points towards important roles for 
these receptors in other tissues such as adipose tissue, epithelial and endothelial cells, 
keratinocytes, and immune cells such as lymphocytes and macrophages (See Table 3 for a 
summary of nAChR expression in non-neuronal cell types).  These receptors have been found to 
be responsible for a number of cellular processes, such as transcription, cell growth, cell 
differentiation and secretion.  Given that the bladder also contains a number of these non-
neuronal tissues, it is conceivable that nAChRs in non-neuronal tissue may also play a role in 
bladder function. 
For example, a growing number of studies have indicated a role for nAChRs in the 
maintenance of epithelial or endothelial barriers.  Human skin keratinocytes have been shown to 
express the α3, α5, α7, α9, α10, β1, β2 and β4 subunits [144], while vascular endothelial cells in 
the human aorta express α3, α5, β2 and β4 [201].  Stimulation of these cells with nicotinic agents 
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have a number of effects that can influence the permeability of the barriers these cells maintain.  
For example, stimulation of human umbilical vein endothelial cells with nicotine increased the 
expression of the cellular adhesion molecules VCAM1, ICAM and E-selectin, as well as 
increased the ability of E. coli to penetrate the endothelial barrier [202].  Additionally, nicotine 
can increase paracellular permeability of the blood-brain barrier, presumably due to decrease in 
connexin 43 expression [203, 204].  Conversely, mecamylamine treatment of organotypic co-
cultures (a experimental model of human skin), diminished epithelial thickness and expression of 
terminal differentiation markers [205], indicating that tonic nAChR activation may be necessary 
for maintaining the epithelial barrier in the skin.  Finally, nAChRs have been shown to stimulate 
the proliferation of bronchial epithelial cells, as well as inhibit apoptosis [206, 207].  Therefore, 
the role of nAChRs in the proliferation and differentiation of epithelial/endothelial cells has been 
well-established. 
In addition to maintenance of epithelial/endothelial barriers, nAChRs have also been 
shown to play a significant role in the immune system.  ACh, acting on α7 receptors, prevents 
activation of macrophages by inhibiting the nuclear translocation of NF-κB [208] as well as 
activating the Jak/Stat3 pathway [209], which in turn prevents the macrophages from releasing 
pro-inflammatory cytokines such as TNF, MIP-2 and IL-6 [210].  This anti-inflammatory 
pathway can also be activated by nicotine, which has led to its use in the treatment of various 
chronic inflammatory diseases, such as ulcerative colitis or pancreatitis [211, 212].   In addition 
to macrophages, nAChRs are also important in down-regulating other inflammatory cell types, 
such B- and T-lymphocytes, as well as dendritic cells, reducing their ability to release 
inflammatory mediators and increasing apoptosis [181, 213-216].  When combined, these effects 
of nAChRs in the immune system results in a significant anti-inflammatory response.  Therefore, 
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clinically, nAChR agents are being examined to combat a host of inflammatory diseases, such as 
sepsis [208].   
These results are only a small sample of the non-neuronal tissues throughout the body 
where nicotinic receptors are present.  However, they illustrate other areas, outside of nervous 
pathways, where nAChRs may play an important role in bladder physiology or pathophysiology.  
For example, nAChRs present on vascular endothelial cells in blood vessels in the bladder could 
modulate vascular permeability and hence influence the ability of immune cells to reach the site 
of a bladder infection.  It is also possible that nicotinic receptor signaling could be responsible 
for changes in the permeability of the urothelial barrier following infection, allowing 
macrophages and other inflammatory responders to gain access to the lumen of the bladder in the 
event of a bladder infection. Some bladder pathologies, such as PBS/IC are thought to have an 
inflammatory etiology, therefore the anti-inflammatory properties of nicotinic agents may help 
alleviate the symptoms associated with PBS/IC.  A thought that may be more pertinent to our 
present research however; given the prevalence of nAChRs in epithelial tissues coupled with the 
knowledge that the bladder epithelium can respond to and release ACh as a part of its 
“sensor/transducer” properties, is the potential exists for nAChRs to be expressed in the 
urothelium and play a significant role in urothelial biology. 
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Table 3 - Expression of nAChRs in Non-Neuronal Tissues 
Cell Type Tissue Nicotinic Receptors Expressed 
Epithelial Cells Airway (Human)  
 Surface epithelium α1, α3, α5, α7, α9, β1, β2, β4, δ, ε 
 Alveolar type 2 cells α4, α7, β1, β2 (rhesus monkey) 
 Glands α4 (rhesus monkey) 
 Skin (Human)  
 Keratinocytes α3, α5, α7, α9, α10, β1, β2, β4 
 Pilosebaceous unit α3, α4, α5, α7, α9, α10, β1, β2, β4 
 Sweat glands - Myoepithelial α3, α4, α5, α7 
 Sweat glands - Acinar cells α9, β2 
 Melanocytes α1, α3, α5, α7, β1, β2, γ, δ 
 Intestine   
 Surface epithelium α3 
 Colonic epithelial cell line α4, α5, α7, β1 
 Glands (salivary cells, gastric 
cells, pancreatic acinar cells) 
α2, α3, α4, α5, α7, β2 (beta cell line, rat) 
Endothelial Cells Aorta/pulmonary vessels  
 Human α3, α5, α7, β2, β4 
 Rat α2, α3, α4, α5, α6, α7, α10, β2, β4 
 Mouse α3, α5, α7, β2 (cerebral microvasculature) 
Immune Cells   
 MNLs (Human) α2, α4, α5, α6, α7, α9, α10, β2, β4 (variable expression 
with dominant expression of α2, α5, α7) 
 Eosinophiles (Human) α3, α4, α7 
 Macrophages (Human) α1, α7, α10 
 Macrophages (Mouse) α2, α4, α5, α6, α7, α10, β2, β4 
 DC cells (Mouse) α2, α5, α6, α7, α10, β2, β4 
 Mast cells (Human) α3, α5, α10 
Adapted with permission from Nature Publishing Group / Macmillian Publishers, Ltd. : Wessler and Kirkpatrick, 
British Journal of Pharmacology [217] © 2008. 
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1.4 FINAL THOUGHTS AND GOALS FOR THIS DISSERTATION 
In summary, we have presented significant evidence in support of the probability of nAChR 
signaling in the urothelium.  As mentioned previously, ACh is a major transmitter in a variety of 
locations along the micturition pathway, acting on cholinergic receptors in the brain, spinal cord, 
autonomic ganglia, afferent nerves and smooth muscle.  ACh has been shown to be released 
from the urothelium in response to stretch and chemical stimulation, and can act on muscarinic 
receptors on the urothelium to modulate bladder reflexes, further suggesting a role for non-
neuronal cholinergic signaling in the urothelium.  Therefore, given the role of nicotinic signaling 
in a number of non-neuronal cell types, as well as the proven role of cholinergic modulation of 
bladder reflexes by the urothelium, the following question arises: does the urothelium express 
functional nAChRs that can influence bladder function?   
To date, only a few cursory studies have examined this question.  For example, two 
recent studies have examined the expression of nAChRs in the urothelium, demonstrating that 
the human urothelium expresses the α7, α9 and α10 subunits [218], while the mouse expresses 
the α2, α4, α5, α6, α7, α9 and α10 subunits [219].  However, no study has yet examined if these 
receptors mediate any type of physiological effects, such as modulation of transmitter release or, 
in the whole animal, modulation of bladder reflexes.  As we have discussed, the urothelium can 
respond to a number of chemical and physical stimuli, including acetylcholine, therefore the 
possibility of nAChRs also participating in urothelial signaling is strong.   
Given the established role anti-muscarinics play in lessening the urge to urinate in some 
cases of overactive bladder, the possibility of a second class of cholinergic drugs to treat bladder 
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pathology could have important clinical ramifications, as well.  If urothelial nAChR agents can 
be shown to modulate bladder reflexes, then this research may have uncovered another potential 
target in addition to muscarinic receptors for the treatment of bladder pathologies.  Additionally, 
since muscarinic and nicotinic receptors often interact in tissues where they are co-expressed, it 
is possible that nicotinic receptor agents could be used as an adjunct therapy with anti-muscarinic 
agents; lessening the doses of anti-muscarinics necessary to effect the desired result, while 
diminishing the undesirable side effects commonly caused by anti-muscarinic treatment.  
The following chapters will describe our research into the potential role of nAChRs in 
urothelial signaling by first demonstrating the expression of nAChRs in the urothelium.  We will 
then demonstrate the functionality of these urothelial nAChRs by examining their ability to 
modulate intracellular calcium concentrations and the release of the neurotransmitter ATP.  
Finally, we will examine if stimulation of urothelial nAChRs can alter bladder reflexes in the 
anesthetized rat, as measured by a cystometrogram.  Our research indicates that nicotinic 
receptors are present in the urothelium and that they do play a role modulation of bladder 
reflexes, an effect most likely mediated through intracellular Ca+2 signaling and modulation of 
ATP release from the urothelium.  These results not only further our understanding of the 
urothelium and how it mediates its “sensor/transducer” properties, but could have a significant 
effect on the treatment of bladder disorders, as they demonstrate a pathway capable of 
modulating bladder reflexes in vivo. 
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2.0  EXPRESSION AND DISTRIBUTION OF NICOTINIC ACETYLCHOLINE 
RECEPTORS IN THE URINARY BLADDER EPITHELIUM 
Although nicotinic acetylcholine receptors (nAChRs) in both the central and peripheral nervous 
systems have been shown to play a prominent role in the control of urinary bladder function, 
little is known regarding expression or function of nicotinic receptors in the bladder epithelium, 
or urothelium.  Nicotinic receptors have been described in epithelial cells lining the upper GI 
tract, respiratory tract, and the skin where they are responsible for a number of physiological 
functions such as cell migration, differentiation, homeostasis and intracellular signaling.  
Because recent studies have demonstrated that the urothelium can participate in the control of 
micturition, the urothelium may represent another epithelial tissue in which nAChR signaling 
may play a physiological role.  Thus, as a first step into determining if urothelial nicotinic 
receptors play a role in the bladder, the present study examined the expression and distribution of 
nicotinic receptors in the urothelium.  mRNA for the α3, α5, α7, β3, and β4 nicotinic subunits 
was identified in rat urothelial cells using RT-PCR.  Similar subunits were also found in the cat 
and the human urothelium.  Western blot analysis also supported the presence of nAChR protein 
in urothelial tissue.  We attempted to localize the expression of nAChRs to specific layers of the 
urothelium using fluorescently tagged antibodies or toxins against nAChR subunits and co-
localizing with known urothelial markers.  Our experiments indicate that α3 receptors co-localize 
with cytokeratin 20, a marker for the umbrella cell layer in the urothelium.  Conversely, α7 
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receptors co-localize with both cytokeratin 17 and 20, suggesting that these receptors are 
expressed in all three layers of the urothelium (umbrella, intermediate and basal).  These data, 
which indicate the presence of nAChRs in the urothelium, are the first step in determining if 
nicotinic acetylcholine receptors could play a role in urothelial physiology. 
 
Note: Figures 2.1 and 2.3 and the text describing them have been previously published in the 
American Journal of Physiology [220]© 2005, however permission to reprint is not required 
under the American Physiological Society’s rules for reprinting published material by authors of 
the original manuscript. 
2.1 INTRODUCTION 
The afferent nerves in the urinary bladder respond to a variety of stimuli including distension and 
contraction of the detrusor muscle, as well as noxious chemicals contained in the urine or 
released during infection [1, 2, 6, 7].  Activity in afferent nerves initiates sensations of bladder 
fullness or pain and can also trigger voiding and urine storage reflexes.  Previous studies of 
sensory mechanisms in the bladder, therefore, have primarily focused on the properties of the 
afferent nerves. 
Recently, however, it has been shown that urothelial cells may influence afferent nerve 
activity by expressing “neuronal-like” properties including: 1) release of neurotransmitters (e.g. 
NO and ATP) [55, 61], 2) expression of receptors commonly found in nerves, such as vanilloid 
receptors (TRPV1) [13] and calcium-activated K+ channels (SK channels) [86] and 3) sensitivity 
to neurotransmitters, such as acetylcholine [58, 77], norepinephrine  [61] and ATP [11].  The 
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urothelium may also release acetylcholine in a fashion similar to that already reported for other 
non-neural tissues including pulmonary endothelial cells [221], placental epithelial cells [202, 
222], and bronchial epithelial cells [223], where it acts in an autocrine/paracrine fashion to 
influence cellular functions.  In this context, recent data suggests that urothelial cells may release 
acetylcholine during the filling phase of micturition [16, 89, 92, 93].  Given the established role 
for nicotinic acetylcholine receptors (nAChRs) in the neural control of bladder function [130, 
131], the current study was aimed at determining if nAChRs are also expressed in the 
urothelium. 
 The nicotinic acetylcholine receptor family is currently known to consist of at least 17 
different subunits (α1-10, β1-4, γ, δ, and ε) [140, 141].  These subunits form pentameric channels 
that can be categorized into 2 different groups; neuronal nicotinic receptors (consisting of α2-10 
and β2-4 subunits) and muscle nicotinic receptors (consisting of α1, β1, γ, δ, and ε subunits).  
Neuronal nAChRs can be further classified into 3 groups: 1) homomeric pentamers (such as α7 
or α9), 2) simple heteromeric pentamers consisting of one type of α subunit and one type of β 
subunit in a 2:3 stoichiometry (e.g. α3β2 receptors) and 3) complex heteromeric pentamers 
consisting of three or more different subunits (e.g. α3α5β2 receptors) [137, 138].  Each type of 
receptor has different electrophysiological and pharmacological properties, which have been 
hypothesized to be the basis for the widely varying effects of acetylcholine throughout the 
central and peripheral nervous system [152, 164, 165, 223-226].  The present study detected, in 
the urothelium of the rat, cat and human, mRNA for several nicotinic receptor subunits known to 
form functional receptors.   We also detected protein for α3 and α7 subunits, utilizing western 
blot and fluorescent staining of bladder tissue.  These data are the first step in determining if 
nicotinic receptors can play a role in urothelial signaling, as well as bladder physiology. 
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2.2 RESULTS 
2.2.1 Nicotinic Subunit mRNA Expression in the Urothelium   
As a first step to determining if nAChRs are expressed in the urothelium, we examined the 
expression of nicotinic receptor subunit mRNA in urothelial tissue of the rat, cat and human.  
The following sections summarize these experiments in each species. 
2.2.1.1  nAChR Expression in the Rat 
In order to determine nAChR expression in rat urothelial tissue, the bladder was first removed, 
cut open and pinned into a dish filled with oxygenated KREBS buffer.  The urothelium was then 
gently teased away from the underlying smooth muscle using fine forceps and scissors and the 
RNA extracted.  RT-PCR experiments using this extracted RNA indicated the presence of 
message for α3, α5, α7, β3, and β4 nicotinic receptor subunits in urothelial tissue (Figure 2.1A).   
In the previous experiment, the possibility exists that contaminating tissue such as nerves, 
myofibroblasts or even small amounts of smooth muscle may be present in our samples, 
resulting in false positives.  In order to rule out products amplified by contaminating tissue, we 
also extracted RNA from primary cultures of rat urothelial cells (Please refer to Section A.1.2 for 
details on our urothelial cell culture technique).  Because the media maintaining our cultured 
cells only supports urothelial cells, we can assume that mRNA extracted from these cells, grown 
in culture for 48 hours, would lack contamination from other tissue types.  RT-PCR in cultured 
cells also indicated the presence of α3, α5, α7, β3 and β4 mRNA (results not shown).   
In both urothelial tissue and cultured cells, the observed bands corresponded to expected 
product sizes (see Table 5 for expected product sizes) and results were repeatable in samples 
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from three separate rat bladders or three independent cultures.  We did not detect products for 
α2, α4, and β2 subunits in either urothelial tissue or cultured cells, however these subunits were 
amplified using RNA from rat brain extract (Clontech) as a positive control (results not shown).   
Because extracted mRNA is sometimes contaminated with genomic DNA, which would 
result in a PCR product being amplified in our experiments, a negative control was also 
performed.  This negative control involved the amplification of a housekeeping gene, GAPDH, 
from first-strand reactions of urothelial RNA where reverse transcriptase (RT) was omitted.  If 
contaminating genomic DNA was present in our RNA samples, then a PCR reaction on these RT 
negative samples would have resulted in amplification of GAPDH DNA.  As shown in Figure 
2.1D, GAPDH is amplified in PCR experiments when RT is included in the first strand synthesis 
reaction, but not when it is omitted, indicating that contaminating genomic DNA is not present.  
Finally, in order to rule out the possibility of amplification of an incorrect product through non-
specific binding of our PCR primers, each product’s identity was confirmed through DNA 
sequencing and subsequent matching through a BLAST search.     
2.2.1.2 nAChR mRNA Expression in the Human  
In order to determine if nAChR subunits are expressed in human urothelial tissue, we obtained 
human bladder tissue from deceased organ donors through the University of Pittsburgh’s Center 
for Organ Recovery and Education (CORE).  The urothelium was obtained in the same manner 
as described above for the rat; the bladder was cut open, pinned in a dish containing oxygenated 
KREBS buffer and the urothelium teased away using fine forceps and scissors.  mRNA was 
obtained from three such samples and RT-PCR was performed using subunit specific primers.  
PCR amplified products for nAChR subunits very similar to that found in the rat: α3, α5, α7, β2 
and β4 (Figure 2.1B).   
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To rule out contamination from non-urothelial tissue in our RT-PCR experiments, human 
urothelial cells were also cultured, as described in Section A.1.2.  RT-PCR performed on RNA 
extracted from three independent cultures of human urothelial cells exhibited identical results to 
urothelial tissue: products were observed for α3, α5, α7, β2 and β4 (data not shown).   
As a negative control to determine if our RNA samples from either urothelial tissue or 
cultured human cells contained contaminating genomic DNA, PCR was performed on samples 
where reverse transcriptase was omitted from the first-strand synthesis reaction.  These reactions 
showed no amplification, indicating that no genomic DNA was present (data not shown).  
Unfortunately, we could not obtain control tissues in the human such as brain or dorsal root 
ganglia to use as positive controls.  The specificity of these primer sets, however, have been 
demonstrated by another group [227] in human brain and skeletal muscle, therefore we are 
confident that our negative results are not due to failure of the primers.   Positive results were 
analyzed through DNA sequencing and their identities confirmed through a BLAST search. 
2.2.1.3 nAChR mRNA Expression in the Cat 
In addition to the rat and human, we also examined nAChR expression in the cat.  Cats are often 
used in bladder physiology experiments due to the natural occurrence of a pathological bladder 
condition similar that which affects humans known as interstitial cystitis.  Therefore, information 
into the expression of nicotinic receptors in the cat urothelium may help further research into this 
disease.  Unfortunately, few nAChR subunits have been cloned in the cat, therefore a thorough 
examination of which subunits are expressed by the urothelium is not yet possible.  Primer sets 
do exist for α3, α4, α7 and β2 [228], which we used to determine if these subunits are expressed 
in the cat urothelium.  Urothelial tissue was obtained from three cat bladders in the same manner 
as described above for the rat; bladders were removed, cut open, pinned into a dish containing 
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oxygenated KREBS buffer and the urothelium gently teased away using fine forceps and 
scissors.  RT-PCR performed on RNA extracted from these tissues indicated the presence of α3 
and α7 mRNA, but not α4 and β2 (Figure 2.1C).  Positive controls for α4 and β2 were performed 
in mRNA extracted from dorsal root ganglia (data not shown).  Additionally, controls for 
GAPDH expression in RT negative reactions were also negative, indicating a lack of non-
specific amplification by genomic DNA contamination (data not shown).   
 
 
 
Figure 2.1- Expression of nAChR mRNA in the Urothelium 
(A) Nicotinic acetylcholine subunit expression was detected in urothelial tissue taken from rat bladders.  Notice 
positive results in α3, α5, α7, β3 and β4 lanes.  1.2% agarose gel in 1X TBE buffer stained with ethidium bromide.  
Results are identical from tissue taken from three separate rat bladders.  Numbers indicate the size, in base pairs, of 
the product band.  (B) RT-PCR of human urothelial tissue.  Positive results are present for the α3, α5, α7, β2 and β4 
subunits.  Results are identical from tissue taken from three separate bladders. Numbers indicate the size, in base 
pairs, of the product band. (C)  RT-PCR of cat urothelial tissue.  Proper bands are present for α3 and α7.  Results are 
identical from tissue taken from three bladders.  Numbers indicate the size, in base pairs, of the product band. (D) 
Negative control experiment demonstrating that the housekeeping gene GAPDH fails to amplify when the reverse 
transcriptase (RT) enzyme is omitted from the cDNA synthesis reaction.  This indicates that no genomic DNA 
contamination exists in our samples. 
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2.2.1.4  Quantitative PCR of nAChRs in the Rat Urothelium 
To determine the relative expression levels of the nAChR subunits found in the urothelium, we 
performed real-time quantitative PCR (qPCR) in rat urothelial tissue.  Urothelial tissue was 
removed as described above and the RNA extracted for use in cDNA synthesis.  This cDNA was 
then used as a template, along with the subunit specific primers in SYBR Green based qPCR 
reactions (Bio-Rad, Inc.).   
The field of real-time qPCR is relatively new, and as a result, a number of popular 
methods for analyzing data have emerged, all having specific strengths depending on the 
experimental setup.  Because we are interested in the relative expression of nAChR mRNA as 
compared to each other, we utilized the 2-ΔΔCT method [229] for comparing gene expression 
through normalization to an endogenous control gene.  In our case, β-actin was used as our 
control gene.  This technique will also allow us to express our data relative to the expression of 
one of our target genes, assuming that the efficiencies of amplification between the subunits are 
the same.  The efficiency of amplification was experimentally tested for each subunit and β-actin 
by performing qPCR reactions on 4 serial dilutions (1X-1,000X dilutions) of cDNA and plotting 
CT versus cDNA concentration.  The efficiency of the amplification was then calculated as E= 
10(-1/slope).   All efficiencies (average: 87.4%) were determined to be not significantly different, 
allowing us to use the 2-ΔΔCT method of analyzation.   
We chose to express our data relative to the α5 subunit, as that subunit was expressed at 
the lowest levels.  Therefore the equation used to determine the relative expression of our 
nAChRs was: 
Relative expression = 2-(ΔCT,q – ΔCT,α5) 
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where ΔCT,q is the difference in the threshold cycle between the gene of interest and the 
housekeeping gene (β-actin) and ΔCT,α5 is the difference in the threshold cycle between α5 and 
the housekeeping gene.   
It should be noted, though, that in our experiments the cDNA to be amplified and 
quantified using qPCR is created using general primers consisting of 15 thymine bases (dT15) 
instead of primers specifically designed for each mRNA target.  These oligo(dT)15 primers bind 
to the poly(A) tail present on all mRNA, which allows binding of reverse transcriptase and 
conversion to cDNA.  Use of these primers may have the potential to skew our results, as the 
reverse transcription of each mRNA may not occur with the same efficiency due to such factors 
as length of the transcript or the presence of a complex secondary structure.  This could cause 
incorrect interpretation of our results, as any differences in the measured CT between two targets 
may not be due to differences in their mRNA levels within the cells, but instead be due to 
differences in the efficiency of the reverse transcriptase reaction between the two targets.  This 
could be controlled for by measuring the efficiency of each reverse transcriptase reaction and 
correcting for it in the ΔCT equation (for review, see [230]).  However, our goal for this part of 
our project was to use qPCR to make an educated guess about the subunit composition of the 
nAChRs that may play a significant role in urothelial signaling based on their prevalence in the 
urothelium.  This only requires us to determine a rough estimate of the relative expressions of the 
nAChRs present in the urothelium, not to determine exact figures on the number of copies of 
mRNA present for each nAChR subunit.  Therefore, for the purposes of our experiments the 
efficiency of the reverse transcriptase reactions for each target was assumed to be equal. 
As shown in Figure 2.2, we estimated that the β4 subunit is expressed at the highest 
levels, followed by the α7, α3, β3 and α5 subunits.   These data are consistent with the α7 and 
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α3β4 subunits being expressed at the highest levels, with α3* receptors containing the α5 or β3 
subunits being much less common. 
 
 
Figure 2.2 - Relative Expression of nAChR Subunit mRNA in the Rat Urothelium 
Relative expression of nAChR mRNA in the rat urothelium.  (A) Real-time PCR data from one experiment, showing 
the increase in relative fluorescent units (RFUs) as a function of cycle number.  Each trace is an average of triplicate 
samples prepared identically from the same cDNA (see Appendix for methods).  The dashed line indicates the 
threshold level of fluorescence, as determined by the computer (68.2 RFUs).  The numbers indicated in the legend 
are the cycle number where the signal crossed the threshold (CT). (B) Graph summarizing the relative expression of 
nAChRs.  Levels are expressed in relation to the α5 subunit, which was expressed at the lowest level.  Results 
shown are the average of experiments before from four separate rat bladders.   
 
2.2.2 nAChR Protein Expression in the Rat Urothelium 
While our experiments have indicated the presence of mRNA for nAChRs in the urothelium, 
they do not determine if the actual nicotinic proteins are expressed.  In order to determine if the 
urothelium of the rat expresses nAChR proteins, we utilized both immunoblotting techniques and 
fluorescent labeling of bladder tissue. 
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2.2.2.1 Western Blots of nAChR Subunits in Rat Urothelium 
To determine the distribution of the nAChRs within the urothelium, we first performed 
immunoblots on protein extracted from urothelial tissue.  Tissue was collected as described 
above for PCR, and the extracted proteins run on a SDS-PAGE gel under denaturing conditions.  
Following transfer to a nitrocellulose membrane, we probed for nicotinic receptor subunits using 
commercially available antibodies (Santa Cruz).  We only probed for the α3 and α7 receptors, 
due to the lack of suitable antibodies against the other subunits.  However, given what is known 
about how nAChR subunits combine to form functional receptors, we believe that any functional 
receptors in the urothelium would most likely include either of these two subunits [139].  
Additionally, only rat tissue was examined due to limitations either in antibody selectivity (i.e. 
antibody does not react with cat receptors) or inability to obtain sufficient amounts of tissue 
(such as in the human).   
As shown in Figure 2.3, immunoblotting revealed a major and minor band for both the α3 
and α7 subunits, with no other bands being present in the lane.  These bands migrated to a 
molecular weight of 30 and 35 kDa, respectively.  These bands were consistent with those 
observed with protein extracted from rat dorsal root ganglia, which we used as a positive control 
(data not shown) [164, 231, 232].  Additionally, bands observed from both DRG and 
urothelially-derived protein disappeared when the antibodies were pretreated with the 
appropriate blocking antigen, suggesting that the binding is specific for nAChR subunits. 
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Figure 2.3 - Western Blot of nAChR Subunits in Protein Extracted from Rat Urothelial 
Tissue 
Western blots stained for α3 (left) and α7 (right) nAChR subunits.  Both blots revealed a major band at 30 kDa and a 
minor band at 35 kDa. 
 
 
2.2.2.2 Co-localization of nAChRs with Urothelial-Specific Markers in the Rat Bladder 
Our immunoblots suggest that urothelial tissue expresses nAChR subunit proteins, however they 
do not give us information on where in the urothelium the receptors are expressed.  In order to 
localize each receptor subunit to a particular layer of the urothelium, we performed co-
localization studies in rat bladder tissue with cytokeratins 17 and 20, which are known to be 
differentially expressed in the urothelium of the rat.  Cytokeratin 20 has been shown to be 
expressed in the umbrella cells of the urothelium [233], while cytokeratin 17 localizes to the 
intermediate and basal cells [234].   
In order to localize the α3 subunit within the urothelium, we stained sections of the rat 
bladder with a commercially available antibody (Santa Cruz).  α3 subunits are also prevalent in 
small to medium sized neurons of the rat DRG [232], which we used as a positive control (Figure 
2.4B).  In rat bladder tissue, the α3 subunit stained a layer of tissue consistent with the 
urothelium, as the staining was prevalent in tissue directly adjacent to the lumen of the bladder 
(Figure 2.5A-C).  This staining disappeared if the antibody was pre-incubated with its antigen or 
if only the secondary antibody was used (Figure 2.5D-G).  Co-localization studies with 
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cytokeratin 20 suggested that the α3 receptor is expressed mainly in the umbrella cells (Figure 
2.6A-C), as the two antibodies co-localize almost exclusively.     
To localize the α7 nAChR subunit, a fluorescently tagged (AlexaFluor 488) epitope of 
the neurotoxin α-bungarotoxin (α-BTX) was used instead of an antibody.  This was done because 
commercially available antibodies against α7 receptors have not yet been fully developed and α-
BTX binds α7 receptors with high affinity and high specificity.  Figure 2.4A shows α-BTX 
binding in all small to medium sized DRG cells, confirming earlier research [231] and acting as a 
positive control for our staining.  α-BTX binding in rat bladder sections revealed staining 
consistent with urothelial localization (Figure 2.7A-C), as staining was prevalent in tissue 
surrounding the bladder lumen.  We also observed α-BTX staining consistent with blood vessels 
(Figure 2.7, arrow), in line with earlier reports that α7 receptors are expressed in vascular 
endothelial cells.  α-BTX staining in the rat bladder was diminished when pre-incubated with a 
100-fold higher concentration of unlabelled α-BTX (Figure 2.7D-F).  The intensity of this 
staining was analyzed using image analysis software (Simple PCI, Hamamatsu, Inc., Sewickley, 
PA).  This was accomplished by analyzing the intensity of staining in select regions of interest 
(ROIs) in the urothelium and comparing between tissue stained with fluorescent α-BTX and 
tissue where α-BTX staining was competed off using un-labeled α-BTX.  These ROIs, which 
were carefully selected to be the same size, were corrected by subtracting background 
fluorescence.  Intensities were averaged from three tissue slices for each type of staining and 
compared using a students’ t-test.  Using this method, it was determined that pre-incubation with 
the unlabeled bungarotoxin decreased the intensity of staining 47.3% (p<0.01), suggesting that 
the staining was specific (Figure 2.7 G-I).   
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In order to determine which layers of the urothelium express α7 receptors, we co-stained 
rat bladder sections with α-BTX and cytokeratins -17 and -20.  As shown in Figure 2.8, α-BTX 
staining co-localized with both cytokeratin 17 (Figure 2.8A-C), suggesting α7 expression in 
intermediate and basal cells, and with cytokeratin 20 (Figure 2.8D-F), suggesting α7 expression 
in umbrella cells.   
 
 
Figure 2.4 - Positive Controls for nAChR Receptor Localization 
(A) α7 and (B) α3 nAChR staining in the rat DRG. (C) An overlay of the green and red channels coupled with a 
DAPI nuclear stain to show co-localization.  Note that the majority of small to medium sized cells (cell diameter < 
50µm) are positive for both α7 and α3, while no cells larger than 50µm are labeled, supporting earlier research [231, 
232].  Pictures are a layered merge of a series of 50 images taken with a confocal microscope with a 40X oil 
immersion objective at 0.08 µm intervals along the z-axis (4 µm total depth).  Calibration bar = 50 µM. 
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Figure 2.5 - Expression of the α3 nAChR Subunit in the Rat Bladder 
Photomicrographs depicting α3 staining in the rat bladder.  The left column depicts the FITC labeling of the α3 
subunit, the middle column shows the Cy3 channel as a control and the right column merges the first two with a 
DAPI nuclear stain.  The Cy3 channel is shown to demonstrate that no “bleed through” of the FITC signal occurs, 
which may affect the interpretation of the co-localization experiments shown in the next figure.  (A-C) Staining for 
the α3 subunit depicts labeling of tissue directly adjacent to the lumen (L), consistent with the location of the 
urothelium.  (D-F) Pre-incubation of the antibody with its blocking peptide antigen abolishes the staining.  (G-I) 
secondary antibody (donkey anti-goat FITC) control to demonstrate that the secondary antibody does not bind non-
specifically.  All photos were taken with a 20X oil immersion objective, calibration bars show 50μm.  
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Figure 2.6 – Co-localization of the α3 nAChR with Cytokeratin 20 
Staining for the α3 nAChR subunit and the umbrella cell specific marker cytokeratin 20 in the rat urothelium.  The 
left column depicts FITC labeling of the α3 subunit, the middle column shows Cy3 labeling of cytokeratin 20 and 
the right column overlays the first two with a DAPI nuclear stain.  (A-C) α3 staining co-localizes with cytokeratin in 
the umbrella cells of the urothelium.  Note the presence of the color yellow directly adjacent to the bladder lumen 
(L) in the right hand column, which depicts co-localization of α3 staining with cytokeratin staining.  (D-F) A control 
experiment to demonstrate that the secondary FITC antibody used to visualize the α3 antibody does not non-
specifically bind in the bladder.  Note the lack of signal in (D), indicating that no cross reactivity is present.  All 
pictures were taken with a 20X oil immersion objective, calibration bars show 50μm.   
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Figure 2.7 - α7 Staining in the Rat Bladder 
Photomicrographs showing α-bungarotoxin (α-BTX) binding in the rat bladder.  The left column depicts α-BTX 
binding, the 2nd column shows the Cy3 channel as a control and the 3rd column merges the first two with a DAPI 
nuclear stain.  The Cy3 channel is shown to demonstrate that no “bleed through” of the FITC signal occurs, which 
may affect the interpretation of the co-localization experiments shown in the next figure.  The right column depicts 
an intensity scatterplot of the green (FITC) and blue (DAPI) signals.  (A-D) Staining with α-BTX shows labeling in 
the bladder directly adjacent to the bladder lumen (L), consistent with the location of the urothelium.  Staining is 
also seen in structures consistent with blood vessels (arrow) which have been previously shown to express α7 
receptors [201, 235, 236].  Panel D shows an intensity scatterplot of the green and blue channels; notice the full 
distribution of both channels across the spectrum.  (E-H) Pre-incubation of the tissue with unlabeled α-BTX 
diminishes the staining.  Panel H shows an intensity scatterplot of the green and blue channels; notice the decrease 
in green intensity as compared to D.  (I-L) Control slide where tissue was incubated with unlabeled α-BTX.  Notice 
the lack of signal in I and the decrease in green intensity as measured in L.  All pictures were taken with a 20X oil 
immersion objective at the same shutter speed and light intensity so that differences in staining intensity between 
slices could be measured.  Calibration bars show 50μm.   
L L 
L L 
L 
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Figure 2.8 - α7 Co-localization with Cytokeratins 
Photomicrographs showing α-BTX binding in rat urothelial cells positive for cytokeratins 17 and 20.   The left 
column depicts the FITC labeling of the α7 subunit, the middle column shows the Cy3 staining of cytokeratins 20 or 
17 and the right column merges the first two with a DAPI nuclear stain.  (A-C) Fluorescent α-BTX co-localizes with 
cytokeratin 17 in the intermediate and basal cells of the urothelium, as demonstrated by the yellow staining seen in 
C (arrows).  (D-F) Fluorescent α-BTX co-localizes with cytokeratin 20 in the umbrella cells of the urothelium as 
demonstrated by the yellow staining seen in F (arrows).  (G-I) As a control to determine if the secondary antibody 
used to visualize the cytokeratins (donkey anti-mouse Cy3) exhibits non-specific binding that would cause a 
misinterpretation in co-localization.  As seen in Panel H, staining with the secondary antibody alone results in no 
labeling, indicating that non-specific binding does not occur.  All pictures were taken with a 20X oil immersion 
objective, calibration bars show 50μm.   
 62 
2.2.3 nAChR Expression in Cultured Urothelial Cells 
We have shown evidence of nAChR expression in rat urothelial tissue, however many of the 
experiments we will perform in later chapters of this thesis will utilize cultured urothelial cells to 
study nAChR function and signaling. It is possible that the culturing procedure could alter 
nAChR expression in rat urothelial cells, however, which could influence our results.  Our earlier 
experiments demonstrated that both tissue and cultured urothelial cells from the rat express 
message for the same nAChR subunits, however, we have not yet demonstrated that nicotinic 
proteins are expressed in cultured cells.  Therefore, we stained cultured rat cells (48 hours in 
culture) for the α3 and α7 nAChR subunits, as we did in bladder tissue above.  As shown in 
Figure 2.9, cultured cells expressed both α3 and α7 subunits.  This staining was observed 
throughout all cells in the culture, and was located both cytoplasmically as well as along the cell 
membrane.   
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Figure 2.9 - nAChR Expression in Cultured Rat Urothelial Cells 
Staining for α3 and α7 nAChRs in cultured rat urothelial cells. (A-C) FITC labeling of α7 receptors using α-BTX.  
(D-F) Cy3 labeling of α3 receptors.  In both rows, the left column depicts staining for the nAChR subunit in 
question, the middle column depicts DAPI nuclear staining and the right column shows a merge of the two.  Pictures 
were taken with a 20X oil immersion objective and zoomed 200% to show detail.  Calibration bar denotes 50μm. 
   
2.3 DISCUSSION 
Acetylcholine is an important transmitter in the neural pathways controlling bladder function; 
being responsible for neurotransmission in the brain, spinal cord, autonomic ganglia and detrusor 
smooth muscle [1, 130-134].  The present study raises the possibility of an additional site for 
cholinergic modulation of bladder function.  RT-PCR revealed that urothelium of the rat, cat and 
human expresses the appropriate nicotinic receptor subunits that can interact to generate 
commonly expressed receptors, while immunoblotting and tissue staining indicated that nAChR 
proteins are also expressed in the urothelium of the rat.    
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RT-PCR analyses indicate that there may be more than one type of nicotinic receptor 
present in the urothelium.  While many combinations of the 16 known subunits are possible, 
research in heterologous expression systems has indicated that only a few of these combinations 
actually form functional receptors [136-138, 140].  Possible functional receptors in the rat 
urothelium include α7 homomeric receptors and α3β4, α3β3β4, α3α5β4, and α3α5β3β4 
heteromeric receptors (commonly referred to collectively as α3*) (see Figure 2.10).   
Additionally, recent evidence suggests that α7 subunits may form functional receptors with β 
subunits in heterologous expression systems, such as oocytes, in addition to their homomeric 
form [226].  These atypical receptors, however, have not yet been demonstrated to exist in vivo, 
therefore their contributions to cellular function are not yet known.  Each subtype of receptor has 
specific pharmacological and electrophysiological properties [140, 152, 165, 166, 170, 172, 174] 
that may be responsible for mediating different effects in the bladder.  nAChRs are responsible 
for a number of physiological effects in vivo such as cell motility [237], differentiation [144, 
148], apoptosis [238], adhesion [237], calcium homeostasis [144, 147, 239] and intracellular 
signaling [231, 240].  Therefore it is possible that urothelial nAChRs mediate a number of 
different physiological effects in the bladder.   
We first examined the expression of nicotinic subunit protein through the use of western 
blot.  One concern in our experiments is that the bands we observed migrated consistent with 
sizes of 30 and 35 kDa, while both the α3 and α7 receptor subunits are 50-55 kDa proteins.  This 
may indicate non-specific binding, however two pieces of data suggest that it is not.  First, these 
bands migrate to the same position in our positive control, DRG protein, where both subunits 
have been previously reported.  Secondly, both bands disappear when the antibody is pre-
incubated with its commercially available antigen.  While these results do not definitively prove 
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that the observed bands are indeed nAChR subunits, as the antigen could also block non-specific 
binding, when considered in conjunction with our PCR and tissue staining, we can conclude that 
urothelial cells express nAChRs. 
 
Figure 2.10 - Possible Composition of Urothelial nAChRs 
Cartoon representation of the possible nAChR subunit compositions that might form functional receptors in the 
urothelium.  While many more combinations are possible, only these have been found to form functional receptors 
either in vivo or in heterologous expression systems, such as oocytes.  Note that each of the possible heteromeric 
receptors are grouped into the “α3-containing” category, as these receptors may be functionally different but are so 
far pharmacologically indistinguishable.   
 
 
Why then would the proteins migrate so far from their widely accepted molecular 
weight?  A number of possibilities exist.  First, it is possible that the nAChR subunit protein was 
subject to proteolytic degradation, reducing the apparent size of the protein.  We believe that this 
possibility is unlikely however.  First, a cocktail of protease inhibitors is included when the 
urothelial tissue is homogenized to extract the protein, which should protect against proteolytic 
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degradation.  Additionally, we would expect that proteolytic degradation would result in more 
than two bands on the blot.  
Additionally, though, a smaller protein may indicate the presence of a slice variant of the 
nAChR subunit.  For example, it has been recently shown that a splice variant of the α7 receptor 
exists which arises from an alternate splicing of intron 9 and results in a protein that is missing a 
large intracellular loop and most of transmembrane region four [241].  This results in a protein 
that migrates to approximately 38-42 kDa in a non-SDS polyacrilamide gel.  Given this data, it is 
possible that the nAChR observed with anti-α7 antibodies in urothelially-derived protein samples 
may represent an alternatively spliced version of the receptor.  To determine if this is indeed the 
case, we would need to probe the urothelium for the splice variant, either by in situ hybridization 
experiments using a cRNA probe that would bind to the alternate version of intron 9 or through 
PCR using primers that flank the splice site and would amplify different sized products 
depending on which splice variant was present.  It should be noted however, that these 
experiments would only detect the specific splice variant described by Saragoza, et. al. [241] and 
not any other variants that may exist.  It would also be possible to collect and sequence the 
protein(s) that bind to our antibody through affinity chromatography and determine if they have 
the same sequence as known nAChRs. 
Another question regarding our immunoblots could be raised by the presence of two 
bands for each subunit.  The presence of two bands could mean that our antibody is also binding 
non-specifically.  However, once again, both bands are present in our positive control and 
disappear when the antibodies are pre-incubated with their respective antigen.  While these data 
do not rule out the possibility of non-specific binding, it is also possible that our antibodies are 
binding two forms of the nAChR subunits, possibly the subunit with and without post-
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transcriptional modulation.  Additions of adjuncts, such as glycosylation, myristoylation or 
acetylation could add mass to a finished protein and slow its movement through a gel [242].  
Therefore, the two separate bands may not indicate non-specific binding, but post-translational 
modifications that could alter migration.  To determine if post-translational modifications are 
responsible for this shift, the proteins would need to purified and analyzed through mass 
spectroscopy.   
While some questions remain following immunoblot analysis, our fluorescent binding 
studies in the rat bladder strengthen the argument that urothelial cells express nAChR protein.  
We have demonstrated that staining bladder tissue with an antibody against the α3 receptor 
subunit or a toxin that binds the α7 receptor binds to bladder tissue directly adjacent to the 
lumen, where the urothelium is located.  Both the antibody and the toxin co-localize to tissue that 
is stained by urothelial-specific markers, suggesting urothelial distribution of these nAChRs.  
Taken together with the immunoblot data, then, we are confident that the urothelium expresses 
nAChRs. 
Our research localizes the α3 subunit to the umbrella cells of the urothelium.  These 
studies, however, do not determine which of the possible α3* receptors are actually expressed in 
the urothelium.  Ideally, co-localization studies between α3, α5, β3 and β4 subunits should be 
performed in order to determine the prevalence of each possible receptor combination.  
However, the lack of proper antibodies prevents us from performing these experiments.  Our 
qPCR experiments suggest that the α3β4 receptor is the most prevalent in the rat urothelium, as 
mRNA for the β4 subunit is expressed at much higher levels than the β3 subunit.  Our studies 
also demonstrate that the α5 and β3 subunits are expressed at a much lower level than the others, 
suggesting that receptors containing these subunits may be much less common.  These findings 
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are consistent with the prevalence of nAChR receptors demonstrated in other tissues; α3β4 
receptors are much more common than receptors containing α5 or β3 subunits [139, 152, 243].  It 
should be pointed out though, that we only examined the relative levels of nAChR message, not 
actual protein, which may differ depending on differences in the control of translation for each 
subunit.  Each of these receptors has distinct pharmacological and electrophysiological 
properties, therefore even though α3β4 receptors may greatly outnumber β3 or α5-containing 
receptors in the urothelium; it is possible that each receptor subtype may have important 
physiological roles in urothelial signaling.  We will attempt to determine the physiological 
effects of α3* receptor stimulation in the following chapter of the dissertation. 
Clues to the physiological roles of nAChRs in the urothelium may be deduced by their 
localization in the urothelium.  Given the low permeability of the umbrella cells maintaining the 
urothelial barrier [19, 38, 39, 119], receptors expressed on the apical surface of the umbrella 
cells, as our research indicates both types of receptor are, would likely only be stimulated by 
ACh present in the lumen of the bladder.  nAChRs have been shown to be present on the luminal 
surface of a number of epithelial/endothelial “sacs”, such as bronchial alveoli [244], where ACh 
is released into the lumen as it is in the bladder.  In these other tissues, ACh released by 
epithelial cells acts in an autocrine or paracrine fashion on epithelial nAChRs to promote cell 
adhesion and inhibit apoptosis, maintaining the epithelial layer [245].  It is possible that ACh, 
released into the lumen of the bladder and acting on urothelial nAChRs, also maintains the 
urothelial barrier in a similar fashion.  Additionally, it is possible that urothelial nAChRs play a 
role in the sensor/transducer role of the urothelium.  ACh, as well as norepinephrine and 
bradykinin, cause the release of transmitters such as NO or ATP from cultured urothelial cells 
[58, 61, 63, 77], which are thought to act on afferent nerves to modulate bladder activity [6, 55, 
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66, 67, 97].  As mentioned previously, it is our aim to determine if urothelial nAChRs can 
influence bladder activity in the next chapter of the dissertation.  
α7 receptors are also expressed in the intermediate and basal layers of the urothelium, 
where they could only be stimulated by luminal ACh when the urothelial barrier is disrupted, 
such as after an injury or infection.  Since α7 receptors have been shown to be responsible for 
motility and terminal cell differentiation in stratified squamous epithelial cells [148], it is 
possible that urothelial α7 receptors mediate terminal differentiation of intermediate cells into the 
polarized umbrella cells in order to maintain the urothelial barrier.  Additionally, there exist 
nerves and fibroblasts directly below the urothelium which may also release ACh [10, 25, 98, 
99].  It is possible that these sources of ACh may also be responsible for nAChR signaling in the 
basal urothelium.   
Our research indicates a high level of conservation in the subunits expressed in the 
urothelium throughout the rat, cat and human.  One variance would be the expression of the β2 
subunit in the human over the expression of the β3 subunit in the rat.  It is difficult to say what 
difference this would make physiologically, if any.  In heterologous expression systems such as 
the frog oocyte, replacing the β2 subunit with the β4 subunit alters the rate of desensitization of 
the receptor and the efficacy of the agonists cytisine and ACh [165].  It is unclear whether this 
would alter function of the receptor between the two species, however.   
Other investigators have also examined the expression of nicotinic receptors in the 
urothelium of the human and the rat and found similar results.  Bschleipfer, et. al. [218] 
examined the expression of nAChRs in human urothelial biopsies and found α7, α9 and α10 
receptor expression using RT-PCR.  Other subunits, such as those examined in our study, were 
not studied.  Little is known about the α9 or α10 receptors, as they are infrequently found in vivo.  
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They can form α-BTX-sensitive homomeric channels, like the α7 receptor, but can also form 
heteropentamers with each other (α9α10) [246].  In addition to RT-PCR, Bschleipfer also 
examined α7 expression using immunohistochemistry and found expression throughout the 
urothelial layers of human urothelium, much the same as we found in the rat.   
Additionally, the same group has studied nAChR in the mouse bladder.  RT-PCR and 
immunohistochemical analysis of FVB mice determined that the α2, α4, α5, α6, α7, α9 and α10 
subunits are present in the urothelium [219].  α7 staining in the mouse urothelium was 
comparable to the rat and human (spread throughout the urothelial layers), however the absence 
of the α3 receptor subunit represents a major difference from the other species.  α4 subunits form 
another major subtype of AChR commonly found in neuronal tissue, however localization of the 
α4 subunit in the mouse bladder was confined to the intermediate and basal cells, unlike the 
umbrella localization of the α3 receptor in the rat.  The investigators were unable to determine 
the localization of the α2 or α6 receptor since antibodies for those subunits do not exist as yet, so 
it is possible that one of these subunits may be expressed in the umbrella cells of the mouse.  One 
last complication we must consider in the mouse is strain differences; it is possible that the 
nAChR subunits present in the urothelium may change depending on the strain of mouse used.  
Therefore, the results obtain by the Lips group in FVB mice may not be representative of all 
mouse strains.   
One additional question raised by our research involves what our studies may suggest 
about the phenotype of the cells in our urothelial cultures.  Our research demonstrates that both 
the α3 and α7 receptors subunits are expressed in the umbrella cells of rat bladder tissue as well 
as throughout all cells in our primary culture.  This would suggest that our cultured cells are of 
umbrella cell origin, which would contradict the current dogma concerning urothelial cell 
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culture.  Umbrella cells in the urothelium are terminally differentiated and would, most likely, 
not multiply upon plating.  Indeed, cells cultured in the manner described in our studies lack a 
number of umbrella cell characteristics, such as multi-nucleation (as shown in Figure 2.9) or the 
expression of the umbrella cell marker cytokeratin 20 [77].  This is generally believed to be a 
consequence of plating and growing the cells on plastic or glass dishes; only culturing urothelial 
cells on a porous support would allow them to differentiate into the polarized layer of cells 
characteristic of umbrella cells [247].  A possible explanation then, for the expression of both 
types of nicotinic receptors in these cultured cells could lie in the regulation of nicotinic receptor 
expression following chronic cholinergic stimulation.  Exposure of cultured cells to nicotinic 
agents can cause an up-regulation in the expression of nAChRs [149, 158, 248].  Choline, a 
specific α7 agonist, has also been shown to be a potent growth factor for keratinocytes [249] and 
is included in defined keratinocyte media, such as those we use to maintain urothelial cell 
cultures (at approximately 100µM, personal communication with Invitrogen, Inc.).  It is possible, 
then, that the expression of nAChRs in cultured urothelial cells is driven by chronic stimulation 
of α7 receptors by choline in the cell culture media.  Therefore, while cultured urothelial cells 
may not be derived wholly from umbrella cells, the expression of both types of nAChRs in 
cultured cells allows us to utilize them as a model of umbrella cell signaling in these in vitro 
studies.  It would be interesting, then, to determine what the effect on α3 receptor expression in 
these cultured cells would be if choline was removed from the media, or if α7 stimulation was 
blocked using a subtype specific antagonist.  However, while these experiments could lead to 
interesting advancements in the understanding of urothelial cell proliferation and differentiation, 
they are out of the scope of our current project and will not be studied. 
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Our results are the first indication that the rat urothelium expresses nicotinic 
acetylcholine receptors.  These receptors are differentially expressed throughout the urothelium, 
suggesting that they may play different roles in bladder function.  Further experimentation, 
detailed in the following chapters, will examine the role of urothelial nicotinic receptors in 
bladder physiology and the signaling pathways involved. 
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3.0  FUNCTIONALITY OF UROTHELIAL NICOTINIC RECEPTORS: 
MODULATION OF CALCIUM SIGNALING AND ATP RELEASE 
The experiments outlined in the previous chapter demonstrated that the urothelium 
expresses mRNA and protein for nicotinic receptor subunits consistent with known functional 
receptors.  However, we have not yet demonstrated that the urothelium expresses functional 
nAChRs.  Nicotinic receptors are highly permeable to calcium; therefore we examined the ability 
of nAChRs to increase intracellular calcium using Fura-2.  Our research revealed two types of 
functional nAChR in the urothelium through the use of subtype-specific agonists and 
antagonists; α7 and α3-containing receptors (α3*).  Additionally, our studies indicated that each 
of these receptors influenced intracellular calcium through distinct pathways.  For example, 
stimulation of cultured urothelial cells with cytisine, an α3* receptor agonist, resulted in 
increases in the Fura-2 ratio that were dependent on extracellular calcium, indicating that α3* 
receptor stimulation increased intracellular calcium through flow of extracellular calcium 
through the receptor’s channel.  Stimulation of α7 receptors with choline also resulted in 
increases in the Fura-2 ratio, however these signals were independent of extracellular calcium, 
indicating that α7 receptors mediate a release of Ca+2 from intracellular stores.  In addition to 
modulating intracellular calcium, nAChRs have also been shown to play a significant role in 
modulating transmitter release in a number of cell types, including nerves.  Because of the 
similarities in transmitter release previously demonstrated between nerves and urothelial cells, 
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we also examined the role of nAChRs to modulate the release of ATP from cultured urothelial 
cells.  Stimulation of both types of nAChRs with specific agonists demonstrated that each 
subtype of nAChRs modulates ATP release from urothelial cells, however in different manners.  
α7 receptor stimulation with choline inhibited mechanically-induced ATP release from urothelial 
cells.  α3* receptor stimulation with cytisine, however, revealed a biphasic response, where low 
concentrations of agonist (1-10µM) inhibited mechanically-induced ATP release while larger 
concentrations (50-100µM) increased release.  These effects were all blocked using subtype 
specific antagonists (α7: methyllycaconitine citrate; α3*: TMPH), confirming that each effect 
was due to specific actions by agonists on urothelial nAChRs.  In addition to demonstrating the 
functionality of nAChRs present on urothelial cells, the present research also uncovered evidence 
of cross-modulation between the two types of nAChRs in the urothelium.  Stimulation of 
cultured urothelial cells with α7 agonists such as choline and PNU-282987 prevented both the 
calcium response and ATP release normally elicited by cytisine stimulation.  These effects were 
prevented in the presence of the α7 antagonist MLA, suggesting that stimulation of α7 receptors 
can effectively turn off α3* receptors.  These data demonstrate that urothelial nicotinic receptors 
are functional and can participate in intercellular and intracellular signaling.   
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3.1 INTRODUCTION 
The experiments in the preceding chapter demonstrated that the urothelium of the rat expresses 
mRNA for the α3, α5, α7, β3 and β4 nicotinic subunits, as well as protein for the α3 and α7 
subunits.  As we have discussed, the subunits revealed by RT-PCR in the urothelium have been 
shown to form functional receptors when found in other tissues or when expressed in 
heterologous expression systems such as CHO cells or frog oocytes [139, 140, 250].   However, 
no research has yet demonstrated that the nicotinic receptors expressed in the urothelium join to 
form functional receptors.  Hence, the experiments outlined in this chapter were designed to 
determine if functional nAChRs exist in the urothelium. 
In order to determine the functionality of urothelial nAChRs, we examined the ability of 
nAChR stimulation to influence both intercellular and intracellular signaling through the use of 
two functional assays.  The first of these experiments was intracellular calcium imaging, using 
the calcium sensitive dye, Fura-2AM.  This technique was used due to the fact that nAChR 
receptors are ligand-gated ion channels that are permeable to calcium [174, 175].  nAChRs, 
especially the α7 receptor, have been shown to play an important role in modulating intracellular 
calcium concentrations in a number of cell types, such as nerves [251], skeletal muscle [138] or 
endothelial cells [235].  Indeed, many of the cellular processes modulated by nAChRs, such as 
transmitter release, proliferation or differentiation are dependent on intracellular calcium [144, 
237].  Additionally, calcium plays a significant role in many cellular processes in the urothelium, 
such as ATP release [58], transcription [252], cell-cell communication and differentiation [253].  
Therefore, given the potential for nAChRs to modulate urothelial function through influencing 
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intracellular calcium, we examined the ability of nicotinic agonists to increase intracellular 
calcium.   
To examine the effect of nicotinic receptor stimulation on intracellular calcium, we 
utilized the calcium sensitive dye Fura-2AM.  Fura-2 is a ratiometric fluorescent dye that, in the 
presence of calcium, undergoes a blue-shift in its maximum excitable wavelength (363nm to 
335nm), while its emission spectra remains relatively unchanged (max: 510nm) [254].  This 
molecule is made cell-permeable by the addition of an acetoxymethyl ester, which is cleaved off 
by esterases present inside the cell, sequestering the dye in the cytoplasm, where it can bind with 
intracellular calcium.  During the experiment, cells are excited at 340 and 380nm and the 
emission at 510nm measured.  The ratio of these readings (340/380) is related to the 
concentration of intracellular calcium; as intracellular calcium increases, the ratio increases.  
Using this technique, we examined if nAChR stimulation could lead to increases in intracellular 
calcium in cultured urothelial cells.  We found that the two subtypes of nAChR both increased 
intracellular calcium (indicated by increases in the Fura-2 ratio from control), however through 
different mechanisms.  For example, α3* receptors, when stimulated by the specific agonist 
cytisine, were responsible for increases in the Fura-2 ratio through influx of extracellular calcium 
while α7 receptors, when stimulated by choline, mediated their increase through release from 
intracellular stores.  Nicotinic receptors also modulate calcium in neurons, where they are 
responsible for, among other things, modulation of transmitter release.  For example, both α7 and 
β2-containing receptors (most likely α4β2) are present in neurons of the rat prefrontal cortex, 
where they play a role the release of aspartate [255].  Each nAChR in prefrontal neurons 
modulates the release of aspartate through distinct, calcium-dependent cellular mechanisms.  α7 
receptors modulate aspartate release by increasing intracellular calcium through a ryanodine 
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sensitive pathway and subsequent activation of the ERK1/2 pathway, while β2-containing 
receptors mediated transmitter release by increasing calcium through a coupling to voltage-
operated calcium channels.  Similar signaling has also been shown in hippocampal cells [256-
258], PC12 cells [259], and isolated synaptosomes [260, 261].  Like neurons, urothelial cells can 
also release transmitters, such as ATP [58, 60, 63].  Given the similarities in signaling between 
neurons and urothelial cells (the sensor/transducer properties of the urothelium, as discussed in 
Chapter 1.2.2), and evidence that urothelial nicotinic receptors can also influence intracellular 
calcium through similar cellular mechanisms, we examined if stimulation of nAChRs could 
influence the release of ATP from cultured urothelial cells.   
To study ATP release from urothelial cells, we utilized the luciferin-luciferase assay to 
directly measure ATP levels in the medium supporting cultured urothelial cells.  The luciferin-
luciferase assay is a commonly used technique that utilizes an ATP-dependent chemical reaction 
that naturally occurs in the firefly [262].  Firefly luciferase is an enzyme that catalyzes its 
substrate, luciferin with the help of the co-substrate ATP.  This reaction creates light and is 
responsible for the luminescent glow of fireflies.  Since ATP is used as a co-substrate for this 
reaction, in the presence of large amounts of luciferin and luciferase, the amount of light is 
related to the concentration of ATP present in the assay.  Therefore, this assay is used to give 
sensitive measurements of the concentration of ATP in experimental samples.  For our 
experiments, we used this technique to measure the concentrations of ATP in samples of media 
taken from cultured urothelial cells.  We will demonstrate that cultured urothelial cells, 
maintained in a chamber continuously infused with HBSS buffer releases a consistent baseline 
concentration of ATP, thought to be caused by mechanical stimulation caused by the continuous 
flow of buffer.  This mechanically-evoked release can be modulated by nicotinic receptor 
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stimulation; for example α7 stimulation can decrease basal release of ATP from urothelial cells, 
while ATP release can be either decreased or increased through stimulation of α3* receptors, 
depending on the concentration of agonist.  These data indicate that nAChRs can modulate the 
release of ATP from urothelial cells and therefore nAChRs may play a role in sensor/transducer 
properties of the urothelium.   
 
3.2 RESULTS 
3.2.1 Intracellular Calcium Increases Following α3* Receptor Stimulation are Due to 
Extracellular Calcium Influx 
To determine the functionality of urothelial nAChRs, we examined their ability to influence 
intracellular calcium using the calcium sensitive dye Fura-2.  To setup our experiments, cultured 
urothelial cells were grown on glass coverslips.  After allowing the cells to grow 2 to 3 days in 
vitro, a coverslip was removed from the culture media and placed into a Hanks Balanced Salt 
Solution (HBSS) containing 1µM Fura-2AM for 30 minutes in an incubator (37ºC) to load the 
dye into the cells.  The coverslip was then transferred to an inverted microscope where the cells 
were maintained through a gravity-fed perfusion system containing HBSS (flow rate: 
~2.4ml/min).  To examine the effects of nicotinic receptor stimulation, drug solutions were 
perfused onto the coverslip, also using the gravity-fed perfusion system.  In order to measure 
each transient, each cell in the microscope’s field of view was carefully traced along the outside 
of its plasma membrane and denoted as a region of interest (ROI).  During the experiment, the 
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fluorescence at 510nm was recorded for each ROI when illuminated at 340 and 380nm and the 
ratios (340/380) for each cell were calculated after subtracting the background fluorescence.  
Data was collected at the rate of 1 sample per second.  For each cell, the magnitude of the Fura-2 
signal was measured using the following equation:  
 
((Peak – Baseline) / Baseline) X 100 = % change from baseline 
 
where “Peak” is the Fura-2 ratio taken at the peak of the calcium transient and “Baseline” is an 
average of five samples taken just prior to drug stimulation.  
To examine the functionality of urothelial nAChRs, we first examined the effect of α3* 
stimulation.  Cytisine (1-100μM in HBSS, EC50: 5.6µM), an α3* receptor agonist, caused a 
concentration-dependent increase in the Fura-2 ratio (2.83 ± 0.54%, 9.35 ± 0.65% and 24.46 ± 
0.80% increase over baseline for 1, 10 and 100µM cytisine, respectively; Figure 3.1).  This effect 
lasted approximately 2 minutes before returning to baseline levels.  These cytisine-induced 
calcium transients could be blocked by a 10 minute pre-incubation with the α3* receptor 
antagonist TPMH (30μM in HBSS, 3.74 ± 0.36% increase over baseline), suggesting that the 
previous response was due to specific actions of the agonist on the receptor.  Additionally, 
cytisine-induced calcium transients were blocked when the cells were perfused with calcium-free 
HBSS with 0.5mM EDTA.  These data indicate that the source of the increase in intracellular 
calcium was due to extracellular calcium entering the cell, as opposed to release of calcium from 
intracellular stores.   
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Figure 3.1 - Cytisine Induced Calcium Transients 
A: Representative traces of calcium transients following stimulation with 100μM cytisine alone (solid trace), 
cytisine following pre-incubation with α3* receptor antagonist TMPH (30μM, dashed trace) and cytisine in HBSS 
containing no extracellular calcium (dotted trace).  B: Summary graph depicting the changes in intracellular calcium 
following cytisine stimulation as a percent change in the Fura-2 ratio from baseline (HBSS perfused).  Statistical 
significance was determined using a one-tailed ANOVA with Tukey’s multiple comparison post test.   **p<0.005 
compared to HBSS baseline.  ╪ p<0.05 as compared to 100µM cytisine.  n = 96, 73, 201, 142 & 214 cells, 
respectively. 
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3.2.2 Activation of α7 Receptors Increases Intracellular Calcium Through a Ryanodine 
Sensitive Pathway  
To determine the contribution of α7 receptors to urothelial calcium signaling, cultured rat 
urothelial cells were stimulated with the α7 agonist choline (1-100μM, in HBSS).  While these 
concentrations are in the lower range of the range of concentrations that can activate α7 receptors 
(EC50: ~400µM), these concentrations were chosen in order to eliminate any effect of 
stimulation of muscarinic receptors, which may also be activated by higher concentrations of 
choline (concentrations greater than 100µM).  Additionally, half of these experiments were 
carried out in the presence of 10µM atropine, a general muscarinic receptor antagonist, with no 
significant differences observed (Figure 3.2C).  When choline was applied, a concentration-
dependent increase in the Fura-2 ratio is observed (4.63 ± 0.19%, 14.25 ± 0.69% and 34.1 ± 
3.30% increase over baseline for 1, 10 and 100µM, respectively; Figure 3.2).  This increase 
lasted for 5-7 minutes (Figure 3.2A), and was completely blocked by pre-incubation with the α7-
specific antagonist α-bungarotoxin (1μM in HBSS, 5 minute incubation), indicating a specific 
action on the α7 receptor.  Unlike cytisine, however, removal of extracellular calcium and the 
addition of EDTA to the HBSS did not block the choline-induced signal, suggesting the 
involvement of calcium release from intracellular stores.  Pre-incubation with ryanodine (10μM 
in HBSS, 15 minutes) blocked this response.  This concentration of ryanodine is generally 
accepted to block ryanodine receptor-mediated release of calcium from the ER [263], thus 
indicating a role for ryanodine receptors in choline-induced release (Figure 3.2B). 
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Figure 3.2 - Choline Increases Intracellular Calcium Through a Ryanodine Sensitive 
Pathway 
(A) Representative traces of calcium imaging experiments following stimulation with 10μM choline alone (solid 
trace), choline following pre-incubation with α7 receptor antagonist α-BTX (1μM, dashed trace) and choline in 
HBSS containing no calcium (dotted trace).  (B) Summary graph depicting the changes in intracellular calcium 
following choline stimulation as a percent change in the Fura-2 ratio from baseline (HBSS perfusion).  Statistical 
significance was determined using a one-tailed ANOVA with Tukey’s multiple comparison post test.  **p<0.005 
compared to HBSS baseline.   ╪ p<0.05 as compared to 10µM choline.  n = 104, 117, 75, 113, 115 & 220 cells, 
respectively. (C) Summary graph demonstrating no difference between Fura-2 signals following stimulation of cells 
with 100µM choline alone and 100µM choline in the presence of 10µM atropine.  NS - not statistically significant as 
compared by students’ t-test. n= 42 and 33, respectively. 
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3.2.3 Cross-Modulation of nAChRs in the Urothelium 
In an attempt to confirm the role of α7 nAChRs in the control of urothelial calcium signaling, we 
utilized another selective agonist of α7 receptors, PNU 282987.  PNU 282987 is highly selective 
and potent α7 agonist [264], which would eliminate the need to include atropine in the bath to 
block potential non-selective activation of muscarinic receptors.  However, stimulation of 
cultured urothelial cells with PNU 282987 (10nM - 1µM, in HBSS) elicited no change in the 
Fura-2 ratio (Figure 3.3A).  It was noted that application of PNU 282987, while having no effect 
itself to elicit calcium transients (100nM, 2 minute pre-incubation), blocked any increase in the 
Fura-2 ratio observed following subsequent stimulation with cytisine (100µM, Figure 3.3A).  
This inhibition of the α3*-mediated transient by an α7 receptor agonist was blocked following 
pre-incubation with the α7 antagonist MLA (100µM, Figure 3.3B), but not if the antagonist was 
given after PNU 282987, indicating that the result was not due to actions of PNU 282987 on the 
α3* receptor.  It was also possible to recover the cytisine response if PNU 282987 was washed 
out of the bath for 10 minutes with normal HBSS prior to stimulation with cytisine.   
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Figure 3.3 - Inhibition of Cytisine-Induced Calcium Signals by the α7 Agonist, PNU 282987 
(A) Representative traces of increases in the Fura-2 ratio following either cytisine stimulation alone (100µM, dashed 
line) or cytisine following PNU 282987 (100 nM, solid line).  Drug applications are denoted by the solid lines below 
the traces.  Note that stimulation of cells with PNU 282987 alone elicited no change in the Fura-2 ratio.  (B) 
Summary graph showing the percent change in Fura-2 ratio from baseline (HBSS perfusion) following stimulation 
of cultured urothelial cells with 100μM cytisine alone and following stimulation with various α7 nAChR agents.  
The cytisine induced signal is blocked following stimulation with the α7 agonist PNU 282987 (100nM, 2nd column).  
This block is recoverable after 10 minute wash with HBSS (3rd column) and is prevented if the cells are pre-
incubated with the α7 antagonist methyllycaconitine citrate (MLA, 100μM, 4th column).  The inhibitory effect is not 
blocked, however, if the antagonist is given after the agonist (5th column).  Statistical significance was determined 
using a one-tailed ANOVA with Tukey’s multiple comparison post test.  **p<0.05 compared to 100μM cytisine.  ╪ 
p<0.05 as compared to cytisine after PNU 282987.  n = 201, 166, 131, 66 & 29 cells, respectively. 
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One well-established mechanism to modulate ion channels is through phosphorylation by 
protein kinases.  While phosphorylation of a receptor could lead to either inhibition or 
potentiation, depending on the ion channel, research has indicated that phosphorylation of 
nicotinic receptors accelerates the rate of desensitization, leading to receptor inhibition [265].  
Therefore, we hypothesized that this inhibition of the α3*-mediated response may be due to 
phosphorylation of the α3* receptor.  Nicotinic receptors are commonly phosphorylated by PKC, 
a group of kinases that are expressed ubiquitously throughout the body.  However, no study to 
date has determined if any PKC isoforms are expressed in the urothelium.  Therefore, to examine 
the isoforms of PKC that are expressed in the urothelium, we performed RT-PCR on rat 
urothelial tissue.  As demonstrated in Figure 3.4, mRNA for a number of PKC isoforms are 
expressed in the urothelium, including PKCα, PKCγ, PKCδ, PKCε, PKCλ, and PKCζ.  Another 
kinase known to modulate nAChRs in other tissues is PKA, a cAMP-dependent kinase that may 
also be expressed in the urothelium [266].  To determine if either of these kinases can influence 
α3* nAChR signaling, we examined how pre-incubation of urothelial cells with PKA or PKC 
modulators influenced cytisine-induced calcium transients.   Because PKA and PKC have 
numerous isoforms, which can be differentially expressed depending on tissue type, the agents 
we utilized in these experiments were chosen to be as general as possible, i.e. acting on as many 
isoforms as possible.  Additionally, because protein kinases are present in the cytoplasm of the 
cell, we chose agents that were cell-permeable.   
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Figure 3.4 - Expression of PKC mRNA in the Urothelium 
mRNA for various PKC isoforms are amplified in urothelial tissue using RT-PCR.  Note positive results for the α, γ, 
δ, ε, λ, and ζ isoforms of PKC.  “HK” indicates amplification of the housekeeping gene β-actin. 1.2% agarose gel in 
1X TBE buffer stained with ethidium bromide.  Results are identical from tissue taken from three separate rat 
bladders.  Outside lanes contain a 100 base pair ladder, from 200-800 base pairs, from bottom to top.   
 
 
Incubation for 15 minutes with either of the PKC activators phorbol 12-myristate, 13 
acetate (PMA, 100nM in 0.1% DMSO) or Pseudo RACK1 (20μM, in HBSS) blocked cytisine-
induced Ca+2 signals (79.1% and 83.2% decrease from cytisine alone, respectively; Figure 3.5A).  
These agents had no effect on the Fura-2 ratio by themselves (data not shown).  0.1% DMSO 
was also tested to rule out any vehicle effect on the Fura-2 ratio; no change in signal was 
observed (data not shown).  Similar results were observed when using activators of PKA; 8-
Bromo-cAMP (30μM, in HBSS) or dibutyryl-cAMP (1mM, in HBSS) blocked cytisine-induced 
increases in the Fura-2 ratio (86.4% and 78.0% decrease from cytisine alone, respectively; Figure 
3.5B).  These agents also did not influence the Fura-2 ratio by themselves.  These results suggest 
that α3* receptors can be inhibited by phosphorylation by either PKA or PKC.   
In addition to examining the effects of activating PKA or PKC on cytisine-induced 
calcium transients, we also studied whether inhibiting PKA or PKC could modulate the effects of 
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cytisine stimulation.  Inhibition of PKC using either chelerythrine chloride (1μM in HBSS, 15 
minute pre-incubation) or Ro 32-0432 (1μM, in 0.1% DMSO, 15 minute pre-incubation) 
potentiated the Ca+2 transient observed following cytisine stimulation (Figure 3.5A).  This 
potentiation was evident as an increase in the peak of the calcium response (20.0% and 193% 
increase over cytisine alone, respectively).  Similarly, PKA inhibitors PKI 14-22 (100nM, in 
HBSS) or PKA Inhibitor 6-22 (10μM, in HBSS) also potentiated the cytisine-induced calcium 
signals (54.3% and 64.0%, respectively; Figure 3.5B).  None of the kinases inhibitors had an 
effect on the Fura-2 ratio when given by themselves.  These data, considered along with our 
previous results, indicate that α3* receptors in the urothelium can be modulated through 
phosphorylation by either PKA or PKC.   
While we have demonstrated that activation of PKA or PKC can inhibit α3*-mediated 
calcium transients, we have not yet demonstrated that the inhibition of the α3* receptor by α7 
receptor stimulation is mediated through PKA or PKC.  To determine if this is the case, we 
examined cytisine-induced calcium signals following pre-incubation with both the α7 receptor 
agonist PNU 282987 and inhibitors of either PKA or PKC.  Pre-incubation with either 1μM 
chelerythrine chloride or 100nM PKI 14-22 for 15 minutes reversed the PNU 282987-induced 
block of the cytisine-induced transient (Figure 3.6).  These data suggest that the inhibitory effects 
of PNU 282987 may be due to activation of PKA or PKC and subsequent phosphorylation of the 
α3* receptor.   
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Figure 3.5 - PKA/PKC Modulation of Cytisine Induced Calcium Signals 
(A) Summary graph depicting the magnitude of calcium transients following cytisine stimulation in the presence of 
PKC modulators, expressed as a percent change in the Fura-2 ratio.  **p<0.05 compared to cytisine alone as 
determined by ANOVA with Dunnett’s multiple post test.  n = 201, 118, 52, 60 & 56 cells, respectively.  (B) 
Summary graph depicting the magnitude of calcium transients following cytisine stimulation in the presence of PKA 
modulators, expressed as a change in the Fura-2 ratio.  **p<0.05 compared to cytisine alone as determined by 
ANOVA with Dunnett’s multiple post test.  n = 201, 190, 127, 65 & 74 cells, respectively. 
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Figure 3.6 - α7 Inhibition of α3* Mediated Transients are Mediated Through Activation of 
PKA/PKC 
Summary of the effects of the PKA inhibitor PKI 14-22 or the PKC inhibitor chelerythrine chloride on the PNU 
282987 mediated inhibition of the calcium transients evoked by cytisine.  100nM PNU 282987 blocks increases in 
the Fura-2 ratio following 100µM cytisine (1st column), but pre-incubation of the cells with either PKI 14-22 or 
chelerythrine chloride removes that inhibition.  **p<0.05 as compared to 100µM cytisine by ANOVA with 
Dunnett’s multiple comparison post test. ╪ p<0.05 as compared to 100µM cytisine after PNU 2829787 by ANOVA 
with Dunnett’s multiple post test.  n= 201, 166, 71 & 128 cells, respectively. 
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3.2.4 Activation of α7 Nicotinic Receptors Inhibits Basal ATP Release from Urothelial 
Cells 
In addition to studying the ability of nAChRs to modulate intracellular calcium signals, we also 
examined their ability to modulate ATP release from the urothelium.  Cells were cultured in the 
same manner as for calcium imaging, with cells being plated on glass coverslips.  At the time of 
the experiment, coverslips were removed from the culture media and placed in a plastic dish 
being perfused with HBSS through the use of a peristaltic pump (flow rate: ~0.6 ml/min).  
During the course of the experiment, 100µl samples were taken from the dish and measured for 
ATP concentrations using a luciferin-luciferase kit and a luminometer.   
For our experiments, readings taken during perfusion of HBSS alone were used as 
control.  Perfusion of HBSS caused a small, but measurable amount of ATP release (average 
concentration: 20-40pM), which is thought to be caused by the mechanical stimulation of the 
cells by the flow of perfusion.  This is supported by previous research that indicated that the 
basal release of ATP was increased in urothelial cells from cats suffering from interstitial 
cystitis, which are also hypersensitive to mechanical stimulation [58].   
To determine the role of each nAChR subunit in modulating ATP release from urothelial 
cells, we examined the effects subtype-specific agents had on this mechanically-induced release 
of ATP.  In our experiments, release of ATP could be inhibited in a concentration-dependent 
manner by the α7 agonist choline (Figure 3.7A&B), decreasing the average release of ATP by 
23.6 pM at 1 mM of choline.  To rule out any non-specific effects of choline activating 
muscarinic receptors, atropine (10µM, in HBSS) was included in the bath for these experiments.  
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This decrease in ATP release was prolonged and could only be washed out after 5 minutes of 
HBSS perfusion.   
To rule out any possibility of choline interfering with the luciferin-luciferase assay being 
the cause of the decreased signal, we performed a standard curve with known concentrations of 
ATP, both in the presence of and in the absence of choline (Figure 3.7D).  These standard curves 
were identical, indicating that choline does not interfere with the assay.  Additionally, the 
possibility exists that the decreases observed following choline perfusion is due to another 
phenomenon, such as cell death or depletion of ATP stores over the course of the experiment.  
To control for this, we continuously perfused HBSS over cultured cells for 30 minutes to 
determine if any decrease in basal ATP release was observed.  As shown in Figure 3.7B, ATP 
concentrations were maintained throughout the length of the experiment, indicating that the 
decreases in ATP release we observe during choline perfusion are not due to cell death or 
depletion of ATP stores. 
To further determine if this decrease in ATP following choline was due to activation of 
α7 receptors, we attempted to block the effects of choline using the α7 antagonist MLA (100µM, 
in HBSS).  MLA successfully blocked the effects of choline, but also increased basal ATP 
release by itself (Figure 3.7C).  This may indicate that α7 receptors are tonically active.  MLA 
also did not alter the standard curve, indicating that the increase in ATP release was not due to 
interference with the assay (Figure 3.7D). 
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Figure 3.7 - Choline Inhibits ATP Release from Urothelial Cells 
(A) Representative trace of choline’s effect on ATP release from cultured urothelial cells.  (B)  Summary of ATP 
experiments involving choline, expressed as a change in the concentration of ATP measured.  These changes were 
calculated in each experiment as the difference between the average of 5 readings taken prior to and during choline 
perfusion.  Each column summarizes the changes in 6 experiments, taken from 3 separate cultures.  To control for 
the possibility of cell death or depletion of ATP stores causing a decrease in ATP concentrations over the course of 
the experiment, normal HBSS was perfused over cultured cells instead of choline (first column) in 6 experiments.  
** p<0.05 by one-way ANOVA followed by a Dunnett’s post-test to compare each column to the control (HBSS 
alone).  (C) Effects of the α7 antagonist MLA on ATP release from urothelial cells.  **p<0.05 as compared by 
unpaired Students’ t-test.  (D) Log-Log plot of ATP standard curves performed either in HBSS alone (black 
squares), or in the presence of 100µM choline (red circles) or 100µM MLA (green diamonds).  Dotted lines indicate 
a linear regression of the measured concentrations. 
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3.2.5 α3* Stimulation Bi-phasically Modulates ATP Release from Cultured Urothelial 
Cells 
To determine the role α3* receptors play in the control of ATP release from urothelial cells, we 
examined the effects of cytisine, an α3* specific agonist, in our experimental setup.  To 
determine if cytisine could interfere with the luciferin-luciferase assay, we first performed a 
standard curve with known amounts of ATP both with and without cytisine.  As shown in Figure 
3.8E, there was no difference in the standard curves, indicating that cytisine has no effect on the 
luciferin-luciferase assay.   
Cytisine stimulation of cultured urothelial cells caused a bi-phasic response in ATP 
release.  For example, basal release of ATP is diminished when low concentrations of cytisine 
(1-10μM in HBSS, Figure 3.8A&C) are perfused over cultured cells, much in the same manner 
as observed following choline stimulation.  This decrease in the release of ATP (decreases from 
control of 4.8 pM for 1µM cytisine, and 7.8 pM for 10µM cytisine) is sustained for the length of 
drug application, but returns immediately following washout with HBSS, unlike the prolonged 
decrease observed following choline (Figure 3.8A).  However, when higher concentrations of 
cytisine are perfused (50-100μM, in HBSS), ATP release increases above that during HBSS 
perfusion alone (Figure 3.8B&C). This effect (an increase over control of 18.4 pM during 
perfusion of 100µM cytisine) is also maintained for the duration of drug application and washes 
off when the perfusate is switched back to normal HBSS (Figure 3.8B).     
To determine if the cytisine-induced effects were due to actions on α3* receptors and not 
through non-specific effects, we attempted to block the effects of cytisine with the α3* 
antagonist TMPH.  Perfusion of the α3* antagonist TMPH (90μM, in HBSS) had no effect on 
ATP release by itself, but did block the response to cytisine at both high and low concentrations 
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(Figure 3.8D).  Because both aspects of the biphasic response are blocked by the antagonist, our 
data suggests that both the decrease in ATP release at low concentration of agonist and the 
increase at high concentrations are due to activation of the α3* receptor.  We will discuss 
possible mechanisms of this biphasic response in Section 3.3. 
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Figure 3.8 - Cytisine Effects on ATP Release from Urothelial Cells 
(From proceeding page) (A&B) Representative trace of ATP release from urothelial cells in response to 10µM (A) 
or 100µM (B) cytisine.  (C) Summary of cytisine’s effects on ATP release from cultured urothelial cells.  These 
changes were calculated in each experiment as the difference between the average of 5 readings taken prior to and 
during choline perfusion.  Each column summarizes the changes in 6 experiments, taken from 3 separate cultures.  
** p<0.05 by one-way ANOVA followed by a Dunnett’s post-test to compare each column to the control (HBSS 
alone).  (D) Summary of the effects of the α3* antagonist TMPH on ATP release from cultured urothelial cells.  
**p<0.05 as compared by unpaired Students’ t-test.  (E) Log-Log plot of ATP standard curves performed either in 
HBSS alone (black squares), or in the presence of 100µM cytisine (blue triangles).  Dotted lines indicate a linear 
regression of the measured concentrations. 
 
 
3.2.6 α7 Stimulation Also Inhibits Cytisine-Induced ATP Release 
Because stimulation of α7 receptors can block cytisine-induced calcium signals, we also 
examined if α7 stimulation could inhibit cytisine-induced ATP release.  ATP release from 
urothelial cells is a calcium-dependent process [58], therefore the possibility exists that a 
treatment that can block calcium signals in response to an agonist may also block ATP release 
mediated by that agonist.  As shown in Figure 3.9, pre-incubation of cultured cells with 100µM 
choline for 5 minutes resulted an inhibition in the release of ATP previously shown to be 
stimulated by 100µM of cytisine.  Specifically, stimulation of cultured cells with 100µM of 
cytisine decreased ATP release 0.95 pM from control when perfused following choline 
pretreatment, as compared to increasing ATP release 18.4 pM from control when perfused alone. 
These data, in conjunction with our earlier data demonstrating an inhibition of cytisine-
induced calcium signals by α7 stimulation, suggest that the two types of may interact to 
influence urothelial signaling.  We will further discuss what the implications of these findings 
might be in the next section. 
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Figure 3.9 - α7 Stimulation Blocks ATP Release Evoked by α3* Stimulation 
Summary of ATP release following cytisine stimulation or cytisine stimulation following choline stimulation.  These 
changes were calculated in each experiment as the difference between the average of 5 readings taken prior to and 
during choline perfusion.  Each column summarizes the changes in 6 experiments, taken from 3 separate cultures.  
**p<0.05 as compared by Students’ t-test. 
3.3 DISCUSSION 
Our research indicates that both types of urothelial nAChRs can modulate intracellular 
calcium concentrations; however they mediate these effects through distinct mechanisms.  
Cytisine-induced increases in [Ca+2]i are dependent on extracellular calcium, indicating a influx 
of Ca+2 ions from outside of the cell.  Conversely, choline-induced [Ca+2]i increases are 
insensitive to extracellular calcium levels, indicating that the α7 receptor mediates its effect 
through the release of calcium from intracellular stores.  This separation of nAChR signaling 
between two distinct calcium pools may be the basis for the observed effects of nAChR agents 
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on the release of ATP from urothelial cells. In this section, we will discuss possible mechanisms 
for nAChR modulation of ATP and how nAChR-mediated calcium transients may play a role in 
this modulation. 
3.3.1 nAChR Mediated Calcium Transients 
Our experiments have demonstrated that stimulation of cultured urothelial cells with nicotinic 
agonists produce calcium transients, however through distinct mechanisms.  For example, 
stimulation of α3* receptors with cytisine induced a calcium transient that was dependent on 
extracellular calcium.  This data suggests that the mechanism underlying this calcium transient is 
the opening of the ion channel, allowing calcium to enter the cell from the extracellular space.  It 
should be noted however, that nAChRs, such as α3* and α4*, have been known to modulate 
voltage operated calcium channels (VOCCs).  Therefore the calcium transients we observe may 
not be mediated fully by influx of calcium through the nicotinic ion channel, but through the 
activation of VOCCs and subsequent influx of calcium through those channels.  There is some 
evidence that urothelial cells may express VOCCs, as urothelial nitric oxide release in response 
to β-adrenergic stimulation is decreased following incubation with the calcium channel blocker 
nifedipine [61].  However, it should be noted that urothelial cells are not electrically excitable, 
therefore it is unclear what role, if any VOCCs, or their modulation by nAChRs might play.   
In contrast to α3* receptors, α7 receptor stimulation causes a calcium transient that is 
completely dependent on extracellular calcium, suggesting a release of calcium from intracellular 
stores.  This is an interesting result, as α7 receptors are widely recognized as being highly 
permeable to calcium, demonstrating a permeability ratio of almost 10:1 as compared to other 
cations (Na+, Mg+2) [267].  Given the receptor’s high permeability to Ca+2, it is strange to find 
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that urothelial α7 signals do not seem to be mediated by influx of extracellular Ca+2.  It is 
possible that the calcium transients we observe following α7 receptor stimulation are mediated 
through current-independent mechanisms.  For example, it has been shown that primary cultures 
of rat brain microglia also demonstrate α7-mediated Ca+2 signals that are independent of 
extracellular calcium concentrations [240].  It appears as though these receptors couple to IP3 
production, possibly through direct activation of PLC, which in turn activates IP3 receptors on 
the ER to release calcium from stores.   Our research does not indicate a role for the IP3 receptor 
pathway, instead indicating a role for ryanodine receptors; however it is possible that 
desensitized nAChRs may also influence this pathway through unknown mediators.  It has been 
hypothesized that the VOCCs may couple directly to ryanodine receptors present on the ER, with 
direct interactions between the receptors causing activation of ryanodine receptors [268, 269].  
Therefore, a similar coupling between nAChRs and ryanodine receptors may play a role in the 
α7 mediated transients we observe in urothelial cells.   
Because our choline-induced calcium transients appear to be completely independent of 
extracellular calcium, we must also address the possibility that the results we observe are due to 
non-specific actions of choline.  Choline can also activate muscarinic receptors, which have been 
shown to increase intracellular calcium through release from intracellular stores [270].  This 
raises the possibility that the calcium transients we observe following choline stimulation are due 
to muscarinic stimulation, not nicotinic stimulation.  There are a number of reasons, however, 
that support nicotinic-specific actions of choline in our experiments.  To begin, the 
concentrations of choline we use in our studies are 100-10,000 times lower than the EC50 of 
choline on muscarinic receptors (for example, the EC50 of choline on the M1 receptor is 
approximately 10mM [271]).  Therefore we would expect that any effect of choline stimulation 
 100 
of muscarinic receptors to be small.  Second, the calcium transients observed following choline 
stimulation are completely blocked by α-bungarotoxin.  α-BTX is an α7 specific antagonist and 
has no known actions on muscarinic receptors.  Therefore, if choline was acting on muscarinic 
receptors, we would expect to observe an α-BTX resistant calcium transient in response to 
choline.  The absence of such a transient suggests that choline’s effect is mediated through 
nicotinic receptors.  Lastly, in half of our experiments 10µM atropine was included in the bath 
when stimulating with choline.  Atropine is a general muscarinic antagonist with low nanomolar 
affinities for each muscarinic receptor subtype [272].  Since no difference was observed between 
choline-induced transients in the presence of atropine and those in the absence of atropine, we 
can conclude that the effects we observe following choline stimulation are due wholly to actions 
on the α7 receptor.   
3.3.2 nAChR Modulation of ATP Release 
We have also demonstrated that nAChRs play a role in the modulation of the release of ATP 
from urothelial cells.  Again, it appears that the two separate subtypes of nAChR modulate ATP 
release in distinct manners, which may be linked to their effects on intracellular calcium.    
For example, our results indicate that stimulation of α7 receptors inhibits ATP release 
from urothelial cells and releases Ca+2 from ryanodine sensitive stores.  Increases in intracellular 
calcium concentrations are generally believed to have an excitatory effect on transmitter release.  
However, it has also been demonstrated that release of intracellular calcium from ryanodine 
sensitive stores can inhibit quantal release at the neuromuscular junction through inhibition of 
calcium permeable ion channels [273].  What might be the mechanism behind this phenomenon?  
One possible mechanism may be depletion of the ryanodine sensitive stores.  In feline urothelial 
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cells, depletion of intracellular stores using caffeine, or through a long-term application of low 
concentrations of ryanodine, resulted in a significant decrease in ATP released in response to 
hypotonic stretch [58].  Therefore, it could be possible that release of calcium from ryanodine 
sensitive stores drives transmitter release in urothelial cells and depletion of these stores could 
inhibit transmitter release.   
 In contrast to the effects of α7 stimulation, stimulation of α3* receptors with cytisine 
demonstrate a bi-phasic modulation of ATP release.  Specifically, low concentrations of cytisine 
inhibit basal ATP release, while higher concentrations increase basal release.  The mechanism 
for this bi-phasic response may also be mediated, in part by the calcium transients evoked by α3* 
stimulation.  For example, when α3* receptors were stimulated with larger concentrations of 
cytisine, intracellular calcium levels increased.  This is consistent with the nAChR signals 
observed in peripheral afferent nerves, which also express α3* type nAChRs [175].  In nerves, an 
increase in calcium is coupled to a release of transmitters from vesicles, such as GABA or 
dopamine [143, 274].  In urothelial cells and other non-neuronal cells, ATP release is also 
calcium sensitive [58, 59], indicating that, similar to the mechanism in nerves, urothelial 
transmitter release may be vesicular.  Therefore, it is possible that ATP release can be influenced 
in urothelial cells through modulation of intracellular calcium levels by nAChRs.   
In addition to evoking ATP release at higher concentrations, stimulation of cultured 
urothelial cells with lower concentrations of cytisine inhibited ATP release.  It is interesting to 
note that this inhibition occurs at concentrations of cytisine that evoke very small calcium 
transients, suggesting that calcium may not play a role in the inhibitory phase of α3* stimulation.  
One possible mechanism that could explain this bi-phasic response could involve actions by 
desensitized nAChRs.  Current research into heteromeric nAChRs have suggested a two-agonist 
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binding model, in which the receptor can enter the desensitized state from either the open, 
activated state or the closed, inactive state [138].  In this model, each binding site has a different 
affinity for agonists, and binding of an agonist to the higher affinity site (with binding constants 
in the nanomolar range) can force the receptor directly into a closed, inactive state without 
opening the receptor channel.  Therefore, with this model, it is possible for nAChRs, in the 
presence of low concentrations of agonist, to stabilize in a desensitized state without first being 
activated.    While it is generally accepted that a desensitized receptor is “turned off” and does 
not participate in cellular signaling, it has become clear through recent research that the 
desensitized state is a functional state for nAChRs that can mediate a number of cellular 
processes such as transcription, transmitter release and cross modulation of other transmitters.  
For example, chronic treatment of rats with nanomolar concentrations of nicotine, which have 
been shown to cause receptor desensitization, results in an increase in dopamine and glutamate 
release [185, 275] in the brain and increased expression of receptors such as the D1 dopamine 
receptor and the NMDA receptor [145].  Intracellular signaling proteins like PKA, PKC, 
MAPK1, and p38 are also increased by chronic treatment with nicotine [276, 277].  Finally, 
chronic application of nicotine increased the affinity of oxotremorine to muscarinic receptors 
[278], indicating that desensitized nAChRs can modulate muscarinic receptor binding.   
Given this data, it seems possible that desensitized nAChRs may be responsible for the 
biphasic response in ATP release that we observe in our experiments.  Desensitized α3* 
receptors could activate an intracellular pathway that can, in turn, inhibit the pathway responsible 
for mechanically evoked ATP release.  While the pathway responsible for ATP release in 
urothelial cells has not yet been elucidated, one possible target is TRPV1.  Both basal release and 
stretch evoked release were diminished in TRPV1 knockout mice, suggesting that TRPV1 
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activation is required for mechanically evoked ATP release.  nAChRs have also been shown to 
inhibit TRPV1 currents in DRG neurons [175], further suggesting that the inhibition of ATP 
release in the urothelium by nAChR stimulation may be due to inhibition of the TRPV1 receptor.  
A number of chemical mediators can also influence ATP release from urothelial cells though, so 
it should be noted that nicotinic modulation of TRPV1 is just one possible mechanism.   
It is interesting to note that MLA, our α7 antagonist, has an excitatory effect on ATP 
release.  This might suggest that the inhibitory α7 receptor was being tonically activated, 
resulting in a reduced basal release of ATP until blocked by the antagonist.  In addition to ATP, 
the urothelium also releases ACh in response to mechanical stimuli [93], therefore it is possible 
that nicotinic receptors on our cultured urothelial cells are being tonically activated in an 
autocrine/paracrine manner by urothelially released ACh.  While this might indicate that the 
increased ATP release following MLA perfusion could be due to a block of the tonically 
activated inhibitory α7 pathway, leading to excitation, another phenomenon may play a role in 
the observed effects.  MLA is a competitive antagonist to the α7 receptor, competing for the ACh 
binding site of the receptor.  Therefore, when MLA is present, there would be increased ACh 
available in the bath, as ACh would be prevented from binding to the α7 receptor.  This, in turn, 
could lead to increased activation of α3* receptors on the urothelial cells, resulting in increased 
ATP release.  If this were the case, we would expect that an α3* antagonist such as TMPH, 
applied concurrently, would block the increase in ATP release observed during MLA perfusion. 
Additionally, we would expect that a non-competitive α7 antagonist, such as α-BTX, would not 
result in an increase in ATP release, since the non-competitive nature of the antagonist would not 
result in an increase in available ACh.  It is also interesting to note that TMPH does not cause an 
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inhibitory effect; TMPH is a non-competitive inhibitor and also would not cause an increase in 
available ACh to act on α7 receptors.   
3.3.3 Interactions Between Urothelial nAChRs 
The most interesting conclusion that can be made following the experiments presented in this 
chapter is the inhibition of the α3* mediated effects following stimulation of α7 receptors.  Both 
cytisine induced calcium transients and ATP release are blocked when cells are previously 
stimulated with α7 agonists, such as PNU 282987 or choline.  This is an interaction that has not 
been previously described; therefore the potential implications for nicotinic receptor research 
may be substantial.   
It is unclear what the full mechanism for this cross-modulation might be, however our 
research indicates that it involves PKA and PKC, presumably through phosphorylation of the 
α3* receptor.  While we do not definitively demonstrate that α7 receptor activation results in the 
activation of either PKA or PKC, it is clear that inhibition of either kinase prevents the inhibition 
mediated through α7 receptor stimulation.  This suggests a pathway where protein kinases are 
activated through α7 receptor stimulation, which in turn phosphorylate and inactivate α3* 
receptors.   
It should be noted that activation of α7 receptors with PNU 282987 inhibited the cytisine 
induced calcium transient, however PNU 282987 elicited no calcium transient by itself.  This 
suggests that the activation of PKA/PKC is a calcium independent process.  It has been 
demonstrated that stimulation of α7 receptors can lead to the activation of PLC, which could, in 
turn activate calcium independent isoforms of PKC through the production of DAG [240].   Our 
RT-PCR experiments suggest that a number of these calcium-independent isoforms of PKC exist 
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in the urothelium, such as the δ and ε isoforms.  Considered together, it is therefore possible that 
the inhibition of α3* receptors by α7 receptor stimulation is calcium independent and modulated 
through these novel PKC isoforms.     
3.3.4 Influence of Urothelial nAChRs on Bladder Physiology? 
We have demonstrated that stimulation of nAChRs present on urothelial cells can 
modulate ATP release, but what effect might this modulation have on bladder physiology?  ATP 
has been demonstrated to be an excitatory transmitter in the bladder; ATP can increase afferent 
excitability and the purinergic antagonist PPADS can decrease afferent excitability.  Given the 
excitatory nature of ATP on afferent nerves and bladder reflexes, we can hypothesize what 
effects nAChR stimulation might have on bladder reflexes in vivo.  α7 receptor stimulation has 
been shown to decrease ATP release from the urothelium, therefore we would expect activation 
of urothelial α7 receptors in vivo would inhibit bladder reflexes, as afferent excitability would 
decrease.  Conversely, we would expect that stimulation of α3* receptors with large 
concentrations of cytisine (above 50 µM) would result in increased bladder activity, as increased 
ATP release would sensitize afferent nerves.  We might also expect that lower concentrations of 
cytisine may inhibit bladder reflexes, as concentrations below 10µM decreased ATP release.  In 
order to determine if our hypotheses are correct, we will have to perform in vivo experiments; 
stimulating urothelial receptors through intravesical administration of nicotinic agents and 
examining the effects the drugs have on bladder reflexes.  In the next chapter, we will perform 
these experiments, utilizing a technique known as the bladder cystometrogram to examine the 
effects of urothelial nAChR stimulation of bladder reflexes of the anesthetized rat. 
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4.0  MODULATION OF BLADDER REFLEXES IN THE ANESTHETIZED RAT 
THROUGH STIMULATION OF UROTHELIAL NICOTINIC RECEPTORS 
Our previous research has demonstrated that the urothelium expresses nicotinic receptor subunits 
and that those subunits can form functional receptors capable of increasing intracellular calcium 
and modulating ATP release.  Given the hypothesized role of urothelially-released ATP to 
sensitize bladder afferent nerves, our data suggests that urothelial nAChRs may be able to 
influence bladder activity.  A number of other urothelial receptors, such as muscarinic or 
bradykinin receptors, have been previously shown to modulate bladder activity in rats, 
supporting this hypothesis.  Therefore the present study was undertaken to measure the influence 
nAChR stimulation can have on bladder reflexes.  Intravesical administration of nicotine (50nM 
& 1µM) resulted in an increase in the interval between bladder contractions (also known as the 
intercontraction interval, or ICI); indicating an inhibition of bladder reflexes.  Further research 
with subtype selective agonists and antagonists, however, revealed the presence of two distinct, 
opposing effects of nAChRs on bladder reflexes.  For example, stimulation of α7 receptors by 
intravesical infusion of choline resulted in a concentration-dependant inhibition of bladder 
reflexes.  Additionally, the α7 selective antagonist methyllycaconitine citrate completely blocked 
the nicotine-induced inhibition of bladder reflexes.  These data suggest that urothelial α7 
nicotinic receptors mediate an inhibitory pathway in the bladder.  Conversely, stimulation of α3* 
receptors, using intravesical cytisine, excited bladder reflexes, while inhibition of α3* receptors 
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using hexamethonium caused an inhibition of bladder reflexes.  This suggests that α3* receptors 
in the urothelium mediate an excitatory bladder pathway.  Further experimentation indicated that 
our results were due to actions of our drugs on urothelial receptors and not direct actions on 
those located deeper in the bladder wall.  These data indicate that urothelial nAChRs may play a 
role in bladder physiology, possibly by controlling the release of neurotransmitters such as ATP 
that can ultimately influence bladder afferent excitability.  Given the observed ability of nicotinic 
agents to modify bladder activity, our research may indicate a role for nAChRs as novel 
pharmacological targets to treat bladder pathophysiology.  
 
Note: All figures in the following chapter, excepting Figure 4.5, and the text describing them 
have been previously published in the American Journal of Physiology [220]© 2005, however 
permission to reprint is not required under the American Physiological Society’s rules for 
reprinting published material by authors of the original manuscript. 
 
4.1 INTRODUCTION 
Our earlier experiments have demonstrated that the urothelium of the rat, cat and human express 
the proper subunits to form proper nicotinic acetylcholine receptors.  At least some of these 
receptors are functional, as stimulation of urothelial cells with nicotine causes increases in 
intracellular calcium and can also modulate urothelial ATP release.   
As we have described previously in Chapter 1.2.2, the urothelium is thought to participate 
in the control of the urinary bladder through the release of transmitters in response to physical or 
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chemical stretch [10, 12, 13].  We have already demonstrated that ATP is released from the 
urothelium, however, another transmitter released by stretch of the urothelium is acetylcholine 
[16, 92, 93], the endogenous ligand for the nicotinic receptor.  Given this proximity in location 
between nAChRs and their endogenous ligand, the possibility exists that urothelial nAChRs can 
be activated by urothelially-released ACh in an autocrine/paracrine manner.  These 
autocrine/paracrine actions on nAChRs have the potential to influence bladder activity.  
Stimulation of other urothelial receptors, such as TRPV1, bradykinin or muscarinic receptors, 
have demonstrated that stimulation of the urothelium can results in the modulation of bladder 
reflexes [60, 63-65].  Additionally, we have already demonstrated that stimulation of urothelial 
cells with nicotinic agents can modulate the release of ATP, and it is thought that urothelially-
released ATP can influence bladder afferent nerves to influence bladder activity.  Given this 
data, the potential exists that urothelial nAChRs can modulate bladder activity; therefore, we 
examined how nicotinic stimulation of the urothelium influenced bladder reflexes. 
In order to accomplish this, we examined the effects of subtype specific agonists and 
antagonists on bladder reflexes in the anesthetized rat, utilizing a technique known as the bladder 
cystometrogram (CMG).  During a CMG, a saline solution is slowly and continuously infused 
into the bladder, mimicking physiological filling by the kidneys, while the pressure in the 
bladder is measured by a transducer (Figure 4.1) [279].  While many different parameters can be 
recorded using the CMG (such as voiding pressure and smooth muscle compliance), the main 
parameter important for the studies we will present is the “intercontraction interval” (ICI), which 
is a measure of the interval between voiding contractions.  Changes in ICI during an experiment 
are generally regarded as indicative of a modulation in afferent excitability.  This follows the 
idea that, in an anesthetized rat, micturition is initiated when the bladder becomes “full”, i.e. the 
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volume of liquid in the bladder causes sufficient stretch to activate the spinobulbospinal reflex 
and initiate micturition.  Because the infusion rate of saline into the bladder during the 
experiment is held constant at 0.04 ml/min, bladder contractions occur at regular intervals 
(normally every 8-10 minutes, depending on bladder size).  Any increase or decrease in this 
interval following a drug treatment must then represent a shift in afferent excitability, shifting the 
threshold volume/pressure required to initiate micturition, resulting in either excitement or 
inhibition of the bladder reflex.  During intravesical administration of drugs, this modulation of 
afferent excitability is thought to be mediated through urothelial signaling as we have previously 
described, i.e. activation of receptors on the urothelium resulting in the release of transmitters to 
influence underlying afferent nerves [10].   
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Figure 4.1- Cystometrogram Setup and Analysis 
(A) The experimental setup for a cystometry experiment.  The bladder of the animal (which is, for our experiments, 
an anesthetized rat) is attached to a syringe pump and a pressure transducer by way of a three-way stopcock.  During 
the experiment, the bladder is filled slowly by the syringe pump (at a rate of 0.04 ml/min) and the pressure in the 
bladder is measured by the transducer.  These readings are recorded for future analyzation through the use of a chart 
recorder or a data acquisition system run by a computer.  (B) A sample cystometric recording, depicting two 
consecutive bladder contractions.  Bladder pressure is measured in cm of H2O (y-axis) over time (in seconds, x-
axis).  Common cystometric parameters are defined, such as pressure threshold, peak pressure or intercontraction 
interval (ICI).   
 
In the following study, we will demonstrate that intravesical administration of nicotinic 
agents specific to the two types of urothelial nAChR can modulate bladder reflexes in vivo.  
Activation of urothelial α7 receptors inhibits bladder reflexes in the anesthetized rat, while 
activation of α3* receptors causes excitation.  Further experimentation indicates that these results 
are due to actions on urothelial nAChRs and not receptors on underlying nerves or deeper into 
the bladder wall.   
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4.2 RESULTS 
4.2.1 Nicotine Inhibits Bladder Reflexes 
To determine if activation of urothelial nicotinic receptors causes changes in reflex bladder 
contractions, we infused a saline solution containing nicotine hydrogen tartrate into the bladder 
of anesthetized rats and examined changes in voiding parameters.  An initial concern during our 
experiments is whether intravesically instilled drugs would act solely on urothelial receptors, or 
if they might pass through the urothelial barrier to act on receptors in the bladder wall, such as 
those on afferent nerves.  Hence, the hydrogen bitartrate form of nicotine was chosen for these 
experiments based on its solubility properties; as a salt form of nicotine, the bitartrate form is 
water soluble, making it less likely to pass through the urothelial barrier to affect receptors 
deeper in the bladder wall.  As shown in Figure 4.2, continuous infusion of nicotine (50nM and 
1μM in normal saline, 0.04 mL/min, n=6) increased the intercontraction interval (ICI) in a 
concentration-dependent manner (17.4 ± 4.9% and 32.0 ± 7.5%, respectively) over saline 
infusion alone.  These concentrations of nicotine were chosen based on earlier experiments that 
demonstrated these concentrations can increases intracellular calcium in urothelial cells (Birder, 
unpublished results).  These inhibitory effects began within 2 minutes after beginning nicotine 
infusion and lasted for the length of the drug application (at least 30 minutes).   Switching the 
infusate back to normal saline resulted in a complete and rapid (within 2 contractions) reversal of 
the increase in ICI (Figure 4.2B).   
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Figure 4.2 - Effects of Intravesical Nicotine on Voiding Function in the Rat. 
(A) Three representative tracings of cystometry recordings.  Notice the increase in the interval between contractions 
(referred to as the intercontraction interval or ICI) with increasing concentrations of nicotine.  All traces were 
recorded in the same animal for comparison.  The flow rate for each experiment was 0.04ml/min.  (B) Summary of 
cystometry experiments.  Intravesical administration of nicotine (NIC, 50nM and 1μM, n=6 each) increases the ICI 
in a concentration-dependent manner, which is reversed following saline washout. *p<0.05 as compared to a saline 
infused control by ANOVA.   
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4.2.2 Inhibition of Bladder Reflexes by Nicotine is Due to Stimulation of the α7 nAChR 
Stimulation of urothelial receptors with nicotine resulted in an inhibition of bladder reflexes, 
however because nicotine is a non-specific agonist of nAChRs, these experiments do not elicit 
which subtype of nAChR is responsible for mediating the inhibitory effect. Therefore, in order to 
determine which nAChR is contributing to the inhibitory effects of nicotine, subtype selective 
agents were utilized.  Choline is the major metabolite of acetylcholine and is a specific agonist of 
the α7 receptor (EC50 on human receptors expressed in oocytes: 0.4 mM).  Intravesical 
administration of choline (1, 10 and 100 μM in saline, n=6 each) also increased ICI by 9.8 ± 
1.5%, 21.0 ± 5.7% and 46.0 ± 14.8%, respectively (Figure 4.3).  Additionally, the inhibitory 
effect of nicotine (50nM and 1μM) was blocked using the α7 specific antagonist 
methyllycaconitine citrate (MLA, 10μM in saline), while MLA had no significant effect by itself 
(1, 10 and 100 μM, Figure 4.4).  This concentration was used because it was approximately 10-
100 times larger than the IC50 as determined experimentally in other tissues [164, 175, 280], and 
would therefore be sufficient to block the majority of receptors.   
Recent research has questioned whether choline is an appropriate agonist to use in these 
studies, as it can also activate certain muscarinic receptors [281].  Muscarinic receptors are also 
present in the urothelium [77, 218, 219], therefore the possibility exists that the inhibitory 
response observed following choline stimulation is due to actions on muscarinic receptors.  
These actions, while theoretically possible, are unlikely as most studies that demonstrate action 
of choline on muscarinic receptors use much higher concentrations than those used in our studies 
(Ki and EC50 for choline on the M1 receptor expressed in CHO cells: 2mM and 10mM, 
respectively [271]).  In order to block muscarinic stimulation by choline, we could have used the 
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muscarinic antagonist atropine, as we did in our previous calcium and ATP experiments.  
However, atropine has already been shown to increase voiding frequency by itself [65], therefore 
any results would be difficult to interpret.  In any case, our experiments demonstrate that MLA, a 
nicotinic antagonist that has no known actions on muscarinic receptors, fully blocks the 
inhibitory actions of nicotine.  Therefore, we believe that our data supports the conclusion that 
α7 receptors in the urothelium mediate an inhibitory bladder pathway.  
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Figure 4.3 - Choline Inhibits Bladder Reflexes in the Anesthetized Rat 
(A) Representative tracings of cystometrogram recordings during intravesical administration of choline.  Traces 
shown were recorded in the same animal at a constant flow rate of 0.04ml/min for comparison.  (B) Graph depicting 
the summary of the choline data presented as a percentage change in ICI over saline infused controls.  *p<0.05 as 
compared to saline infused control by ANOVA.  n=8 for each concentration. 
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Figure 4.4 - The α7 Antagonist MLA Blocks Nicotine-Induced Inhibition of Bladder 
Reflexes 
(A-B) Representative traces of the effects of the α7 antagonist methyllycaconitine citrate (MLA, 100μM) infusion 
on the bladder cystometrogram.  Traces shown were recorded from the same animal at a constant flow rate of 
0.04ml/min for comparison.  (C) Graph summarizing the effects of MLA (1, 10, 100μM, n=8 each) alone.  NS - not 
statistically significant as compared to saline-infused controls by ANOVA (D) Effects on ICI of nicotine infusion 
alone (50nM and 1μM, columns 1 and 3) as compared to simultaneous infusion of MLA (10μM) and nicotine (NIC, 
columns 2 & 4).  n=6 for each, columns 1 & 3 are taken from different rats than columns 2 & 4.  All results are 
shown as a percent change from saline infused controls.  NS – not statistically significant as compared by students’ 
t-test.  *p<0.05 as compared by students’ t-test. 
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4.2.3 α3* Stimulation Excites Bladder Reflexes in the Anesthetized Rat 
To examine the role of urothelial α3* receptors in bladder function, we used the α3* specific 
agonist cytisine (EC50 on human α3β4 expressed in oocytes: 5.6 μM).  As shown in Figure 4.5, 
intravesical administration of 1, 10 or 100 μM cytisine (in saline, n=6 for each) resulted in 
decreases in ICI up to 42.1% from saline infused controls.  Conversely, intravesical instillation 
of the α3* antagonist hexamethonium (1, 10, 100 μM in saline, n=6 each) inhibited bladder 
reflexes, increasing the ICI in a concentration-dependent manner (10.9 ± 8.1%, 33.7 ± 8.5% and 
39.3 ± 10.3%, respectively, Figure 4.6).  These data suggest that urothelial α3* receptors mediate 
an excitatory pathway, which may be tonically active, since the antagonist inhibited bladder 
reflexes by itself.   
These data indicate that the two distinct subtypes of nicotinic receptors present in the 
urothelium mediate opposing effects in the bladder.  This raises the possibility that the inhibitory 
effects of the non-specific agonist nicotine observed earlier may be attenuated by the concurrent 
stimulation of the excitatory α3* pathway by nicotine.  To determine if non-specific activation of 
α3* receptors by nicotine diminishes the inhibitory effects of α7 receptor stimulation, we 
concurrently instilled the bladder with nicotine (50 nM & 1 µM) and the α3* antagonist 
hexamethonium (20 μM).  Concurrent instillation had additive effects to inhibit reflex voiding 
(Figure 4.6C), with hexamethonium increasing the inhibitory effects of both concentrations of 
nicotine (29.8 ± 7.5% and 67.2 ± 4.0% increase from control for 50nM and 1µM nicotine in the 
presence of 20µM hexamethonium, respectively).  These data indicate that the bladder may also 
be inhibited by blocking the excitatory pathway mediated by the α3* receptor, and that this effect 
can be additive when combined with stimulation of the α7 receptor. 
 118 
We have also demonstrated that the inhibition of α3* receptors results in the inhibition of 
bladder reflexes.  This effect could be due, in part, through blocking tonic activation of α3* 
receptors by ACh released from the urothelium in response to stretch.  However, it is also 
possible that prevention of ACh binding on α3* receptors by hexamethonium would lead to 
greater concentrations of ACh being available to bind to and activate inhibitory α7 receptors.  
Therefore, it is possible that the observed inhibitory effect of hexamethonium is due to a 
combination of thee two actions.  To determine if the inhibitory effects of hexamethonium are 
potentiated by activation of α7 receptors, we concurrently instilled MLA (100μM) and 
hexamethonium (10, 100μM, n=6) into the bladder.  As shown in Figure 4.7, the α7 antagonist 
MLA reversed the inhibition of bladder reflexes observed following hexamethonium instillation, 
indicating that some of this inhibition is mediated through the activation of α7 receptors.  
However, this reversal was not complete, suggesting that some of the hexamethonium-induced 
inhibition was mediated through another pathway, most likely the prevention of tonic activation 
of α3* receptors by urothelially released ACh. 
These results observed with nicotine, hexamethonium and MLA suggest that urothelial 
nicotinic receptors exist in a careful balance with each other and can coordinate to influence 
bladder reflexes in the rat.  We will discuss the implications of these results further in Section 
4.3.   
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Figure 4.5 - Effects of the α3* Agonist Cytisine on Bladder Reflexes 
Summary graph depicting the effects of cytisine (1, 10, 100μM, n=6 each) on bladder reflexes in the anesthetized 
rat.  Data is expressed as a change in ICI from saline infused controls.  *p<0.05 as compared to saline infused 
controls by ANOVA. 
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Figure 4.6 - Effect of the α3* Antagonist Hexamethonium on Bladder Reflexes in the Rat 
(A) Representative traces of CMG recordings during intravesical administration of hexamethonium (C6).  Traces 
shown were recorded from the same animal at a constant filling rate of 0.04 ml/min for comparison.  (B) 
Intercontraction interval changes following instillation of hexamethonium (C6) intravesically. n=8 for each 
concentration.  *p <0 .05 as compared to saline-infused control by ANOVA. (C) Effects on ICI of nicotine infusion 
alone (50nM and 1μM, columns 1 & 3) as compared to simultaneous infusion of C6 (20μM) and nicotine (NIC, 
columns 2 & 4).  n=6 for each, columns 1 & 3 are taken from different rats than columns 2 & 4.  *p <0 .05 as 
compared by students’ t-test.  All results are shown as a percent change from saline infused controls.  
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Figure 4.7 - Effect of Simultaneous Infusion of MLA and Hexamethonium on Bladder 
Reflexes 
Comparison in the percent change in ICI from saline control following instillation of hexamethonium (C6, 10, 
100μM) alone or concurrent instillation of C6 and methyllycaconitine citrate (MLA, 10, 100μM).  *p<0.05 as 
compared by students’ t-test.  NS – not statistically significant.  n=6 for each.  
 
4.2.4 Intravesical Effects of Nicotinic Agents are Due to Actions on Urothelial Receptors 
We have applied all of the agents above intravesically with the intention of specifically 
stimulating urothelial receptors.  This follows our hypothesis that stimulation of receptors 
present on the luminal surface of the urothelium would activate intracellular pathways that cause 
the release of a transmitter that could influence bladder afferents.  However, the possibility exists 
that agents instilled into the bladder are, in fact, permeating through the urothelial barrier to 
stimulate nAChRs located deeper in the bladder wall, such as those present on afferent nerves.  
With this in mind, it would be helpful to determine what effects stimulation of these other 
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receptors would cause on bladder reflexes, in order to determine if the effects we observe 
following intravesical administration can be attributed to actions on these deeper receptors.  To 
this end, we performed cystometrograms where protamine sulfate was instilled intravesically 
prior to nicotinic stimulation in order to disrupt the urothelial barrier.  Protamine sulfate 
treatment has been shown to allow intravesically perfused drugs to reach deeper into the bladder 
wall and activate receptors located on underlying afferent nerves [282, 283].  Following one hour 
of protamine sulfate (10 mg/ml, in saline) infusion, the infusate was switched to nicotine.  
Protamine sulfate treatment did not significantly alter the ICI (Figure 4.8B) by itself, suggesting 
that the treatment did not result in damage to bladder afferent nerves.  However, nicotine (1 μM) 
infusion following protamine sulfate treatment decreased the ICI 38.8 ± 9.9% (Figure 4.8A&B), 
indicating an excitation of bladder reflexes.   This effect could not be reversed by washout with 
normal saline.    
It may also be possible to stimulate nAChRs located deeper in the bladder wall through 
the use of a compound that can cross lipophilic barriers.  Epibatidine is an ultrapotent, highly 
lipophilic α3* receptor agonist, which readily crosses the blood-brain barrier.  Given these 
properties, we can also assume that it could easily pass the urothelial barrier as well.  Intravesical 
administration of epibatidine (250 nM in saline, 0.04 mL/min, n=4), elicited an immediate 
increase in voiding pressure (approximately 50%) without significantly changing the ICI (Figure 
4.9A&B).  Continued infusion of epibatidine for one hour resulted in complete urinary retention 
and overflow incontinence (Figure 4.9C), presumably through desensitization of nAChR in the 
autonomic ganglia.  This hypothesis is supported by the actions of a systemic dose of epibatidine 
(0.05 μg/kg, i.p. n=4), which also suppressed reflex bladder contractions and produced urinary 
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retention (Figure 4.9D), however the onset occurred much more rapidly (onset of approximately 
10 minutes compared to one hour following intravesical administration). 
These data suggest that the actions observed earlier (in Sections 4.2.1-4.2.3) are due to 
activation of urothelial nicotinic receptors by our intravesically instilled agents; as our research 
indicates that activation of nicotinic receptors deeper in the bladder wall has an excitatory effect, 
contrary to the inhibitory effect observed previously. 
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Figure 4.8 - Nicotine Excites Bladder Reflexes Following Disruption of the Urothelium with 
Protamine Sulfate. 
Effect of permeabilization of the urothelial barrier by protamine sulfate (PS) on nicotine-induced changes in bladder 
reflexes.  (A) Representative tracings of CMG recordings taken during a control period of protamine sulfate 
(10mg/ml) infusion and PS infusion with simultaneous nicotine (NIC, 1 μM) infusion.  Traces shown were recorded 
from the same animal at a constant filling rate of 0.04ml/min for comparison.  (B) Graph depicting changes in ICI 
during PS infusion or simultaneous PS and nicotine infusion as a change from saline infused controls.  n=6 for each 
column.  * p < 0.05 as compared to saline-infused control by students’ t-test. 
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Figure 4.9 - Effect of Epibatidine, an Ultrapotent, Lipophilic α3* Agonist on Bladder 
Reflexes 
Effect of the potent nicotinic agonist, epibatidine on bladder function.  (A) Control recordings (B) After 250nM 
epibatidine instillation into the bladder (continuous infusion, 0.04ml/min) (C) After one hour of continuous 
instillation of epibatidine.   (D) Cystometrogram of bladder pressure following systemic administration of 
epibatidine (0.01 μg, i.p.).  Traces A-C were recorded from the same animal, D was recorded in a separate 
experiment. 
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4.3  DISCUSSION 
Nicotinic receptor signaling is important at many levels in the neural pathways controlling 
bladder function; being responsible for neurotransmission in the brain, spinal cord, autonomic 
ganglia and detrusor smooth muscle [1, 131-134, 180].  The present study raises the possibility 
of an additional site for nicotinic modulation of bladder function; the urothelium.  As discussed 
earlier, when the bladder stretches, ACh is released from the urothelium [16, 92].  Our 
experiments raise the possibility that this ACh can then act in an autocrine or paracrine manner 
on urothelial nAChRs to modulate bladder reflexes. 
4.3.1 nAChR Modulation of Bladder Reflexes: Do in vitro Experiments Suggest 
Mechanism? 
Our research indicates that the two different types of nicotinic receptors in the urothelium 
have directly opposing effects on bladder reflexes.  α7 receptors, for example, mediate an 
inhibitory pathway in the bladder; as evidenced by the inhibitory effect of choline, as well as the 
ability of MLA, an α7 antagonist, to block nicotine’s inhibitory effects.  This inhibitory effect 
could be mediated through a number of different pathways.  The most probable scenario, given 
the research performed in Sections 3.2.4-3.2.5, is the modulation of the release of ATP from the 
urothelium.  nAChRs stimulation can alter mechanically stimulated ATP release from the 
urothelium; α7 stimulation inhibited ATP release, while α3 stimulation inhibited ATP release at 
low concentrations of agonist and evoked release at high concentrations of agonist.  ATP is an 
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excitatory transmitter in the bladder that is thought to modulate afferent excitability through 
actions on P2X receptors present on afferent nerve terminals [6, 73].  Given the ability of ATP to 
increase afferent excitability [128], our previous in vitro results concerning ATP release match 
well with our in vivo data.  For example, α7 stimulation inhibits mechanically-stimulated ATP 
release from urothelial cells.  This coincides well with the observed in vivo inhibition of bladder 
reflexes; with decreased ATP release, afferent excitability would decrease, leading to an 
inhibition of the bladder reflexes.  Additionally, stimulation of urothelial cells with large 
concentrations of cytisine increases ATP release, which fits well with the observed excitation of 
bladder reflexes.  In this case, increased ATP would lead to a sensitization of bladder afferents, 
decreasing the amount of stretch needed to activate the micturition pathway and increasing the 
frequency of voiding.   
It should be noted however, that while our data support the hypothesis that nAChRs 
mediate their effects on bladder reflexes though the release of ATP, we have not yet definitively 
linked the in vivo and in vitro effects.  The urothelium can release a number of other transmitters, 
which may also be responsible for the observed effects in vivo.  For example, it is known that 
stimulation of muscarinic receptors in the urothelium causes the release of an, as yet, 
unidentified soluble factor that can inhibit bladder smooth muscle contractions [14, 15].  It is 
possible then, that α7 stimulation can also cause the release of some soluble factor that inhibits 
bladder reflexes, most likely through actions on afferent nerves.  Although research into the 
identity of this unidentified, muscarinically-released inhibitory has factor ruled out the 
involvement of nitric oxide, α7 receptors have been shown to activate nitric oxide synthase in 
dorsal root ganglion cells [231].  Additionally, recent studies have shown that NO is released 
from cultured urothelial cells following cholinergic [284] or adrenergic stimulation [61] and that 
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NO-donors can increase the ICI, when instilled into the bladder [66].  Oxyhemoglobin, a NO 
scavenger, also induces bladder overactivity in unanesthetized rats when applied intravesically 
[68].  It is thought that NO released from the urothelium can act on underlying afferent nerves, 
decreasing excitability and promoting storage.  This is supported by research that demonstrates 
NO can modulate Ca+2 [97], Na+2 [285] and K+ channels [286] in afferent nerves, which could 
influence the resting membrane potential or transmitter release.  Therefore, while our in vitro 
experiments suggest modulation of ATP release as a mechanism for our in vivo results, a number 
of other transmitters may also play a role. 
The actions of nicotinic antagonists alone on bladder reflexes in the rat also give us clues 
on the role on cholinergic signaling in the urothelium.  Hexamethonium, by itself, has an 
inhibitory effect on bladder reflexes, while MLA has no significant effect.  Both of these 
antagonists are competitive, meaning that they compete with ACh to bind to their respective 
receptors.  This raises the possibility of increased activation of the opposing nAChR following 
application of an antagonist.  To clarify, it has been shown that ACh is released from the 
urothelium as the bladder stretches.  When hexamethonium is instilled intravesically, it would 
compete with ACh, preventing binding and increasing the available concentration of ACh in the 
bladder lumen.  This would lead to increased activation of the α7 receptor, leading to inhibition.  
It is curious, though, why MLA does not have an excitatory effect in vivo.  MLA is also a 
competitive agonist, which would suggest that more ACh would be available in the lumen to 
bind and activate the excitatory α3* receptors.  We demonstrated in the last chapter that MLA 
alone can increase ATP release from the urothelial cells, which should lead to increased afferent 
excitability and increased voiding frequency.  It may be that an excitatory effect is not observed 
because ACh levels much reach a sufficient level to activate the α3* excitatory pathway.  As we 
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demonstrated in the last chapter, stimulation of α3* receptors with low concentrations of cytisine 
inhibited ATP release.  It is possible that low concentrations of nicotine also result in the 
inhibition of urothelial ATP release through α3* receptors and this is responsible for the trend 
towards inhibition with MLA in our in vivo experiments.   
4.3.2 Does Intravesical Administration of nAChR Agents Activate Urothelial Receptors?  
Implications for Urothelial Signaling 
During the course of these experiments, one question in particular becomes apparent: are 
the nicotinic agents perfused intravesically acting on urothelial receptors or are they passing 
through the barrier to act directly on receptors located on afferent nerves in the bladder wall.  
This is an important question to answer not only to properly analyze the data presented in this 
dissertation, but also to address a basic physiological question concerning urothelial signaling: 
does cholinergic signaling take place at the apical or abluminal surface of the urothelium?  This 
question is of the highest importance when we consider the possible role of urothelial signaling 
in bladder signaling.  The location of urothelial nAChRs could have profound implications on 
how they influence the control of the bladder.  For example, receptors present on the lumen of 
the bladder suggest that activation of the receptor would modulate some trans-urothelial 
pathway, where stimulation of the receptor on the luminal surface would cause the release of a 
transmitter from the abluminal surface.  However, nicotinic receptors are present in other 
locations in the bladder, such as afferent or efferent nerves.  In order to determine if urothelial 
nAChRs can influence bladder reflexes, we must rule out the possibility that the effects we 
observe are not due to effects at the other sites.  Our experiments, in addition to others [63, 65], 
indicate that our intravesically instilled agents can act on the luminal surface of the urothelium.   
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The first evidence that cholinergic signaling takes place at the luminal surface of the 
bladder involves the selection of the compounds used in our studies.  The urothelium forms a 
highly effective barrier to the potential toxins in the urine with a permeability that is much higher 
than even that of the blood brain barrier [19].  Therefore, we would expect that polar, hydrophilic 
or large agents, such as the quaternary amine hexamethonium would not cross the urothelial 
barrier (Figure 4.10).  We would also expect that nicotine, in its hydrogen tartrate form would be 
less likely to cross the urothelial barrier.  This is due to the ionization state of nicotine; at a pH of 
approximately 7, nicotine would exist primarily in an ionized form and not in the free base form 
that would readily cross the urothelium.   This is supported by our experiments showing that 
nicotine’s effects can be rapidly washed out, suggesting that very little nicotine reached the inner 
layers of the bladder wall.  The other two compounds that we utilized for this study, cytisine and 
MLA are lipophilic and capable of passing the blood brain barrier, which suggests that they may 
also pass the urothelial barrier.  This may allow these agents to bind nicotinic receptors deeper in 
the bladder wall, influencing our results.  However, in our experiments, changes in ICI were 
observed almost immediately after infusion of the agents began, suggesting that the drugs’ 
actions were urothelial in nature.  As we demonstrate in experiments with epibatidine, even a 
highly lipophilic agent took approximately an hour before systemic effects became apparent.  
Therefore, we believe that the results we observed with MLA and cytisine are due to actions on 
urothelial receptors. 
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Figure 4.10 - Chemical Structures of Nicotinic Agents Used 
Chemical structures of (A) nicotine hydrogen tartrate, (B) hexamethonium, (C) cytisine, and (D) methyllycaconitine 
citrate (MLA).   
 
 
To test what might happen if a nicotinic agent did cross the urothelial barrier to work in 
the periphery, we examined the effect of protamine sulfate, which has been shown to disrupt the 
urothelial barrier and allow intravesically administered agents to pass into the underlying tissue 
[282, 283].  Prior to protamine sulfate treatment, nicotine has an inhibitory effect, increasing the 
ICI.  However, when administered after protamine sulfate treatment, nicotine has the opposite 
effect, exciting the bladder reflex and decreasing the ICI.  This switch in nicotine’s effects 
following permeability of the urothelial barrier suggests that protamine sulfate allows nicotine to 
act on sub-urothelial targets such as afferent nerve terminals while nicotine infusion without 
protamine sulfate treatment activates receptors on the urothelium.  This research is supported by 
studies performed by Masuda, et. al. [180], which shows that large doses of nicotine (1-10mM) 
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can also cause an excitation of bladder reflexes.  It was hypothesized that at these concentrations, 
the amount of nicotine present in the free base form, and hence capable of crossing the urothelial 
barrier, would be sufficient to have physiological effects.  Because our experiments use much 
lower concentrations of nicotine (50nM & 1µM), we would expect that we lack a sufficient 
concentration of nicotine to cross the urothelial barrier and activate afferent nerve terminals. 
We also examined the effects of the nicotinic agonist epibatidine, which readily crosses 
the blood brain barrier and has a greater affinity for α3β4 receptors than α7 receptors (EC50: 
0.01-0.02 μM vs. 1.0-2.0μM) [287].  We believe that epibatidine would also cross the urothelial 
carrier, given its lipophilic nature.  Initially, intravesically administered epibatidine had an 
excitatory effect on the bladder; however it did not influence the intercontraction interval, but 
rather altered the threshold pressure necessary to initiate a bladder contraction.  These changes 
do not indicate actions on afferent nerves (either directly or indirectly through urothelial 
signaling), but instead indicate actions on bladder smooth muscle.  This is most likely 
accomplished through actions on pre-junctional parasympathetic efferent neurons, where it is 
thought that nicotinic receptors can modulate ACh release and hence influence bladder smooth 
muscle contractility.  Additionally, after two hours of continuous infusion, voiding was blocked, 
leading to a state of urinary retention and overflow incontinence.  The onset of overflow 
incontinence was much more rapid following a systemic dose of epibatidine, indicating that 
urinary retention is a result of effects of the drug outside the bladder, most likely through 
desensitization of nicotinic receptors on sensory nerves or in autonomic ganglia [133].  Both of 
these effects are indicative of actions outside of the lumen of the bladder, therefore the lack of 
similar effects following intravesical nicotine, suggests that its actions are due to actions on 
urothelial receptors.   
 133 
Therefore, given these experimental data, we believe that the nicotinic agents used in 
these experiments are acting primarily on urothelial receptors because: 1) the chemical structures 
and proposed ionization states of the compounds suggest a reduced or limited ability to diffuse 
across the urothelial barrier, 2) the ability to wash out the nicotinic effect and return to normal, 
suggesting that the compound did not cross the urothelial barrier, 3) the reversal of nicotine’s 
effects following disruption of the urothelial barrier, allowing nicotine to penetrate to sub-
urothelial afferent nerves, and 4) a lack of a biphasic response, that would indicate an early 
action on urothelial receptors followed by diffusion through the barrier and subsequent action at 
other sites.   
4.3.3 Integrating nAChR Effects into the Model of Urothelial Signaling 
We have demonstrated that activation of urothelial nicotinic receptors using pharmacological 
agents can modulate bladder reflexes, however we have not yet discussed how these results give 
us insight into how urothelial cholinergic signaling plays a role in normal bladder physiology.  In 
the next chapter we will discuss in better detail how what is already known about nicotinic 
receptors fits together with our experimental data into a hypothetical model of nicotinic signaling 
in the urothelium and how nicotinic receptors might fit into urothelial signaling as a whole.  We 
will also discuss further directions our research can take, as well as the clinical implications of 
the research presented. 
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5.0  FINAL CONCLUSIONS 
In the previous chapters, we have demonstrated that the urothelium expresses functional 
nicotinic receptors which, when stimulated, can alter cellular processes such as calcium 
homeostasis and ATP release.  Additionally, stimulation of nicotinic receptors in vivo can also 
modulate bladder reflexes.  In this chapter, we will discuss how these results complement each 
other to suggest a model of urothelial signaling in the bladder and how nicotinic receptors may 
play a role in modulating bladder reflexes.  Additionally, we will also discuss the implications 
these results have in regards to bladder pathology and the clinical possibilities of nicotinic 
receptors in the treatment of common bladder disorders.  Finally, we will discuss other areas of 
urothelial physiology where nicotinic receptors may play an important role and why researchers 
will want to examine them in the recent future. 
5.1 MODEL OF NICOTINIC RECEPTOR-MEDIATED MODULATION OF 
BLADDER REFLEXES 
The research presented in this dissertation has demonstrated that stimulation of nicotinic 
receptors on urothelial cells can mediate a number of cellular and physiological responses.  First, 
stimulation of urothelial nAChRs can modulate intracellular calcium transients as well as 
influence the release of ATP from urothelial cells.  Additionally, stimulation of the urothelium in 
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vivo causes alterations in bladder reflexes.  Could these effects be linked, with modulation of 
ATP release being the cause of the altered bladder reflexes?  While a number of possibilities 
exist, we believe our data and that of other labs suggest a model that involves the indirect 
modulation of bladder afferent nerves through the release of transmitters, including ATP, from 
the urothelium. 
ATP has been shown to be an important transmitter in the urothelial sensory pathway.  
For example, ATP can be released from the urothelium in response to physical stimuli such as 
osmotic stress [58, 59, 88] or chemical stimuli like capsaicin [13, 58, 60], bradykinin [63] or 
acetylcholine [77].  This ATP is thought to act on afferent nerves underlying the urothelium by 
acting on P2X receptors and modulating afferent excitability [73, 91].  This hypothesis is 
supported by a number of studies; for example, ATP applied intravesically can excite bladder 
reflexes [67] and the purinergic antagonist PPADS can block bladder hyperactivity caused by 
intravesical administration of ACh and other cholinergic agents [65].  Additionally, a recent 
study performed in an in vitro bladder-pelvic nerve preparation demonstrated that an application 
of ATP to bladder afferent nerves sensitized them to mechanical or electrical stimulation, 
lowering the threshold required to elicit an action potential [128].  Taken together, these data 
form a strong case for urothelially released ATP playing a role in modulating bladder afferent 
excitability and hence modulate bladder activity. 
Our research clearly demonstrates that stimulation of cultured cells with nicotinic agents 
can modulate the release of ATP.  Could this, then, be the mechanism for the modulation of 
bladder reflexes observed in vivo in the rat?  The results we observed involving ATP release in 
vitro could suggest events that we have demonstrated in vivo.  For example, α7 stimulation with 
choline results in inhibition of both ATP release in cultured cells and bladder reflexes in the 
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anesthetized rat.  Additionally, cytisine stimulation at high concentrations results in both an 
increase in ATP release and an increase in the frequency of reflex bladder contractions in the 
anesthetized rat.  These results support the hypothesis that urothelial nAChRs can modulate 
bladder activity through the release of ATP.   
It should be noted, however, that we don’t conclusively link the release of ATP from 
urothelial cells following stimulation with nicotinic agents with increased bladder activity or 
even increased afferent activity.  To determine if the in vivo effects of nAChR stimulation are 
due to modulation of ATP release from the urothelium, a number of experiments could be 
performed.  A direct experiment to test if the excitation caused by α3* stimulation during a 
cystometrogram is due to urothelially released ATP would be to concurrently apply a purinergic 
antagonist such as PPADS.  We would expect PPADS to block the excitation caused by α3* 
stimulation.  However, this result may be difficult to interpret, as the urothelium also expresses 
purinergic receptors [64] which may be the target for any effects observed following treatment 
with PPADS or other purinergic antagonists.  Additionally, ATP is an important transmitter in 
the central nervous system [288, 289], therefore any actions of purinergic antagonists may be due 
to central effects, as well.  It would, then, be beneficial to examine the effects of nicotinic 
receptor agents in afferent excitability in the bladder-nerve preparation, an in vitro experimental 
setup that removes the bladder and the pelvic nerve in order to record nerve impulses in response 
to stretch or chemical stimulation [128].  Using this model, it would be possible to record 
changes in afferent nerve activity in response to stretch with and without intravesical instillation 
of cytisine, to determine if activation of urothelial α3* receptors leads to an increase in afferent 
excitability.  If our hypothesis is correct, we would expect that intravesical cytisine would 
increase afferent excitability and this effect would be blocked by the addition of PPADS or 
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another purinergic antagonist to the bath, where it could act by blocking purinergic receptors on 
afferent terminals.  This model would eliminate the possibility of blocking purinergic signaling 
in the central nervous system, hence eliminating any non-specific effects.   
5.1.1 A Hypothesized Role for Nicotinic Receptors in the Physiological Control of the 
Normal Bladder 
While we have demonstrated a role for urothelial nAChRs in modulating bladder reflexes 
following stimulation with exogenous agents such as nicotine, our research indicates that 
urothelial nicotinic receptors play a physiological role in the control of micturition in the absence 
of any pharmacological intervention.  For example, blocking α3* receptors using 
hexamethonium caused an inhibition of bladder reflexes, indicating the presence of an 
endogenous agonist that is activating the receptor.  Acetylcholine is the endogenous ligand for 
the α3* receptor, and it has been shown that the urothelium can release ACh in response to 
stretch [16, 92].  It has been long hypothesized that this non-neuronal ACh could act in an 
autocrine/paracrine manner, stimulating cholinergic receptors on the urothelium to modulate a 
number of cellular functions.  This kind of signaling has been shown in a number of non-
neuronal tissues, such as bronchial epithelia [216, 244, 245, 290], vascular endothelial cells [221] 
and skin keratinocytes [205, 237].  Could urothelially released ACh act on urothelial nAChR to 
modulate ATP release to influence bladder physiology?  If we consider our current research 
together with what is known about ACh release from the urothelium, as well as the 
pharmacological properties of the nAChRs as determined in other tissues, we can hypothesize a 
model of nicotinic signaling in the urothelium and how it plays a role in the normal operation of 
the bladder. 
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It is known that ACh is released from the mucosa in a stretch dependent manner; i.e. the 
more bladder strips are stretched, the more ACh is released [16, 92].  This suggests that a 
concentration gradient of ACh over time in the lumen of the bladder, when the bladder is empty, 
ACh levels would be low, however when the bladder is full and the urothelium is stretched, ACh 
levels would increase.  We believe that this gradient in the concentration of ACh in the bladder 
over time is the basis for how nAChRs could play a role in the control of the bladder, i.e. by 
relaying information on the fullness of the bladder to underlying afferent nerves through 
controlling the release of ATP.  In this manner, urothelial nAChR signaling would play a unique 
role in converting physical conditions in the bladder (i.e. stretch) into chemical signals that can 
modulate bladder afferent nerves; promoting storage when the bladder is empty and promoting 
voiding when the bladder is full. 
In order to explain this hypothesis, let us first examine the effects of cytisine stimulation 
on ATP release and relate them to their perceived effects in vivo.  Low concentrations of cytisine 
inhibit basal ATP release in cultured cells.  Assuming that ACh acts on α3* receptors in a similar 
manner to cytisine, this would mean that urothelial production of ATP would be diminished 
when ACh levels were low.  If ATP release is diminished then it would be less likely to sensitize 
afferent nerves, leading to higher thresholds of activation and promoting storage.  We also 
demonstrated in our experiments that higher concentrations of cytisine elevated ATP release 
from cultured cells.  ACh release from the urothelium increases as the bladder stretches, 
therefore we would expect concentrations of ACh in the bladder to rise as the bladder fills.  
Based on the effects of cytisine, we would expect that as ACh levels increase, urothelial cells 
would switch from inhibiting ATP release to promoting it.  This ATP could then act on afferent 
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nerves to increase their excitability and increase sensations felt from the bladder (in a conscious 
patient) or activate bladder reflexes (in the anesthetized animal) (Figure 5.1B).   
 
 
Figure 5.1 - Hypothetical Model of α3 Modulation of Bladder Reflexes 
(A) Depiction of the classical hypothesis on stretch-activation of bladder afferent nerves.  As the bladder fills, the 
bladder wall stretches (1), which activates stretch-sensitive receptors on afferent nerve terminals (2), causing 
increased afferent activity.  (B) Hypothetical model depicting how we believe urothelial α3 nAChRs modulate this 
response.  When the bladder is full and the bladder is stretched (1), discoidal vesicles in the umbrella cells of the 
urothelium fuse with the apical surface (2), releasing ACh (3).  This ACh can then act in an autocrine/paracrine 
manner on urothelial α3 receptors, increasing intracellular calcium (4).  Increased [Ca+2]i leads to increased fusion of 
vesicles and hence increased release of ATP.  ATP can then act on P2X3 receptors on underlying afferent nerves (5), 
increasing their excitability and decreasing the stimulus needed to activate them.  This would lead to a decrease in 
the threshold volume needed to initiate a micturition contraction and therefore decrease the intercontraction interval 
in a cystometrogram. 
 
 
How, then, does the α7 receptor fit into this model?  Our research demonstrates that 
stimulation of the α7 receptor results in a decrease in ATP release.  Because ATP excites bladder 
afferent nerves [6, 73, 128], the inhibition of release could decrease afferent excitability and 
hence inhibit bladder reflexes.  As discussed in Chapter 3.3.2, it is unclear what the mechanism 
of this inhibition might be; it could involve the inhibition of the α3* receptor of be mediated 
through an, as yet, undiscovered pathway.  We have demonstrated that stimulation of α7 
receptors also releases calcium from ryanodine sensitive stores.  Could this then be a mechanism 
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for the inhibition of ATP release?  This seems unlikely, as ATP release from urothelial cells in 
response to stretch is inhibited if intracellular calcium is chelated using BAPTA-AM [58], 
suggesting an excitatory role for intracellular calcium in ATP release.  Therefore, the possibility 
exists that the inhibition of ATP release we observe following α7 stimulation is independent of 
the changes in intracellular calcium also elicited by α7 stimulation, much in the same way it 
appears that the inhibition of α3* receptor signaling following α7 receptor stimulation appears to 
be calcium-independent.  Despite the fact that more experimentation must be completed to fully 
understand how α7 receptors mediate their inhibitory effects on ATP release, this inhibition fits 
well with the observed effects during our in vivo rat experiments.  Whether α7 receptors mediate 
their effect through direct inhibition of transmitter release, through phosphorylation and 
subsequent desensitization of excitatory α3* receptors or through some other, unknown 
mechanism, the result is inhibition of bladder reflexes.  This inhibitory nature of the α7 receptor 
fits well with what is known about nAChR pharmacology and urothelial physiology.   
In contrast to α3β4 receptors, α7 receptors are activated by lower concentrations of ACh 
(EC50: ~20µM) and desensitized by higher concentrations [169, 173].  These properties allow for 
a steady state current in the continuous presence of ACh that increases with growing 
concentrations of ACh up to approximately 20µM and decreasing from there.  These properties 
suggest that urothelial α7 receptors, then, would be active in the presence of low concentrations 
of ACh and inactivate when levels increase.  This coincides with the inhibitory nature of the 
receptor, as when the bladder is empty and ACh levels are low, promotion of storage would be 
desirable.  Therefore, the urothelium could have a two-fold mechanism in place to modulate 
bladder activity in the rat: when the bladder is empty and ACh levels are low, α7 receptors would 
be activated and α3* receptors desensitized, resulting in a prevention of ATP release (Figure 
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5.2).  However, as the bladder fills and stretches, higher ACh levels would desensitize α7 
receptors and activate α3* receptors, leading to the removal of inhibition and increased ATP 
release.  As mentioned previously, this release of ATP would increase afferent excitability, 
promoting voiding. 
In addition to acetylcholine, choline can also activate α7 receptors [169, 170].  While 
choline is much less efficacious on α7 than ACh (EC50: ~2mM), it is much more selective for α7 
receptors, exhibiting very little activity on other nicotinic receptors.  Because urothelial cells 
express cholinesterase enzymes [291], urothelially released ACh could be metabolized into 
choline, which could also activate the α7 inhibitory pathway.  With this is mind, we believe that 
when the bladder is empty and ACh concentrations are low, urothelially released ACh can be 
metabolized by acetylcholinesterase in the urothelium to produce choline, which would activate 
the α7 inhibitory pathway, decreasing ATP release.  As the bladder stretches and ACh release 
increases, acetylcholinesterase could become saturated, allowing for a buildup of ACh and the 
eventual desensitization of α7 receptors and the activation of α3* receptors, leading to increased 
ATP release and excitation of afferent nerves.  Therefore acetylcholinesterase may act as the 
enzymatic “switch” that would determine which nicotinic pathway would be activated, 
depending on the concentration of ACh in the lumen of the bladder. 
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Figure 5.2 - Hypothetical Model of α7 Signaling in the Urothelium 
(A) When the bladder is filling, the bladder stretches (1), vesicles fuse to the plasma membrane in the umbrella cells 
(2) and ACh is released (3).  The urothelium expresses acetylcholinesterase (ACh), which degrades ACh into 
choline (4) a specific agonist for the α7 nAChR.  Stimulation of α7 receptors causes an inhibition of ATP release, 
possibly through a mechanism involving release of intracellular calcium from ryanodine sensitive stores.  Without 
the action of ATP on bladder afferent nerves, excitability would be decreased, resulting in inhibition of the bladder 
reflex.  (B) Our research also suggests that the inhibitory effect of α7 receptors could be mediated through an 
inhibition of α3* receptors.  This could happen through phosphorylation of the a3* receptor through the activation of 
protein kinases, such as PKA or PKC (5). 
 
 
 
It is important to realize that this hypothesis proposes only that urothelial nAChRs can, 
through modulation of ATP release, influence bladder reflexes.  In other words, urothelial 
nicotinic receptor stimulation is not required to initiate a bladder contraction.  This is indicated 
by our experiments using hexamethonium; even though blocking the α3* receptor resulted in an 
inhibition of bladder reflexes, a contraction did eventually occur.  We then hypothesize that the 
nicotinic signaling pathway represents a mechanism for modulating the micturition reflex 
mediated by stretch-sensitive afferents in the bladder wall.  In this way, urothelial nAChR 
signaling could modulate excitability of the stretch-activated nerves controlling micturition, 
increasing or decreasing the threshold necessary to activate micturition depending on conditions 
in the lumen of the bladder.  In other words, this type of signaling could transform physical 
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stimuli stretch of the urothelium) into a chemical signals that could coordinate cellular responses 
throughout the bladder lumen. 
5.1.2 Future Directions 
While the research presented in this dissertation significantly furthers what is known 
about nicotinic signaling in the urothelium, we should point out that there exist some 
discrepancies in the research presented that will require additional experimentation in order for 
our model to be confirmed.  For example, while it is known that the urothelium releases ACh in a 
stretch-dependent manner, no study to date has measured the levels of ACh in the bladder of the 
rat in vivo during filling to determine the range of ACh or choline concentrations present in the 
lumen.  Therefore, the question of whether ACh concentrations in the lumen of the bladder could 
ever reach physiological relevance remains.  To determine the feasibility of our model, it would 
be necessary to measure the levels of ACh near the urothelium while the bladder is stretched in 
varying amounts.  Classically, ACh release is measured in one of two ways: 1) by incubating 
cells in radiolabeled choline and examining the amount of radiolabeled ACh released following a 
stimulus, or 2) through the use of high-performance liquid chromatography.  Neither of these 
techniques, however, is desirable to use in vivo, as they would measure the levels in the lumen as 
a whole and may not give an accurate account of what ACh or choline concentrations are close 
to the urothelium.  Recent advances in technology, however, have allowed for the development 
of ACh-specific microsensors, capable of measuring ACh and choline levels in real time [292].  
The development of these sensors may now allow sensitive readings of ACh and choline levels 
near the urothelium, which would allow us to determine the feasibility of our hypothetical model. 
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Additionally, while we can make assumptions on the pharmacological properties of 
nAChRs in urothelial cells based on properties exhibited by those receptors expressed in other 
tissues or heterologous expression systems, no study as yet as examined the properties of these 
receptors in urothelial cells.  Attempts have been made to patch clamp urothelial cells, with some 
limited success [293], however to date no group has examined nAChR-mediated currents.  Until 
such experiments are performed, it is impossible to conclusively state that properties such as 
agonist affinity, steady-state current, peak current, desensitization rate and recovery from 
desensitization rate in urothelial nAChRs is the same as they are in other tissues or heterologous 
expression systems.  Differences in these properties between urothelial cells and the cells already 
studied may necessitate a revision of our hypothetical model. 
While our research indicates that nicotinic receptor stimulation modulates both 
intracellular calcium and ATP release, it should be noted that we have not definitively linked the 
two phenomena together.  For example, while choline evokes release of calcium from ryanodine 
sensitive stores and inhibits ATP release, we have not demonstrated that the inhibition of ATP 
release is due to the intracellular calcium transients.  Additionally, we did not demonstrate that 
the increase in ATP release in response to higher concentrations of cytisine is dependent on the 
increase in intracellular calcium that cytisine also produces.  In order to fully develop our 
hypothetical model, these links must be made experimentally.  If these links exist, we would 
expect that stimulation of ryanodine receptors using low concentrations of ryanodine would 
result in a decrease in ATP release from cultured urothelial cells.  We would also expect that 
removing extracellular calcium from our ATP experiments would block cytisine induced ATP 
release.   
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It should also be noted that while we have shown that α3*-mediated calcium transients 
can be modulated by kinases such as PKA and PKC, we have not shown that these kinases can 
alter α3*-mediated ATP release.  This is due to the fact that kinase activation has been shown to 
increase vesicular transmitter release in nerve cells, which may be due to phosphorylation of 
SNAP-25, a member of the SNARE complex responsible for vesicle docking and fusion [294].  
Activation of PKC or PKA with the non-specific agents we use in Chapter 3.2.3 also increases 
ATP release from urothelial cells (unpublished data), which would make any effect on cytisine-
induced ATP release difficult to interpret.  Therefore, in order to determine if α3*-mediated ATP 
release can be influenced by protein kinases, other techniques would have to be utilized.  The 
urothelium expresses a number of PKC isoforms, and general stimulation would activate 
multiple isoforms which may have multiple effects on cellular signaling.  To better elucidate 
which isoform could phosphorylate and inhibit the α3* receptor, we could either utilize more 
subtype specific pharmacological agents or genetic techniques to knockout specific isoforms of 
PKC.   
Nicotinic receptors have also been shown to affect a number of cellular processes that 
could affect bladder function, but for which we have not tested.  It is possible that one of these 
processes also plays a role in urothelial signaling and will have to be addressed before a 
comprehensive model of urothelial nAChR signaling can be formed.  For example, nicotinic 
receptors have been shown to modulate gap junction function in a number of experimental 
models [295, 296].  Urothelial cells also express gap junctions, composed mainly of the protein 
connexin 26 [297, 298].  These gap junction proteins are upregulated in the neonatal rat as well 
as in the spinal cord- transected rat, where they appear to play a role in coordinating calcium 
signals in the urothelium [297].  This increased expression of gap junctions, both in the 
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urothelium and in the suburothelium, are thought to drive the spontaneous muscle activity 
observed in neonatal and spinal cord transected rats, as this activity disappears when 18β-
glycyrrhetinic acid is applied to the preparation.  Nicotinic agents have also been shown to 
modulate gap junction functionality; in adrenal chromaffin cells nicotinic antagonists increase 
the flow of dye between cells, indicating an opening of gap junctions [295].  This suggests that 
nAChR activation tonically inhibits gap junction function.   Could the same mechanism be at 
work in the urothelium, and could nAChR modulation of gap junctions play a role in influencing 
smooth muscle activity?  nAChR expression in a number of tissues are commonly altered during 
development [151, 182, 202, 228] as well as in adults following pathology [162, 299, 300]; 
therefore if nicotinic receptors can modulate gap junctions, nAChR plasticity in neonates and 
pathology may help explain the differences in spontaneous activity in bladders taken from those 
animals.  Further studies would have to be completed to determine if nAChRs can alter gap 
junction communication in urothelium, however these studies would help elucidate the entire 
role of urothelial nicotinic receptor signaling. 
While our combined experiments suggest the hypothetical model we have proposed, a 
number of inconsistencies between our in vivo and in vitro studies exist that must be addressed.  
Table 4 lists the effects each of our nicotinic agents had in our experiments.  As denoted by the 
asterisks, there are some discrepancies between the effect of an agent in vitro and its effect in 
vivo.   For example, MLA increases ATP release in vitro, however the same concentration 
(100µM) has no effect on bladder cystometrograms.  Additionally, choline effectively inhibits 
bladder reflexes in vivo at concentrations as low as 1µM, while choline’s effect on ATP release 
does not begin until a concentration of 100µM.  Given our hypothetical model, we would expect 
changes in ATP release to mirror the effects seen in vivo.    
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It would be easy to attempt to explain these incongruities with a simple “cultured cells 
never behave completely the same as cells in vivo” comment.  However, it should also be 
possible to hypothesize specifically what the cause of the differences between the two 
experimental models might be and design experiments to determine if these differences could be 
explained.  For example, urothelial cells resident in the bladder in vivo are subjected to stretch 
during the course of the experiment (as the bladder fills and expands), whereas cultured cells are 
not.  Stretch of urothelial cells results in a number of physiological changes, such as increases in 
vesicle trafficking (both endo- and exocytsis) [56, 57, 72, 266, 301, 302], increases in expression 
of urothelial proteins [53, 54] and release of a number of transmitters, such as ACh [16, 93].  All 
of these stretch-induced processes could influence bladder reflexes in vivo in ways that could 
lead to results inconsistent with our in vitro results.  For example, it could be hypothesized that 
ACh, released from the urothelium in response to stretch, could act in synergy with the nicotinic 
agents we perfused during the cystometrogram, lowering the concentration needed to evoke a 
response.  Since the urothelial cells used in our in vitro experiments aren’t being stretched, a 
higher concentration of agent would be needed.  Additionally, it is also possible that stretch 
could induce changes in nAChR expression in urothelial cells in the rat, which could alter the 
concentrations needed to affect a result. 
If either of these scenarios is correct, simply subjecting cultured urothelial cells to stretch 
should alter nAChR signaling in our in vitro experiments to more closely match the results 
observed in vivo.  Urothelial cells can be grown on stretchable supports, which would allow us to 
examine how nAChR signaling could be affected by stretch.  Additionally, some researchers 
have used hypotonic stress as a model of stretch [58, 59, 93], based on the fact that urothelial 
cells swell when presented with hypotonic conditions.  We would expect the addition of either 
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hypotonic or physical stretch of urothelial cells would lower the concentrations of agonist needed 
to elicit a response.   
 
 
Table 4 - Summary of in vivo and in vitro Experiments 
Agent Concentration Effect in vivo Effect in vitro 
Choline  
 
1 μM Increase ICI Ca+2: none * 
ATP: none * 
 10 μM  Increase ICI  Ca+2: increase (intracellular stores)  
ATP: none * 
 100 μM Increase ICI Ca+2: increase (intracellular stores) 
ATP: decrease 
MLA 1 μM No change in ICI Ca+2: none 
ATP: N/D 
 10 μM No change in ICI 
Blocks nicotine 
Ca+2: none 
ATP: N/D 
 100 μM No change in ICI  Ca+2: none  
ATP: increase * 
Cytisine 1 μM Decrease ICI Ca+2: none * 
ATP: N/D  
 10 μM Decrease ICI  Ca+2: increase (extracellular) 
ATP: decrease  
 100 μM Decrease ICI Ca+2: increase (extracellular) 
ATP: increase 
C6/ 
TMPH 
1 μM / - Increase ICI  
(not significant) 
Ca+2: N/D 
ATP: N/D 
 10 μM / 30 μM Increase ICI  Ca+2: none (blocks cytisine) *  
ATP: no effect * 
 100 μM / 90 μM Increase ICI  Ca+2: N/D  
ATP: none (blocks cytisine)  
 
Summary of the effects of nicotinic agents in our experiments.  An * denotes a discrepancy between in vivo and in 
vitro effects. 
 
5.1.3 Interactions Between nAChRs and Other Signaling Pathways: Possible Implications 
for Urothelial Signaling 
In the future, we would also like to examine the interactions urothelial nAChRs may have with 
other signaling pathways in the urothelium.  It is well known that nicotinic receptors can interact 
to modulate and be modulated by a number of different cellular pathways, some of which are 
also important players in bladder physiology.  Interactions with some of these pathways could 
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have significant effects on nicotinic receptor-mediated signaling in the urothelium and allow us 
to better understand how nicotinic receptors fit into the whole of urothelial physiology. 
For example, nicotinic receptors are not the only receptors present in the urothelium that 
respond to ACh.  It has been well established that the urothelium also expresses muscarinic 
receptors, metabotropic receptors that are also activated by acetylcholine [14, 15, 31, 32, 65, 74, 
77, 123, 124, 218, 219].  Muscarinic receptors in the urothelium were first deemed important to 
bladder physiology when muscarinic antagonists began to be studied as a possible treatment of 
overactive bladder syndrome [7, 32, 74, 123, 124].  The rationale behind anti-muscarinics for the 
treatment of OAB was simple; if bladder overactivity was being caused by increased 
parasympathetic activation of bladder smooth muscle, then anti-muscarinics should be effective 
in blocking this overstimulation.  However, it became clear that anti-muscarinics were mediating 
their effect during the filling phase of micturition when parasympathetic activity is virtually non-
existent.  This suggested a second site of muscarinic modulation of the bladder.  Attention was 
turned to the urothelium when research by Chapple and Chess-Williams discovered that 
muscarinic stimulation of the urothelium led to the release of a diffusible factor that inhibited 
bladder smooth muscle contractions [14, 15].  As a result of these experiments, and the efficacy 
of anti-muscarinics in the treatment of OAB, many researchers have begun to study muscarinic 
signaling in the urothelium. 
A number of recent studies have examined the role of muscarinic receptors in urothelial 
signaling.  For example, RT-PCR has indicated that the urothelium of the rat, mouse and human 
express all five muscarinic receptors (M1-M5) [218, 219].  Stimulation of these receptors, using 
Oxotremorine-M (Oxo-M) results in increases in intracellular calcium, release of ATP, and 
alteration of bladder reflexes [65, 77].  Much in the same manner as nicotinic receptors, it 
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appears as though different receptor subtypes mediate different effects; for example, low 
concentrations of Oxo-M have an inhibitory effect on bladder reflexes in the anesthetized rat, 
while large concentrations have an excitatory effect [65].  Additionally, it appears as though each 
muscarinic receptor subtype influences intracellular calcium signals uniquely, as some subtype 
specific antagonists block increases in intracellular calcium following stimulation with a non-
specific muscarinic agonist, while others potentiate the increases [77].  These data, interestingly, 
are very similar to those we have reported above with the nicotinic receptors in that they 
demonstrate opposing physiological effects depending on which receptor is stimulated.   
While these data involving muscarinic signaling in the urothelium have garnered a lot of 
attention in the bladder research community due to the use of anti-muscarinics in the treatment of 
bladder hyperactivity, our current research may open up a new area of interest for clinical 
researchers.  Given that both muscarinic and nicotinic receptors modulate intracellular calcium 
homeostasis as well as ATP release, the potential for the two related classes of receptors to 
interact is great.  Indeed, muscarinic and nicotinic receptors are present together in a number of 
tissues, including neurons in the brain [277] and the spinal cord [132], as well as in the 
periphery, such as the enteric nervous system [303].  Both types of receptor are also present in a 
number of inflammatory cell types, such as neutrophils, mast cells, and macrophages [304].  In 
many of these tissues, it has been shown that interactions between muscarinic and nicotinic 
receptors exist, sometimes leading to an increase in cholinergic signaling in the target tissue and 
sometimes inhibiting it.  For example, in the human brain, simultaneous antagonism of 
muscarinic and nicotinic receptors impaired cognitive abilities to a greater extent than 
antagonism of either class alone [277].   This research suggests that the two types of cholinergic 
receptor act in concert to affect selective cognitive processes, such as working memory and 
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visual attention.  However, in the enteric nervous system, it has been demonstrated that 
muscarinic receptor stimulation can result in an increase in the rate and length of nicotinic 
receptor desensitization [303].  In enteric neurons, M1 receptor stimulation leads to the 
activation of phospholipase C, and hence the production of IP3 and DAG.  DAG can activate 
PKC, which in turn acts on nAChRs to phosphorylate and desensitize them.   As we have 
demonstrated in our research, α3* receptors can also be inhibited through actions by kinases such 
as PKC.  Could this suggest that α3* receptors in the urothelium may also be modulated through 
M1 stimulation and subsequent PKC activation?  Since M1 receptors also increase intracellular 
calcium though IP3-sensitve stores, could M1 receptors also play a role in modulating the 
intracellular calcium changes produced by nicotinic receptor stimulation?  Could the other 
muscarinic receptors modulate nicotinic receptors in different ways?  For example, M2 receptors 
have been known to inhibit adenylate cyclase production, decreasing levels of cAMP [31].  
Could this lead to a downregulation in the activity of PKA in the urothelium and increase α3* 
signals, as our research suggests might occur when PKA activity is blocked?  The answers to 
these questions will take further study, however they will lead to a greater understanding of 
cholinergic signaling in the urothelium and perhaps elucidate more effective treatments for 
bladder pathologies than the current treatment of anti-muscarinics alone.   
In addition to muscarinic receptors, nicotinic receptors have also been shown to interact 
with other receptor pathways that are important players in urothelial physiology.  The first is 
TRPV1, the capsaicin- and proton-sensitive ion channel found in both urothelial cells and 
bladder afferent nerves [13, 60, 105, 305, 306].  As we discussed in Chapter 1.2.2.3, TRPV1 has 
an important sensory role in the urothelium, as TRPV1 KO mice exhibit decreases in stretch-
evoked ATP release from the urothelium [60].  TRPV1 is also expressed in C-fiber nerves 
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innervating the bladder, and is thought to play a role in the propagation of urgency or painful 
sensations felt during bladder pathology [105].  This hypothesis led to the development of 
capsaicin or resiniferatoxin (RTX), two specific TRPV1 agonists, as treatments for overactive 
bladder disorders, as discussed later in Section 5.2 [62].   It is thought that this treatment is due to 
actions of capsaicin and RTX on afferent nerves to desensitize them to noxious stimuli.  
Nicotinic receptors also reside on C-fiber neurons and activation of these receptors with agonists 
can also block nociception [194, 199, 307].  One hypothesis on how this might occur is through 
modulation of TRPV1 channels by nAChRs.  Studies have demonstrated that TRPV1 mediated 
currents exhibit both acute desensitization and tachyphylaxis in response to α7 nAChR 
stimulation [175].  It is thought that this decrease in sensitivity of TRPV1 channels to further 
stimuli is mediated through nAChR-mediated Ca+2 influx, possibly through a second messenger, 
such as PKC.  The urothelium also expresses nAChR and TRPV1 channels, therefore a question 
presents itself: Can nAChRs in the urothelium modulate TRPV1 channels?  Since TRPV1 
channels seem to play an important role in ATP release due to physical stimulation, such as 
stretch, could the inhibition of ATP release observed in our experiments be due to nAChR-
mediated inhibition of TRPV1?  Given the role of TRPV1 in urothelial signaling, these questions 
will be important to answer. 
Another potential interaction with nicotinic receptors in the urothelium could be the 
ionotropic nucleotide receptors (P2X receptors).  P2X receptors are activated by ATP and are 
commonly found co-localized with nicotinic receptors in the spinal cord and brain [308].  In 
these neurons, nicotinic and purinergic receptors cross-modulate each other in an inhibitory 
fashion.  For example, currents elicited by co-stimulation of sympathetic neurons with ATP and 
ACh were smaller than currents elicited by either stimulus alone [309-311].  The currents elicited 
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by co-stimulation were also larger when an antagonist for either receptor was included, 
indicating that each receptor has an inhibitory effect on the other.  Because P2X receptors have 
been shown to be important in the transmission of nociception [73], these interactions may 
represent a mechanism for the anti-nociceptive properties of nicotinic agonists such as 
epibatidine [194, 199].  The urothelium of the rat, cat and human also expresses a number of 
P2X receptors (e.g. P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, and P2X7 in the cat [79]).  Therefore, 
the possibility of cross-modulation between nicotinic and purinergic receptors in the urothelium 
playing a significant role in bladder signaling exists.  One hypothesis into a possible role for 
cross-modulation in the urothelium could be as a feedback mechanism to inhibit ATP release.  
We have demonstrated that nicotinic receptor stimulation can release ATP, therefore it is 
plausible to hypothesize that, if P2X receptors in the urothelium do inhibit nicotinic receptors, 
that this could represent a mechanism to control extracellular ATP release.   
Given these possible interactions, it is clear that nicotinic receptor signaling in the 
urothelium has the potential to become much more complicated than the model we have outlined 
above.  Further studies must be performed in order to fully elucidate the role of nicotinic 
receptors in the sensor/transducer properties of the urothelium.   
5.2  CLINICAL POSSIBILITIES FOR UROTHELIAL NICOTINIC 
RECPTORS 
The possibility that nicotinic receptors can influence afferent excitability through the release of 
ATP has important clinical implications.  A number of bladder disorders exist, such as overactive 
bladder or interstitial cystitis, which present symptoms of urgency or even bladder pain [1, 8, 12, 
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124].  It is thought that these feelings are driven by increased afferent activity, however it is not 
yet known how the increased activity in generated.  While we have not examined urothelial 
nicotinic receptors in the human, if we make the assumption that they behave in a similar fashion 
to the rat, we can make a few reasoned hypotheses on the clinical applications of nicotinic agents 
as related to bladder pathologies. 
One possibility of how afferent activity is increased in pathological bladder conditions is 
the overproduction of excitatory transmitters that could lower the threshold required to activate 
afferents.  For example, cats that suffer from a similar disorder to interstitial cystitis in humans 
(known as feline interstitial cystitis or FIC) exhibit increased ATP release from the urothelium in 
response to physical stimuli such as stretch [58].  ATP is an important transmitter in nociception 
[73], therefore it is possible that bladder pathology in humans is driven by increased release of 
ATP from the urothelium, increasing afferent activity and driving the urge to urinate.  Another 
possibility could be plasticity in the purinergic receptors present on afferent nerves that bind 
urothelially-released ATP.  Increased expression of P2X receptors on bladder afferents, or 
increased sensitivity of these receptors to ATP could also result in increased afferent activity.  
This hypothesis is supported by research that indicates increased P2X3 immunostaining on 
afferent nerves in patients suffering from overactive bladder [54, 55].  Additionally, DRG cells 
taken from rats with chemically induced cystitis exhibit increased purinergic signaling [122].   
Given the apparent importance of purinergic signaling in bladder pathology, researchers 
have focused on this system in the search for potential pharmacological targets to treat bladder 
disorders.  The research presented here adds another potential set of targets to modulate 
purinergic signaling in the bladder.  Our data suggests that stimulation of the urothelium with α7 
agonists inhibits the release of ATP from urothelial cells and inhibits bladder reflexes.  Therefore 
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pharmacological agents that could selectively activate urothelial α7 receptors may have 
beneficial effects against the urgency exhibited by patients with OAB or IC.   
In addition to α7 agonists, α3* antagonists may also be beneficial to treat bladder 
pathology.  While TMPH failed to decrease ATP release in cultured cells by itself, 
hexamethonium successfully inhibited bladder reflexes in vivo.  While these two data may at first 
seem inconsistent, as we discussed in the previous section, the cells in the in vitro preparation are 
not subject to stretch as is the urothelium in vivo.  Stretch of the urothelium causes ACh release, 
therefore while the α3* antagonist has no effect on ATP release in unstretched cultured cells, it 
may prevent activation of the receptor from stretch-induced ACh release, resulting in inhibition 
of the ATP release exhibited by α3* receptors.  This could explain the inhibitory effect 
hexamethonium has in vivo. 
While our research suggests that modulation of urothelial nicotinic receptors may benefit 
patients with bladder pathologies, a number of difficulties exist that may complicate their 
practical use as clinical treatments.  The most important of these would be the lack of a drug that 
could specifically act on an urothelial receptor.  For example, one would expect an orally 
administered drug to be biologically available to activate nicotinic receptors in a number of 
locations throughout the body.  This could be especially true for nicotinic agents currently in 
clinical development, mostly for treatment of psychological disorders such as schizophrenia 
[161] or Alzheimer’s Disease [163], since these agents are designed to cross the blood-brain 
barrier in order to reach their targets.  Given the prevalence of nicotinic receptors throughout the 
body and the wide range of effects they mediate, the possibility for non-specific effects becomes 
significant.  According to earlier research, some of the non-specific effects may be desirable.  
For example, stimulation of α3 receptors in the brain and the spinal cord excites bladder reflexes 
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[133].  Therefore, α3 antagonists acting centrally should also have inhibitory effects on bladder 
reflexes.  However, α3 receptors are prevalent throughout autonomic ganglia [130, 131, 167, 
181, 312], therefore inhibition of these receptors may have significant effects on other autonomic 
functions, such as the digestive or respiratory systems. 
 Activation of α7 receptors could have similar beneficial effects towards bladder 
pathologies, but also result in undesirable side effects.  α7 receptor agonists are beginning to be 
classified as effective analgesics, presumably through actions on the central terminals of afferent 
nerves, preventing transmitter release in the spinal cord and preventing propagation of the 
nociceptive signal [280, 313].  It could be hypothesized that these central actions of α7 agonists 
could benefit patients suffering from overactive bladder disorders, as they could block the 
propagation of nociceptive signals from bladder afferent nerves into the spinal cord.  Similar to 
α3 receptors though, α7 receptors also mediate a number of physiological effects throughout the 
body which could be influenced by a systemic dose.  For example, α7 agonists are also being 
studied as potent anti-inflammatory agents, as macrophages express α7 receptors and respond to 
nicotinic stimulation by down-regulating the release of inflammatory cytokines and chemokines 
[304, 314-316].  While these anti-inflammatory properties of nicotinic agonists may be desirable 
as an acute treatment to block sepsis [208], for example, chronic treatment may lead to the 
undesirable side effect of increased susceptibility to infection.    
Keeping these possible side effects in mind, it becomes apparent that treatment of 
hyperactive bladder disorders through the use of systemic nicotinic agents may not be the most 
desirable choice clinically.  Given that the nature of the bladder is to contain harmful waste apart 
from the rest of the body, an intriguing way to get around non-specific actions would be to target 
the drug specifically to the bladder.  The easiest way to accomplish this would be to inject agents 
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directly into the bladder.  This is already being done with certain treatments for bladder 
disorders, such as capsaicin, resiniferatoxin (RTX) and botulinum toxin type A (BOTOX-A) in a 
clinical setting.   Capsaicin and RTX, instilled intravesically, act by desensitizing the TRPV1 
receptor on C-fiber bladder afferent nerves, effectively destroying the nociceptors driving 
bladder pathology while sparing the A-δ fibers that drive normal bladder activity [62].  BOTOX-
A treatment differs in that it is injected directly into the detrusor muscle, where it is thought to 
act on efferent nerves, preventing the release of ACh and ATP that drives urinary bladder 
contractions [90, 317].  BOTOX-A may also have effects on afferent nerve terminals, preventing 
the release of substance P or glutamate, reducing their effects on the sensory pathway.  
Application of these agents directly to the bladder allows them to act specifically on bladder 
nerves, without any non-specific actions on receptors outside of the bladder.  These agents have 
long-lasting effects due to their actions on nerves, where stimulation of axonal terminals can 
result in a desensitization that can last up to 6 months, depending on the dose used.   
While intravesical treatments with nicotinic agents could also avoid actions on receptors 
outside of the bladder, it is doubtful that they could have the same long lasting actions on 
micturition.  Capsaicin and RTX are thought to act through numerous pathways, including 
phosphorylation of TRPV1 receptors, inhibition of voltage gated sodium channels through the 
activation of second messenger systems and depolarization of mitochondria, resulting in long 
term disruption of the nerve’s ability to produce an action potential [62].  Our research indicates, 
that while it is possible that urothelial nicotinic receptors also cause phosphorylation through the 
activation of PKA or PKC, these effects do not seem to last very long.  In our ATP experiments, 
stimulation of urothelial cells with either choline or cytisine resulted in a sustainable modulation 
of ATP release, however ATP levels rapidly return to normal following washout of the agent.  
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This is mirrored in vivo, as intravesical administration of nicotine causes inhibition of bladder 
reflexes that can be rapidly washed out.  Given this data, it seems as though any nicotinic agent 
used intravesically to treat bladder disorders would have to be continuously infused, a limitation 
that would seriously reduce its desirability as a treatment for bladder pathologies.  Therefore, it 
appears as though another route of administration would have to be taken for urothelial nicotinic 
receptors to become a viable pharmacological target in the treatment of bladder disorders. 
Another possibility to specifically target urothelial nicotinic receptors could be to design 
drugs that would be active predominately in the bladder and inactive in other parts of the body.  
This might be accomplished by designing a drug as an inactive, precursor form that would 
become active following metabolism in the liver.  This utilization of the “first-pass effect” would 
maximize the percentage of the drug being filtered by the kidneys and minimize the percentage 
in the blood stream, where it could have non-specific effects.   
It may also be possible to take advantage of urine’s lower pH in order to develop an 
urothelium-specific agent.  Urine has a pH of between 4.5 and 8, as compared to the pH of blood 
plasma, which is tightly controlled at 7.4.  Urine pH can be influenced by a number of factors, 
such as diet, bladder infections or other pathologies such as diabetes or respiratory problems.  
The pH of urine can be modified through changing one’s diet or through the use of drugs, such 
as potassium citrate, which increases the alkalinity of urine [318], or chlorothiazide diuretics, 
which can increase the acidity of urine [319].  This manipulation of urine pH is an important 
factor in the treatment of urinary tract infections, as antibiotics such as kanamycin or neomycin 
exhibit increased activity when the pH of urine is alkaline.  Therefore, it may be possible to 
design a drug that would be relatively inert in the blood stream at pH 7.4, but activate in either an 
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alkaline or acidic environment in the urine.  This would then potentially allow the drug to only 
act on urothelial receptors, instead of other nicotinic receptors located around the body. 
While these two hypothetical means of specifically targeting urothelial receptors may 
give us a glimpse of what may be in the future of pathological bladder treatments, they will 
require years of research and trial before becoming reality.  The development of a drug precursor 
that could be activated by modification by metabolic enzymes is an enormous task, given that the 
liver contains a number of enzymes that could modify any drug precursor in unpredictable, and 
possibly undesirable ways.  Could there, then, be a way of activating urothelial nicotinic 
receptors that minimizes the risk of activating non-urothelial receptors already in our 
pharmacological arsenal?  A promising possibility lies with a new class of compounds termed α7 
nAChR positive allosteric modulators (PAMs).  These compounds do not act as agonists on the 
α7 receptor, but rather change the receptors conformation upon binding, increasing their affinity 
for agonists [320].  These compounds include PNU-120596, genistein, 5-hydroxyindole (5-HI) 
and 4-napthalene-1-yl-3a,4,5,9b-tetrahydro-3-H-cyclopenta[c]quinoline-8-sulfonic acid amide 
(TQS) (see Figure 5.3).  These compounds can left-shift the concentration response curve to a 
number of nicotinic agonists such as ACh or PNU-282987, as well as reactivate desensitized 
receptors.  However, none of the reported α7 PAMs evoked a current by themselves and none 
exhibited any type of action (either as an agonist or a PAM) or other nicotinic receptors such as 
α3β4 [320].  This, then would make α7 PAMs the ideal compounds to increase α7 signaling in 
response to endogenous stimulation by ACh, but limit side effects due to non-specific activation 
of α7 receptors elsewhere in the body.  Because ACh is released from the urothelium during the 
filling phase, we would expect that an α7 PAM would increase the activity of urothelial α7 
receptors, leading to increased inhibition of bladder reflexes (in the anesthetized rat) or decreased 
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sensations of urgency (in the human).  However, as we mention in Chapter 3, it is possible that 
the effects we observe following α7 stimulation may actually due to the receptor in its 
desensitized form, not due to activation of the receptor.  If this is the case, then we would expect 
PMAs to have no beneficial effect on bladder reflexes, since they stabilize α7 receptors in their 
open state, not the desensitized state. 
 
 
Figure 5.3 - Positive Allosteric Modulators of α7 nAChRs 
Structures of some current positive allosteric modulators of the α7 nAChR.   
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5.3 FINAL THOUGHTS 
In conclusion, we believe that our current research, presented in this dissertation, indicates an 
important role in the sensor/transducer role of urothelial signaling.  The urothelium expresses 
two main classes of nicotinic receptor which, when stimulated, have opposing effects on bladder 
reflexes in the rat.  These effects may be mediated through a modulation of extracellular ATP 
release, as our in vitro experiments with cultured urothelial cells suggest.  These data reveals 
another possible mechanism concerning how the urothelium can sense and transmit information 
about conditions in the bladder to underlying afferent nerves, influencing bladder function.  This 
mechanism is important clinically, as modulation of urothelial nicotinic receptors can influence 
bladder reflexes and may represent a novel target in the treatment of bladder hyperactivity as a 
result of pathology.    
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APPENDIX A 
MATERIALS AND METHODS 
A.1.1 Animals 
All experiments used female Sprague-Dawley (SD) rats (250-300g) that were fed a standard diet 
with free access to water prior to experimentation.  Tissues were harvested from rats that were 
euthanized by inhalation of 100% CO2.  All studies were carried out with the approval of the 
University of Pittsburgh Institutional Animal Care and Use Committee and maintained according 
to the standards set forth in the American Physiological Society’s handbook on the care and use 
of laboratory animals. 
A.1.2 Rat Urothelial Cell Culture  
Rat urinary bladders were excised and stored in oxygenated Krebs solution.  The bladder was cut 
open, gently stretched with the epithelial side up and pinned in a sylgard coated dish.  The 
bladder was incubated overnight in minimal essential medium, penicillin/streptomycin/fungizone 
and 2.5 mg/ml dispase (all from Invitrogen).  The epithelium was then gently scraped from the 
underlying tissue using a spatula, placed in a culture flask and treated with enzyme (0.25% 
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trypsin) for 10 minutes with periodic tituration to dissociate urothelial cells.  Following 
dissociation, the cell suspension was placed in MEM containing 10% FBS to inhibit trypsin and 
centrifuged at 416xg for 15 minutes.  The pellet was then re-suspended in keratinocyte medium 
(Invitrogen) and centrifuged again.  This pellet was again suspended in keratinocyte media 
(~1ml) and 0.1 ml of the cell suspension (50,000-250,000 cells/ml) was added to the surface of 
collagen-coated plates.  Cells were used within the first 1-2 days following plating.    
A.1.3 RNA Extraction and RT-PCR 
mRNA for RT-PCR experiments was obtained from both cultured urothelial cells and whole 
urothelial tissue.  To collect whole urothelial tissue, bladders were obtained from three female 
SD rats, cut open and pinned flat on Sylgard dishes.  The urothelium was then gently teased 
away from the underlying tissue using fine forceps and scissors and placed in RNase free buffer.  
The RNeasy RNA Extraction Kit from Qiagen was used to extract RNA following the published 
protocol for tissue samples or cultured cells.  The RNA was resuspended in RNAse free water 
and tested for quality, purity and concentration by UV spectrophotometry and gel electrophoresis 
(1.2% formaldehyde agarose gel).  First-strand cDNA synthesis was performed using the Roche 
Molecular Biochemicals First-Strand cDNA Synthesis Kit for RT-PCR, using an oligo-dT15 
primer.  PCR was performed using Qiagen’s Taq PCR Core Kit, using the optional Q-solution, 
sequence-specific primers designed for each subunit, and annealing temperatures determined by 
the sequence of the primers.  Primers for PCR are shown in Table 5.  Rat primers were designed 
in-house using online primer design software Primer3 (http://primer3.sourceforge.net); cat 
primers were taken from Bairam, et. al. [228] and human primers were taken from Maus, et. al. 
[227].   
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Table 5 - Primer Sets for RT-PCR of nAChRs 
Subunit 
Species 
Primer Pair 
(5’→3’) 
Tm (˚C) Expected 
Product Size (bp) 
α2 
Rat 
(L) CGAGTCGGGGAGTATGGTAA 
(R) AGGAAGTGGCTTCTCAGTCG 60 300 
α3 
Rat 
(L) GTGAATTCAGCCGTGCAGACTCCA 
(R) ATAAGCTTGGCAACGTACTTCCAATCATC 60 271 
α4 
Rat 
(L) GTGAATTCCACAGGTCGTACACGGGTCG 
(R) ATAAGCTTGCGAGCCCGGCATCTTGAGT 62 257 
α5 
Rat 
(L) AGTGGGCTGGACCTAAATCTCG 
(R) CAAAAAGCCCTAAAGTCCCAATGA 61 286 
α7 
Rat 
(L) GTGAATTCAAGAGGCCCGGAGAGGACAA 
(R) ATAAGCTTCGCCACATACGACCCCAGAG 67 190 
β2 
Rat 
(L) GTGAATTCAGGGCGAGGCGGTTTTCTT 
(R) ATAAGCTTGCGTACGCCATCCACTGCT 65 180 
β3 
Rat 
(L) GTGAATTCTGGGTGAAGAGGCTGTT 
(R) ATAAGCTTATCGCTGGCGGGAGTCTGTT 63 157 
β4 
Rat 
(L) GTGAATTCCATGGCATCCTGGGTCAAG 
(R) ATAAGCTTCTGGGGAGGCCTGCTGTGT 65 258 
α1 
Human 
(L) CGTCTGGTGGCAAAGCT 
(R) CCGCTCTCCATGAAGTT 55 580/505 
α2 
Human 
(L) CCGGTGGCTTCTGATGA 
(R) CAGATCATTCCAGCTAGG 55 466 
α3 
Human 
(L) CTGGTGAAGGRGGATGAAGT 
(R) CTCGCAGCAGTTGTACTTGA 58 464 
α4 
Human 
(L) GGATGAGAAGAACCAGATGA 
(R) CTCGTACTTCCTGGTGTTGT 58 444 
α5 
Human 
(L) GATAATGCAGATGGACGT 
(R) TGATGGTATGATCTCTTC 55 525 
α6 
Human 
(L) GTGGCCTCTGGACAAGACAA 
(R) CCTGCAGTTCCAAATACACA 58 372 
α7 
Human 
(L) GAGGCAGATATCAGTGGCTA 
(R) GATGATGGTGAAGACCGAGA 55 893 
β2 
Human 
(L) CAGCTCATCAGTGTGCA 
(R) GTGCGGTCGTAGGTCCA 55 347 
β3 
Human 
(L) TGGAGAGTACCTGCTGTTCA 
(R) CGAGCCTGTTACTGACACTA 58 439 
β4 
Human 
(L) CTGAAACAGGAATGGACT 
(R) CCATGTCTATCTCCGTGT 55 310 
α3 
Cat 
(L) ATCATCCCCTGCCTGGTCA 
(R) GAGGTGGAAGGGATTGTCTCG 66 149 
α4 
Cat 
(L) GTCCACTTCGGGCTGTCCAT 
(R) GCTTGTAGTCGTGCCATTCCTG 66 103 
α7 
Cat 
(L) CAGCCGCTCACCGTCTACTT 
(R) CCATCTGGGAAACGAACAGTCT 66 170 
β2 
Cat 
(L) AGCACTTCCCCTTCGACCA 
(R) TCCACGAGCGGAACTTCATG 66 51 
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To amplify PKC isoforms in Chapter 3, the following primers were designed in-house using 
online primer design software Primer3 (http://primer3.sourceforge.net): 
 
Table 6 - Primers for PKC Isoforms 
Primer Sequence (5’-3’) Tm (˚C) Expected 
Product Size 
α (L) TGAACCCTCAGTGGAATGAGT (R) GGCTGCTTCCTGTCTTCTGAA 59 325 
β (L) TGTGATGGAGTGTGTGAACGGGGG (R) TCGAAGTTGGAGGTGTCTCGCTTG 59 639 
γ (L) TTGATGGGGAAGATGAGGAGG (R) GAAATCAGCTTGGTCGATGCTG 59 347 
δ (L) CACCATCTTCCAGAAAGAACG (R) CTTGCCATAGGTCCCGTTGTTG 59 352 
ε (L) CGAGGACGACTTGTTTGAATCC (R) CAGTTTCTCAGGGCATCAGGTC 59 389 
λ (L) GCTTATGTTTGAGATGATGGCGG (R) TGACAACCCAATCGTTCCTTTG 59 201 
ζ (L) CGATGGGGTGGATGGGATCAAAA (R) GTATTCATGTCAGGGTTGTCTG 59 681 
β-actin (L) ATGGTGGGTATGGGTCAGAA (R) GCTGTGGTGGTGAAGCTGTA 59 482 
 
 
PCR was performed using the GeneAmp 9700 thermocycler from Applied Biosystems.  PCR 
products were run on a 1.2% agarose gel using ethidium bromide to visualize bands.  Results 
were analyzed using the Eagle Eye II digital imaging system (Stratagene).  Positive results were 
sequenced using ABI PRISM 3100 Automated Genetic Analyzer in the University of Pittsburgh 
DNA Sequencing Core Facility. 
Quantitative RT-PCR was also performed to determine the relative expression of nAChR 
subunit message in the rat.  Following first-strand synthesis, as described above, the iQ SYBR 
Green Supermix kit (Bio-Rad, Inc.) was utilized to perform qPCR.  For each reaction, 12.5µl of 
the Supermix were added to 0.5µl of cDNA and 0.25µl of the subunit-specific primers listed 
above (at a final concentration of 100nM each) and 11.25µl of sterile water.  Each reaction was 
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set-up in triplicate, plated in a 96-well plate and run in a MyiQ Quantitative thermocycler (Bio-
Rad, Inc.), using the following protocol: 95.0ºC for 3 minutes, 35 cycles of 95.0ºC for 15 
seconds and the annealing temperature listed in Table 5 for 45 seconds.  Quantitative readings 
were taken each cycle during the annealing temperature hold.  Following completion of 
amplification cycles, a melting temperature curve was performed to determine specificity of 
primer annealing.  This was accomplished by first holding the reactions at 95.0ºC for 1 minute to 
denature the reaction products, then rapidly cool the reaction to 55ºC to force annealing.  The 
temperature of the reaction was then raised by 0.5ºC every 10 seconds and fluorescence readings 
taken.  Because the iQ SYBR only fluoresces when combined with double-stranded DNA, the 
signal drops significantly when the temperature reaches a significant level to break apart the two 
strands of the product.  Primers are assumed to be amplifying the proper product if only one drop 
in fluorescence is observed; if two or more drops are present then some non-specific 
amplification must have taken place.  To double check the specificity of our primers, even 
following a favorable annealing temperature curve, each reaction product was also sent for DNA 
sequencing as described above and matched against a BLAST search for the subunit in question. 
A.1.4 Immunohistochemistry:   
Bladders were removed from female Sprague Dawley rats (200-250g), cut open longitudinally 
and snap frozen in OCT compound using liquid nitrogen.  These bladders were then sectioned at 
6μm, placed on slides and air dried.  Slides were then fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS) for 30 minutes.  Following washes in PBS, the slides were 
incubated in 0.3M glycine for 20 minutes to reduce auto-fluorescence.  The slides were then 
permeabilized in 0.1% Triton X-100 and then blocked for 30 minutes.  The blocking solution 
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contained 0.1% Triton X-100, 0.5% bovine serum albumin and 10% normal donkey serum.  The 
slides were then incubated with Alexa-488 α-bungarotoxin (for α7 receptors, 1μM) or goat anti-
α3 polyclonal antibody (1:100 dilution) for 2 hours at 25˚C.  After primary incubation, α3 slides 
were washed with PBS and incubated with a donkey anti-goat-FITC secondary antibody (1:250 
in PBS) for 1 hour.  For co-localization studies, slides were also incubated with mouse 
monoclonal antibodies against either cytokeratin -17 or -20 (1:50 dilution each) followed by a 
donkey anti-mouse-Cy3 (1:250) secondary antibody.  All slides were also incubated with DAPI 
(1:5000 in PBS for 5 minutes) to provide a nuclear counterstain.  Following final washes with 
PBS, the slides were mounted and viewed.  Results shown are representative of experiments 
performed from bladders of three separate animals.  Antibodies for the cytokeratins were 
obtained from Dako; the anti-α3 polyclonal antibody, Alexa labeled α-bungarotoxin and all 
secondary antibodies were obtained through Invitrogen. 
A.1.5 ATP Release:   
Urothelial cells were cultured as described above, plated on 35mm plastic culture dishes and 
allowed to grow for 24-48 hours until they became approximately 30-50% confluent.  These 
dishes were then perfused with HBSS using a peristaltic pump at 0.6ml/min for 10 minutes to 
completely wash off the culture media.  Following wash, the cells continued to be perfused with 
HBSS and 100μl samples of the perfusate was taken every 30 seconds for 5 minutes from the 
dish using a pipetteman.  These samples were read in a luminometer (Turner Designs, TD 20/20 
Sunnyvale, CA) using the ATP luminescence kit (Sigma Aldrich, St. Louis, MO) to establish the 
basal levels of ATP release.  For all samples, the luminometer was set at a sensitivity of 49.2% 
and an integration time of 10 seconds.  The cells were then stimulated by switching the perfusate 
 168 
to the appropriate nicotinic agent and samples taken every 30 seconds for 10 minutes.  For 
antagonist studies, the appropriate antagonist was perfused over the cells for 10 minutes prior to 
as well as during agonist stimulation.   Results reported were obtained using cells cultured 
separately from three rats.   
A.1.6 Calcium Imaging (Fura-2):  
Urothelial cells grown on collagen coated coverslips for 24-48 hours were washed with Hanks 
Balanced Saline Solution (HBSS) then loaded with Fura-2 AM dye (1μM dye, 30 min incubation 
at 37˚C).  Following loading the coverslips were placed into a flow chamber specifically 
designed to fit the microscope stage (Olympus IX70 inverted microscope).  Cells were 
maintained in HBSS throughout the experiment by use of a gravity-fed perfusion system with a 
flow rate of approximately 2.4ml/min.   To record changes in [Ca+2]i the cells were alternatively 
illuminated at 340 and 380nm by using a xenon lamp and imaged at 510nm with a Dage-MTI 
cooled CCD camera with 640x480 pixel resolution.  A Dage-MTI Gen. II system image 
intensifier and software package from Compix Inc. (Cranberry, PA, USA) was used to collect 
data.  The cells were then stimulated by switching the perfusate to the appropriate nicotinic agent 
and samples taken every 5 seconds for the duration of stimulation.  For antagonist studies, the 
appropriate antagonist was perfused over the cells for 10 minutes prior to as well as during 
agonist stimulation.    Kinase agents were perfused for 15 minutes prior to and during agonist 
stimulation.  Results reported were obtained using cells cultured from three separate rats.   
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A.1.7 Rat In Vivo Bladder Cystometrogram:   
Female SD rats (weight 250-275g) were anesthetized with urethane (1.2 g/kg, s.c.).  A midline 
incision was made and a catheter (intramedic tubing, PE 50) was inserted into the bladder lumen 
through a small incision in the bladder dome and secured with a suture.  The catheter was 
connected by way of a three-way stopcock to a syringe pump for fluid infusion and a pressure 
transducer connected to a computer to record changes in bladder pressure.  The ureters were also 
tied and cut to prevent filling of the bladder from the kidneys.  A wick of sterile gauze was 
inserted into the midline incision and sewn in place to drain urine from the abdominal cavity.  
Saline was infused intravesically (0.04 ml/min) for 1 hour in order to allow the bladder to 
recover from surgery.   Saline infusion continued for an additional hour while bladder pressure 
was recorded to obtain control data.  The bladder infusate was then switched to a drug solution 
and recorded for at least another hour before switching to another drug solution.  In 4 animals, 
epibatidine was administered (0.05 μg/kg i.p. injection) at the end of the experiment and bladder 
pressure recordings were obtained for 2 hours. 
A.1.8 Solutions and Reagents 
All nicotinic agents used in this study were obtained by Tocris Bioscience, Ellisville, MO.  All 
other reagents, unless otherwise noted were obtained from Sigma-Aldrich, Inc., St. Louis, MO.  
The composition of Krebs solution was (in mM): NaCl: 113, KCl: 4.7, MgSO4: 1.2, NaHCO3: 
25.0, KH2PO4: 1.2, Glucose: 11.5, CaCl2: 2.5, HEPES: 10.0.  The composition of HBSS was (in 
mM): KCl: 5.0, KH2PO4: 0.3, NaCl: 138, NaHCO3: 4.0, Na2HPO4: 0.3, Glucose: 5.6, CaCl2: 2.0, 
MgCl2: 1.0, HEPES 10.0.  In experiments where extracellular calcium was to be removed, CaCl2 
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was omitted, the concentration of NaCl was increased to 140mM and 0.5mM EGTA was added.  
All solutions were adjusted to pH 7.4 with 10N NaOH and 300-310 mOsM using NaCl.  
A.1.9 Statistical Analyses 
Statistical significance was assessed in all experiments using either unpaired, two-tailed 
Student’s t-tests or one-way ANOVA with Tukey’s multiple comparison post test to compare all 
columns to each other or Dunnett’s post test to compare all columns to a control, when 
appropriate.  Statistical significance was accepted when p < 0.05. 
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